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Background: Urinary incontinence affects one in three women worldwide. Pelvic floor muscle training is
an effective treatment. Electromyography biofeedback (providing visual or auditory feedback of internal
muscle movement) is an adjunct that may improve outcomes.
Objectives: To determine the clinical effectiveness and cost-effectiveness of biofeedback-mediated
intensive pelvic floor muscle training (biofeedback pelvic floor muscle training) compared with basic pelvic
floor muscle training for treating female stress urinary incontinence or mixed urinary incontinence.
Design: A multicentre, parallel-group randomised controlled trial of the clinical effectiveness and cost-
effectiveness of biofeedback pelvic floor muscle training compared with basic pelvic floor muscle training,
with a mixed-methods process evaluation and a longitudinal qualitative case study. Group allocation was
by web-based application, with minimisation by urinary incontinence type, centre, age and baseline urinary
incontinence severity. Participants, therapy providers and researchers were not blinded to group allocation.
Six-month pelvic floor muscle assessments were conducted by a blinded assessor.
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Setting: This trial was set in UK community and outpatient care settings.
Participants: Women aged ≥ 18 years, with new stress urinary incontinence or mixed urinary incontinence.
The following women were excluded: those with urgency urinary incontinence alone, those who had
received formal instruction in pelvic floor muscle training in the previous year, those unable to contract their
pelvic floor muscles, those pregnant or < 6 months postnatal, those with prolapse greater than stage II,
those currently having treatment for pelvic cancer, those with cognitive impairment affecting capacity to
give informed consent, those with neurological disease, those with a known nickel allergy or sensitivity and
those currently participating in other research relating to their urinary incontinence.
Interventions: Both groups were offered six appointments over 16 weeks to receive biofeedback pelvic
floor muscle training or basic pelvic floor muscle training. Home biofeedback units were provided to
the biofeedback pelvic floor muscle training group. Behaviour change techniques were built in to
both interventions.
Main outcome measures: The primary outcome was urinary incontinence severity at 24 months (measured
using the International Consultation on Incontinence Questionnaire Urinary Incontinence Short Form
score, range 0–21, with a higher score indicating greater severity). The secondary outcomes were urinary
incontinence cure/improvement, other urinary and pelvic floor symptoms, urinary incontinence-specific
quality of life, self-efficacy for pelvic floor muscle training, global impression of improvement in urinary
incontinence, adherence to the exercise, uptake of other urinary incontinence treatment and pelvic floor
muscle function. The primary health economic outcome was incremental cost per quality-adjusted-life-year
gained at 24 months.
Results: A total of 300 participants were randomised per group. The primary analysis included 225 and
235 participants (biofeedback and basic pelvic floor muscle training, respectively). The mean 24-month
International Consultation on Incontinence Questionnaire Urinary Incontinence Short Form score was
8.2 (standard deviation 5.1) for biofeedback pelvic floor muscle training and 8.5 (standard deviation 4.9)
for basic pelvic floor muscle training (adjusted mean difference –0.09, 95% confidence interval –0.92 to
0.75; p = 0.84). A total of 48 participants had a non-serious adverse event (34 in the biofeedback pelvic
floor muscle training group and 14 in the basic pelvic floor muscle training group), of whom 23 (21 in the
biofeedback pelvic floor muscle training group and 2 in the basic pelvic floor muscle training group) had
an event related/possibly related to the interventions. In addition, there were eight serious adverse events
(six in the biofeedback pelvic floor muscle training group and two in the basic pelvic floor muscle training
group), all unrelated to the interventions. At 24 months, biofeedback pelvic floor muscle training was
not significantly more expensive than basic pelvic floor muscle training, but neither was it associated with
significantly more quality-adjusted life-years. The probability that biofeedback pelvic floor muscle training
would be cost-effective was 48% at a £20,000 willingness to pay for a quality-adjusted life-year threshold.
The process evaluation confirmed that the biofeedback pelvic floor muscle training group received an
intensified intervention and both groups received basic pelvic floor muscle training core components.
Women were positive about both interventions, adherence to both interventions was similar and both
interventions were facilitated by desire to improve their urinary incontinence and hindered by lack of time.
Limitations: Women unable to contract their muscles were excluded, as biofeedback is recommended for
these women.
Conclusions: There was no evidence of a difference between biofeedback pelvic floor muscle training and
basic pelvic floor muscle training.
Future work: Research should investigate other ways to intensify pelvic floor muscle training to improve
continence outcomes.
Trial registration: Current Controlled Trial ISRCTN57746448.
Funding: This project was funded by the NIHR Health Technology Assessment programme and will be
published in full in Health Technology Assessment; Vol. 24, No. 70. See the NIHR Journals Library website
for further project information.
ABSTRACT
NIHR Journals Library www.journalslibrary.nihr.ac.uk
viii
Contents
List of tables xiii
List of figures xv
List of abbreviations xvii
Plain English summary xix
Scientific summary xxi
Chapter 1 Introduction 1
Scientific background and current evidence base 1
Possible mechanisms for how biofeedback might improve continence 1
Evidence for the effectiveness of biofeedback for female urinary incontinence 2
Rationale for research 2
Aims and objectives 2
Development of the OPAL trial interventions 3
Chapter 2 Trial design and methods 5
Trial design 5
Ethics approval and research governance 5
Management of the trial 5





Randomisation, concealment and blinding 6
Therapist training 7
Treatment group allocation 7
Both trial groups (biofeedback PFMT and basic PFMT) 7
Biofeedback PFMT 7









Important changes to the project protocol 12




Primary outcome measure 18
DOI: 10.3310/hta24700 HEALTH TECHNOLOGY ASSESSMENT 2020 VOL. 24 NO. 70
© Queen’s Printer and Controller of HMSO 2020. This work was produced by Hagen et al. under the terms of a commissioning contract issued by the Secretary of State for
Health and Social Care. This issue may be freely reproduced for the purposes of private research and study and extracts (or indeed, the full report) may be included in professional
journals provided that suitable acknowledgement is made and the reproduction is not associated with any form of advertising. Applications for commercial reproduction should
be addressed to: NIHR Journals Library, National Institute for Health Research, Evaluation, Trials and Studies Coordinating Centre, Alpha House, University of Southampton Science





Further treatment for urinary incontinence 23
Pelvic floor outcomes 24
Adherence 26
Adverse events 27






Estimation of participant costs 31




Incremental cost per quality-adjusted life-year gained 33






Intervention and follow-up costs 37
Generic and condition-specific quality-of-life measures 37
Costs incurred by and quality-adjusted life-years of cured and incontinent participants 38
Costs directly incurred by participants and carers and indirect costs of time and
productivity lost due to urinary incontinence 40
Base-case cost-effectiveness analysis 40
Sensitivity analysis 42
Subgroup analysis 43
Type of incontinence 45
Age 46
Severity of incontinence 46
Quality-of-life scores 46
Discounting and unadjusted costs and quality-adjusted life-years 46
Assuming that data were missing not at random 46
Discussion 46
Conclusion 48
Chapter 5 Process evaluation 49
Introduction 49
Methods 49




PFMT exercise diaries 50
CONTENTS
NIHR Journals Library www.journalslibrary.nihr.ac.uk
x












Chapter 6 Longitudinal qualitative case study 65
Introduction 65
Methods 65
Sampling and recruitment 65
Case study data collection 66
Case study data analysis 66
Management and governance 67
Findings 67
Sample 67
Women’s adherence to the interventions 68
Facilitators of adherence during the active treatment phase 68
Barriers to intervention adherence during active treatment phase 71
Facilitators of women’s adherence in the maintenance phase 73
Barriers to women’s adherence in the maintenance phase 75
Women’s urinary incontinence outcomes in the short and long term 77
Theoretical propositions 78
Discussion 78
Strengths and limitations of the case study 78
Comparison of findings to existing literature 79





Chapter 8 Discussion and conclusions 85
Statement of principal findings 85
Robustness of primary outcome analysis 85
Further analyses of the primary outcome 85
Strength and limitations 86
Strengths 86
Limitations 86
Interpretation of results 87
Implications for health care 88
Future research implications 89
Acknowledgements 91
References 95
DOI: 10.3310/hta24700 HEALTH TECHNOLOGY ASSESSMENT 2020 VOL. 24 NO. 70
© Queen’s Printer and Controller of HMSO 2020. This work was produced by Hagen et al. under the terms of a commissioning contract issued by the Secretary of State for
Health and Social Care. This issue may be freely reproduced for the purposes of private research and study and extracts (or indeed, the full report) may be included in professional
journals provided that suitable acknowledgement is made and the reproduction is not associated with any form of advertising. Applications for commercial reproduction should
be addressed to: NIHR Journals Library, National Institute for Health Research, Evaluation, Trials and Studies Coordinating Centre, Alpha House, University of Southampton Science
Park, Southampton SO16 7NS, UK.
xi
Appendix 1 Trial components 101
Appendix 2 Overview of participant data collected via questionnaires 103
Appendix 3 Recruitment by centre 105
Appendix 4 Reasons for ineligibility 107
Appendix 5 Sensitivity analysis under assumptions of missing not at random 109
Appendix 6 Subgroup analysis 111
Appendix 7 Patient Global Impression of Improvement in urinary incontinence 113
Appendix 8 Bowel and prolapse symptoms 115
Appendix 9 Estimation of unit cost of biofeedback machines per participant 119
Appendix 10 Unit costs of patient-reported medications 121
Appendix 11 Unit cost of incontinence products (pads that women wear and
disposable bed pads) 123
Appendix 12 Generalised linear model diagnostics test results 125
Appendix 13 Missing data (costs) 127
Appendix 14 Missing data (utility measures) 129
Appendix 15 Proportion of participants experiencing any problems on each of
the EQ-5D-3L domains: analysis based on all of the available EQ-5D-3L data points 131
Appendix 16 Proportion of participants who reported issues on each domain of
the ICIQ-LUTSqol: analysis based on all of the available EQ-5D-3L data points 133
Appendix 17 Sensitivity analysis cost-effectiveness acceptability curves and
incremental cost-effectiveness ratio scatterplots 135
Appendix 18 Examples of core and optional components of the basic PFMT and
biofeedback PFMT intervention protocols, as worded on the therapist assessment
form checklists 143
CONTENTS
NIHR Journals Library www.journalslibrary.nihr.ac.uk
xii
List of tables
TABLE 1 Baseline characteristics 16
TABLE 2 Urinary measures at baseline 16
TABLE 3 Pelvic floor measures at baseline 17
TABLE 4 Appointment attendance and therapist type 18
TABLE 5 Home exercise programme recommended 19
TABLE 6 Summary of ICIQ-UI SF responses and analysis of differences between
groups (models correct for minimisation variables and baseline ICIQ-UI SF) 19
TABLE 7 Lower urinary tract symptoms (ICIQ-FLUTS and ICIQ-LUTSqol) 21
TABLE 8 Cure and improvement in urinary symptoms 22
TABLE 9 Further treatment for UI 23
TABLE 10 Hospital admissions and non-surgical treatment for UI 24
TABLE 11 Self-efficacy for PFMT 25
TABLE 12 Pelvic floor muscle function assessed by therapist via vaginal
examination at baseline and 6 months (blinded) 25
TABLE 13 Therapists’ adherence to intervention delivery protocol at
appointments and women’s adherence to prescribed intervention at home 27
TABLE 14 Participant-reported frequency of PFMEs 28
TABLE 15 Average NHS unit costs 30
TABLE 16 Participant time and travel unit cost 32
TABLE 17 Missing resource use/cost and QALY data 35
TABLE 18 Summary of intervention and follow-up care resource use
(complete-case data) 36
TABLE 19 Summary of intervention and follow-up costs (complete-case data) 37
TABLE 20 Mean EQ-5D-3L scores at each time point, QALYs and differences
between treatment groups 38
TABLE 21 Mean ICIQ-LUTSqol scores at each time point, second-year QALYs and
differences between treatment groups 40
TABLE 22 Direct and indirect costs to participants and carers (complete-case data) 42
DOI: 10.3310/hta24700 HEALTH TECHNOLOGY ASSESSMENT 2020 VOL. 24 NO. 70
© Queen’s Printer and Controller of HMSO 2020. This work was produced by Hagen et al. under the terms of a commissioning contract issued by the Secretary of State for
Health and Social Care. This issue may be freely reproduced for the purposes of private research and study and extracts (or indeed, the full report) may be included in professional
journals provided that suitable acknowledgement is made and the reproduction is not associated with any form of advertising. Applications for commercial reproduction should
be addressed to: NIHR Journals Library, National Institute for Health Research, Evaluation, Trials and Studies Coordinating Centre, Alpha House, University of Southampton Science
Park, Southampton SO16 7NS, UK.
xiii
TABLE 23 Base-case cost-effectiveness results: therapist-reported duration of
appointment (imputed data set) 42
TABLE 24 Recommended appointment time (3.5 hours for six appointments)
(imputed data set) 43
TABLE 25 Sensitivity analyses 44
TABLE 26 Number of available checklists compared with potential total number
of checklists by group and by appointment 52
TABLE 27 Summary of checklist core components ticked for each appointment
by group: differentiating between basic PFMT core components and
biofeedback-specific PFMT core components 53
TABLE 28 Summary of checklist optional components ticked for each
appointment by group: differentiating between basic PFMT optional
components and biofeedback-specific PFMT optional components 54
TABLE 29 Summary of audio-recordings made by appointment and by group 55
TABLE 30 Summary of audio-recorded evidence of delivery of core components
by group and by appointment 56
TABLE 31 Characteristics of women in the case study by group allocation 67
TABLE 32 Case study examples of variation in adherence to treatment by
allocated treatment group and across time 68
TABLE 33 Case study examples of variance in UI outcomes at 24 months by
allocated treatment group 77
TABLE 34 Convergence coding matrix 82
TABLE 35 Bowel symptoms 115
TABLE 36 Prolapse symptoms (POP-SS) 118
LIST OF TABLES
NIHR Journals Library www.journalslibrary.nihr.ac.uk
xiv
List of figures
FIGURE 1 Projected and actual recruitment 13
FIGURE 2 The CONSORT flow diagram 15
FIGURE 3 Sensitivity analyses 20
FIGURE 4 Subgroup analyses 21
FIGURE 5 Proportion of participants experiencing any problems in each of the
EQ-5D-3L domains 39
FIGURE 6 Proportion of participants experiencing any problems in each of the
ICIQ-LUTSqol domains by group 41
FIGURE 7 Cost-effectiveness acceptability curves: therapist-reported duration
of appointment (imputed data set) 42
FIGURE 8 Scatterplot of incremental costs and QALYs for biofeedback PFMT vs.
basic PFMT: therapist-reported duration of appointment (imputed data set) 43
FIGURE 9 Cost-effectiveness acceptability curves: recommended appointment
time (3.5 hours for six appointments) 43
FIGURE 10 Scatterplot of incremental costs and QALYs for biofeedback PFMT vs.
basic PFMT: recommended appointment time (3.5 hours for six appointments) 44
FIGURE 11 Proportion of exercise diaries signed (by participant and therapist)
and returned by appointment and by group (in respect to the total number
attending that appointment in that group) 60
FIGURE 12 Pattern mixture model under assumptions of MNAR 109
FIGURE 13 Cost-effectiveness acceptability curve: SUI subgroup analysis 135
FIGURE 14 Scatterplot of incremental cost and incremental QALYs: SUI
subgroup analysis 135
FIGURE 15 Cost-effectiveness acceptability curve: MUI subgroup analysis 136
FIGURE 16 Scatterplot of incremental costs and incremental QALYs: MUI
subgroup analysis 136
FIGURE 17 Cost-effectiveness acceptability curve: age < 50 years subgroup analysis 136
FIGURE 18 Scatterplot of incremental costs and QALYs: age < 50 years
subgroup analysis 137
FIGURE 19 Cost-effectiveness acceptability curve: age ≥ 50 years subgroup analysis 137
DOI: 10.3310/hta24700 HEALTH TECHNOLOGY ASSESSMENT 2020 VOL. 24 NO. 70
© Queen’s Printer and Controller of HMSO 2020. This work was produced by Hagen et al. under the terms of a commissioning contract issued by the Secretary of State for
Health and Social Care. This issue may be freely reproduced for the purposes of private research and study and extracts (or indeed, the full report) may be included in professional
journals provided that suitable acknowledgement is made and the reproduction is not associated with any form of advertising. Applications for commercial reproduction should
be addressed to: NIHR Journals Library, National Institute for Health Research, Evaluation, Trials and Studies Coordinating Centre, Alpha House, University of Southampton Science
Park, Southampton SO16 7NS, UK.
xv
FIGURE 20 Scatterplot of incremental costs and incremental QALYs: age
≥ 50 years subgroup analysis 137
FIGURE 21 Cost-effectiveness acceptability curve: lower severity incontinence
level (ICIQ-UI SF score of < 13) subgroup analysis 138
FIGURE 22 Scatterplot of incremental cost and incremental QALYs: lower severity
incontinence level (ICIQ-UI SF score of < 13) subgroup analysis 138
FIGURE 23 Cost-effectiveness acceptability curve: higher severity incontinence
level (ICIQ-UI SF score of ≥ 13) subgroup analysis 138
FIGURE 24 Scatterplot of incremental costs and incremental QALYs: higher
severity incontinence level (ICIQ-UI SF score of ≥ 13) subgroup analysis 139
FIGURE 25 Cost-effectiveness acceptability curve: using ICIQ-LUTSqol scores as a
utility measure 139
FIGURE 26 Scatterplot of incremental costs and incremental QALYs: using
ICIQ-LUTSqol scores as a utility measure 139
FIGURE 27 Cost-effectiveness acceptability curve: undiscounted costs and effects 140
FIGURE 28 Scatterplot of incremental costs and incremental QALYs:
undiscounted costs and effects 140
FIGURE 29 Cost-effectiveness acceptability curve: discounted costs and effects at 6% 140
FIGURE 30 Scatterplot of incremental costs and incremental QALYs: discounted
costs and effects at 6% 141
FIGURE 31 Cost-effectiveness acceptability curve: unadjusted cost-effectiveness analysis 141
FIGURE 32 Scatterplot of incremental cost and incremental QALYs: unadjusted
cost-effectiveness analysis 141
LIST OF FIGURES




BCT behaviour change technique
CACE complier-average causal effect
CEAC cost-effectiveness acceptability
curve
CHaRT Centre for Healthcare
Randomised Trials
CI confidence interval
CONSORT Consolidated Standards of
Reporting Trials





GCU Glasgow Caledonian University
GLM generalised linear model
GP general practitioner




ICIQ-FLUTS International Consultation on
Incontinence Questionnaire for
Female Lower Urinary Tract
Symptoms
ICIQ-LUTSqol International Consultation on
Incontinence Questionnaire for
Lower Urinary Tract Symptoms
Quality of Life
ICIQ-UI SF International Consultation on
Incontinence Questionnaire




ITT intention to treat
MNAR missing not at random
MUI mixed urinary incontinence
NICE National Institute for Health and
Care Excellence
NIHR National Institute for Health
Research
NMAHP RU Nursing, Midwifery and Allied
Health Professions Research Unit
NMB net monetary benefit
OPAL Optimal Pelvic floor muscle
training for Adherence Long-term
OR odds ratio
PFME pelvic floor muscle exercise
PFMT pelvic floor muscle training
PGI-I Patient Global Impression of
Improvement
PGI-S Patient Global Impression of Severity
PhD Doctor of Philosophy
PMG Project Management Group
POP-SS pelvic organ prolapse symptom
score
QALY quality-adjusted life-year
R&D research and development
RCT randomised controlled trial
SAE serious adverse event
SD standard deviation
SUI stress urinary incontinence
TAF therapist assessment form
TSC Trial Steering Committee
UI urinary incontinence
WTP willingness to pay
DOI: 10.3310/hta24700 HEALTH TECHNOLOGY ASSESSMENT 2020 VOL. 24 NO. 70
© Queen’s Printer and Controller of HMSO 2020. This work was produced by Hagen et al. under the terms of a commissioning contract issued by the Secretary of State for
Health and Social Care. This issue may be freely reproduced for the purposes of private research and study and extracts (or indeed, the full report) may be included in professional
journals provided that suitable acknowledgement is made and the reproduction is not associated with any form of advertising. Applications for commercial reproduction should
be addressed to: NIHR Journals Library, National Institute for Health Research, Evaluation, Trials and Studies Coordinating Centre, Alpha House, University of Southampton Science




U rinary incontinence (accidental leakage of urine) is a common and embarrassing problem for women.Pregnancy and childbirth may contribute by leading to less muscle support and bladder control. Pelvic
floor exercises and ‘biofeedback’ equipment (a device that lets women see the muscles working as they
exercise) are often used in treatment. There is good evidence that exercises (for the pelvic floor) can help,
but less evidence about whether or not adding biofeedback provides better results.
This trial compared pelvic floor exercises alone with pelvic floor exercises plus biofeedback. Six hundred
women with urinary incontinence participated. Three hundred women were randomly assigned to the
exercise group and 300 women were randomised to the exercise plus biofeedback group. Each woman
had an equal chance of being in either group. Women were offered six appointments with a therapist over
16 weeks to receive their allocated treatment.
After 2 years, there was no difference between the groups in the severity of women’s urinary incontinence.
Women in both groups varied in how much exercise they managed to do. Some managed to exercise
consistently over the 2 years and others less so. There were many factors (other than the treatment received)
that affected a woman’s ability to exercise. Notably, women viewed the therapists’ input very positively.
The therapists reported some problems fitting biofeedback into the appointments, but, overall, they delivered
both treatments as intended. Women carried out exercises at home and many in the biofeedback pelvic floor
muscle training group also used biofeedback at home; however, for both groups, time issues, forgetting and
other health problems affected their adherence. There were no serious complications related to either treatment.
Overall, exercise plus biofeedback was not significantly more expensive than exercise alone and the quality
of life associated with exercise plus biofeedback was not better than the quality of life for exercise alone.
In summary, exercises plus biofeedback was no better than exercise alone. The findings do not support
using biofeedback routinely as part of pelvic floor exercise treatment for women with urinary incontinence.
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Urinary incontinence (accidental urine leakage) is a distressing problem that affects around one in three
women. The main types of urinary incontinence are stress (involuntary urine leakage associated with exertion
or effort, or with sneezing or coughing), urgency (involuntary urine leakage accompanied by, or immediately
preceding, a compelling desire to pass urine) and mixed (combined stress and urgency), with stress being the
most common. Current UK guidelines recommend that women with urinary incontinence are offered at least
3 months of pelvic floor muscle training. There is evidence that pelvic floor muscle training is effective in
treating urinary incontinence; however, it is not clear how intensively women have to exercise their pelvic
floor muscles to give the maximum sustained improvement in symptoms, and how to enable women to
achieve this. Electromyography biofeedback is an adjunct to pelvic floor muscle training that may help
women exercise more intensively for longer and, thus, may improve continence outcomes when compared
with pelvic floor muscle training alone.
The need for a definitive trial of biofeedback as an intensifier of pelvic floor muscle training is supported
by the current evidence base. The Cochrane systematic review of biofeedback-assisted pelvic floor muscle
training for women with urinary incontinence (Herderschee R, Hay-Smith EJ, Herbison GP, Roovers JP,
Heineman MJ. Feedback or biofeedback to augment pelvic floor muscle training for urinary incontinence
in women. Cochrane Database Syst Rev 2011;7:CD009252) found that biofeedback-assisted pelvic floor
muscle training appeared to offer benefit over basic pelvic floor muscle training; however, this effect may
have been confounded by the greater amount of health professional contact in the biofeedback groups
within trials. Thus, a trial in which women in both groups have similar amounts of contact is needed to
allow firm conclusions to be drawn about biofeedback as an intensifier of pelvic floor muscle training in its
own right.
The Optimal Pelvic floor muscle training for Adherence Long-term (OPAL) trial was designed to address this
gap by answering a pragmatic question concerned with the clinical effectiveness and cost-effectiveness of
electromyography biofeedback-mediated intensive pelvic floor muscle training (biofeedback pelvic floor
muscle training) compared with pelvic floor muscle training alone (basic pelvic floor muscle training) for the
treatment of stress or mixed female urinary incontinence.
Objective
The overall objective of the trial was to evaluate the clinical effectiveness and cost-effectiveness of
electromyography biofeedback as an adjunct to pelvic floor muscle training, the latter being the
recommended first-line treatment for female urinary incontinence in the UK. We conducted a randomised
controlled trial in which electromyography biofeedback was delivered in addition to pelvic floor muscle
training as an intensifier (both in clinic and at home), and compared with pelvic floor muscle training
alone. We included a process evaluation to identify mediating factors, such as intervention fidelity, that
might affect the clinical effectiveness of the intervention, and to establish how these factors influence
clinical effectiveness and whether or not they differ between randomised groups. A nested longitudinal
qualitative case study was also included to explore women’s experiences of the trial interventions, to
identify the barriers to and facilitators of adherence, to establish how they influence adherence and to
assess whether or not they differ between randomised groups.
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Methods
We carried out an individually randomised, multicentre controlled trial in which we compared biofeedback
pelvic floor muscle training with basic pelvic floor muscle training for women with stress or mixed urinary
incontinence to assess superiority. The allocation ratio was 1 : 1. The allocation was carried out remotely
via a web-based automated application, with minimisation by type of urinary incontinence, centre, age and
urinary incontinence severity at baseline. A sample size of 600 women was needed to detect a difference
of 2.5 points on the primary outcome measure between the groups, with 90% power and 5% significance
level, assuming a standard deviation of 10 and allowing for attrition of > 20%.
Participants were recruited from UK centres in community and outpatient care settings, where continence
care is usually provided. During the trial recruitment period, women attending for their first continence
appointment were identified by the health-care team at each centre. Eligibility was assessed by a clinician
who saw the woman at a screening appointment, which included a vaginal examination. The inclusion
criteria were being female, being aged ≥ 18 years and newly presenting with stress or mixed urinary
incontinence. Women excluded were those with urgency urinary incontinence alone, those who had received
formal instruction in pelvic floor muscle training in the previous year, those unable to contract their pelvic
floor muscles, those who were pregnant or < 6 months postnatal, those with prolapse greater than stage II,
those currently having treatment for pelvic cancer, those with cognitive impairment affecting capacity to give
informed consent, those with neurological disease, those with a known nickel allergy or sensitivity and those
currently participating in other research relating to their urinary incontinence.
The primary outcome measure was severity of urinary incontinence at 24 months post randomisation, as
measured by the validated International Consultation on Incontinence Questionnaire – Urinary Incontinence
Short Form. Interim follow-ups were conducted at 6 and 12 months. Secondary outcome measures included
number of participants who were cured/improved, uptake of other treatment for urinary incontinence,
presence of other pelvic floor symptoms (bladder, bowel, prolapse), self-efficacy for and adherence to pelvic
floor muscle training, and quality of life. Resource use data were collected by participant self-report at the
follow-up time points. The primary health economic outcome measure of cost-effectiveness was incremental
cost per quality-adjusted life-year at 24 months.
Participants were offered six appointments with a trained therapist over 16 weeks, during which the trial
intervention (biofeedback pelvic floor muscle training or basic pelvic floor muscle training) was delivered.
Biofeedback units were provided to participants in the biofeedback pelvic floor muscle training group for
home use. A written intervention manual was prepared for the therapists to guide intervention delivery.
A checklist was provided for each appointment, detailing the intervention components to be delivered.
Behaviour change techniques, both core and optional, were built in to the intervention protocols delivered
(e.g. to help participants with goal-setting, action-planning and problem-solving).
As part of the process evaluation, therapists delivering the intervention at each centre were interviewed.
In addition, to record their delivery of the intervention, therapists completed an intervention checklist at
every appointment with a participant. A selection of appointments from across centres, where therapists
were delivering the trial interventions, were audio-recorded. A subset of participants took part in a
longitudinal case study and were interviewed at baseline and at 6, 12 and 24 months. These interviews
were transcribed and analysed at different levels: within time points, within-case, cross-case and between
trial groups. Quantitative descriptive summaries and framework analysis methods were used to analyse
these mixed-methods data sets.
Results
Twenty-three centres agreed to take part in the trial and 687 women were screened for eligibility:
a total of 600 women were randomised (300 women to the biofeedback pelvic floor muscle training
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group and 300 women to the basic pelvic floor muscle training group). The two randomised groups were
comparable at baseline. Follow-up questionnaire return rates were 74% at 6 months, 84% at 12 months
and 78% at 24 months. Adherence to the intervention appointments was good: 92% attended at least
one appointment (95% biofeedback pelvic floor muscle training, 89% basic pelvic floor muscle training)
and 36% attended all six appointments (37% biofeedback pelvic floor muscle training, 36% basic pelvic
floor muscle training). The average number of appointments attended was 4.1 (4.2 biofeedback pelvic
floor muscle training, 4.0 basic pelvic floor muscle training).
The primary analysis indicated that there was no difference between groups in the severity of urinary
incontinence at 24 months (mean difference –0.09, 95% confidence interval –0.92 to 0.75; p = 0.84).
This finding was robust to sensitivity analysis that investigated assumptions about non-compliance and
missing data. There were no significant differences between groups in the primary outcome within
the predefined subgroups of type of urinary incontinence, age, baseline severity or type of therapist.
There were no significant differences between groups in International Consultation on Incontinence
Questionnaire Urinary Incontinence Short Form score at 6 or 12 months.
The analysis of secondary outcomes indicated no significant differences between groups, at any time point,
in urinary incontinence cure or improvement, other lower urinary tract symptoms, condition-specific quality
of life, participant impression of improvement, uptake of further treatment for urinary incontinence, pelvic
floor function, prolapse symptoms or bowel symptoms. The biofeedback pelvic floor muscle training group
had statistically significantly better scores for self-efficacy for pelvic floor muscle exercises at 24 months,
but the difference was small and unlikely to be clinically significant.
There were 48 participants who had a non-serious adverse event (34 biofeedback pelvic floor muscle training,
14 basic pelvic floor muscle training), of whom 23 (21 biofeedback pelvic floor muscle training, 2 basic pelvic
floor muscle training) had a complication related or possibly related to one of the interventions. There were
eight serious adverse events (6 biofeedback pelvic floor muscle training, 2 basic pelvic floor muscle training),
all of which were unrelated.
The base-case economic analysis concluded that, at 24 months, biofeedback pelvic floor muscle training
(£956) was not significantly more expensive than basic pelvic floor muscle training (£906) (mean difference
£50, 95% confidence interval –£84 to £184), but neither was it associated with significantly more quality-
adjusted life-years (1.567 vs. 1.566, mean difference –0.0009, 95% confidence interval –0.06 to 0.06).
The incremental cost-effectiveness ratio of £56,617 per quality-adjusted life-year gained exceeded society’s
willingness-to-pay threshold of £30,000. Biofeedback pelvic floor muscle training was associated with a
49% chance of being cost-effective if society was willing to pay £30,000 for a quality-adjusted life-year.
The process evaluation had two key findings. First, therapists did deliver a more intensive intervention to
the biofeedback pelvic floor muscle training group, despite time pressures. Second, most participants
in both groups did receive core behavioural change techniques embedded in the basic pelvic floor muscle
training, as intended, but few optional behavioural change techniques were used by therapists in
either group.
Women from both groups who were interviewed reported positive experiences of the interventions received.
There was variation in adherence and urinary incontinence outcomes in both groups, with no clear differences
between groups. Factors that helped women adhere in the short and long term that were similar in both
groups were their desire to improve their continence, having the belief that they were able to undertake
pelvic floor muscle training and the expectation of what they might achieve in terms of symptoms and quality
of life. Adherence was facilitated by the therapists and their input was particularly valued. Having time
to undertake pelvic floor muscle training and ‘life taking over’ were important barriers to short- and
long-term adherence.
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Conclusions
Implications for health care
l We can be confident in concluding that the addition of biofeedback to pelvic floor muscle training
treatment does not improve incontinence severity at 2 years and is unlikely to be cost-effective.
Therefore, we think it unlikely that routinely offering this adjunct to pelvic floor muscle training will
benefit continence outcomes for women.
l It is feasible for the behaviour change techniques that were embedded in the basic pelvic floor muscle
training (which have evidence of effectiveness in other fields) to be used within the context of pelvic
floor muscle training for women with urinary incontinence.
Recommendations for research (in priority order)
l Investigate other intensive forms of pelvic floor muscle training to improve continence outcomes
(e.g. a pelvic floor muscle training programme with the addition of more health professional support).
l Establish if there is potential for evaluation of newer biofeedback devices in the context of treatment of
urinary incontinence.
Trial registration
This trial is registered as ISRCTN57746448.
Funding
Funding for this study was provided by the Health Technology Assessment programme of the National
Institute for Health Research.
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Chapter 1 Introduction
Scientific background and current evidence base
There are various options for the management of female urinary incontinence (UI), including behavioural
approaches, pelvic floor muscle training (PFMT), medication, surgery, nerve stimulation, injectable bulking
agents, a botulinum toxin injection to the bladder wall, vaginal continence pessaries and the use of
containment products, such as pads and catheters. These options may be used in combination.
Currently in the UK, supervised PFMT of at least 3 months’ duration is the first-line treatment for stress
urinary incontinence (SUI) and mixed urinary incontinence (MUI).1 ‘Supervised PFMT’ refers to a course of
treatment that involves one-to-one supervision by a health-care professional (usually a physiotherapist
or nurse) who carries out a digital vaginal examination to ensure that the woman can correctly contract
her pelvic floor muscles, and provides ongoing teaching, guidance and motivation relating to pelvic floor
muscle exercises (PFMEs). The potential annual spend on PFMT is estimated at £38M (0.03% of the NHS
budget of £106B), based on 0.8% of women aged ≥ 15 years being referred to UI services each year.2
PFMT refers to the regular practice of repeated and progressive pelvic floor muscle contractions in order to
produce a training effect on the muscles. The aim of a PFMT programme is to increase functionality of the
pelvic floor through several mechanisms, detailed by Bo et al.3
Adjuncts used with supervised PFMT in clinical practice include vaginal cones, electrical stimulation and
biofeedback. Biofeedback is the technique by which information about a normally unconscious physiological
process is presented to the patient and/or the therapist as a visual, auditory or tactile signal.4 Electromyography
(EMG) is the study of minute electrical potentials produced by depolarisation of muscle membrane.5 In EMG
biofeedback, which is the focus of this research, electrical activity arising from muscle activity (during exercise
and voluntary effort) is recorded in microvolts and displayed as a visual and/or auditory signal for both the
patient and therapist to view. In a PFMT programme, an internal vaginal or anal probe is used to record
electrical information from pelvic floor muscles through surface recordings. The probe is connected by cables
to a biofeedback unit. Handheld units, with a small visual display screen, are available for home use. The
display provides a visual representation of the muscles contracting and relaxing, allowing monitoring of
strength, endurance and repetitions.
Possible mechanisms for how biofeedback might improve continence
Biofeedback acts as a strong and specific training stimulus, which has the potential to markedly intensify
a training programme. This effect is evidenced in the biofeedback and general exercise literature.6 In this
report, the exercise being referred to is PFME. In the context of supervised PFMT for treatment of UI,
biofeedback contributes to:
l teaching women the precise, correct muscle contraction in terms of technique, force and timing, and
assisting the therapist in prescribing the correct exercise dose to ensure that appropriate physiological
responses occur in the muscles
l informing adjustments to the exercise prescribed by the therapist (modulating)
l highlighting to women improvements in their muscle function (encouraging)7
l increasing the quality of the interaction with the therapist (via biofeedback used in ways congruent with
health behaviour change theory and practice)
l change in women’s behaviour relating to home exercise, as biofeedback has been classified as a
behaviour change technique (BCT) in a taxonomy of BCTs.8
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These features have the potential to increase a woman’s confidence (self-efficacy) in doing PFMT; self-efficacy
for PFMT is a determinant of intention to adhere9 and adherence itself.10,11 For PFMT to have an effect on UI,
sufficient exercise must be carried out over a long enough period to strengthen (hypertrophy) the muscle.12
Thus, maximising adherence to exercise is key to an intensive PFMT intervention. Intensive PFMT, which fosters
PFMT self-efficacy, can potentially be achieved through the addition of biofeedback, leading to improvement in
the quality and quantity of PFMT performed by women, and to more improvement in the severity of their UI
than a less intensive programme.
Evidence for the effectiveness of biofeedback for female urinary incontinence
Both a Cochrane systematic review of biofeedback-assisted PFMT for women with UI7 and a Health
Technology Assessment-funded systematic review of non-surgical treatments for women with SUI13 found
that biofeedback-assisted PFMT appeared to offer benefit over basic PFMT alone. However, the Cochrane
review,7 with its more restricted scope, conducted a more detailed analysis of the biofeedback trials and
found that this effect may be confounded by the greater amount of health professional contact received
by women in the biofeedback groups.
Rationale for research
Based on current evidence, it is not clear if the apparent benefit of biofeedback can be attributed to the
biofeedback or to some other variable, such as additional health professional contact. Some of the trials in
the Cochrane review7 had the same PFMT programme in both arms of the trial and the same amount of
health professional contact. The results from these trials still favoured biofeedback, although the difference
between groups was not statistically significant. A common problem in all these trials was the failure to
clearly state the purpose of biofeedback, or to describe the intervention protocol. Thus, it was not clear if
biofeedback could, theoretically or in practice, change the clinical effectiveness of the PFMT. Currently, the
routine use of biofeedback as part of PFMT is not recommended and should be considered only for women
who are unable to contract their pelvic floor muscles.1 Despite this, we know that therapists use biofeedback
in their clinical practice as an adjunct to a supervised PFMT programme when treating female UI.14
Thus, a robust comparison of biofeedback-mediated intensive PFMT compared with basic PFMT, in which
both groups have the same basic PFMT programme and the same amount of health professional contact,
is imperative to establish whether or not biofeedback does add value and improve incontinence outcomes.
Aims and objectives
The overall aim of the Optimal Pelvic floor muscle training for Adherence Long-term (OPAL) trial was to
carry out a randomised controlled trial (RCT) to evaluate a theoretically based biofeedback-intensified
PFMT intervention to answer the primary research question: is biofeedback-mediated intensive PFMT,
compared with basic PFMT, a clinically effective and cost-effective treatment for women with SUI or
MUI (stress and urgency)?
The trial comprised the following components:
l Development of biofeedback-mediated intensive PFMT and basic PFMT interventions based on health
behaviour theory designed to treat SUI and MUI.
l A RCT in which the use of biofeedback as an adjunct to basic PFMT (biofeedback PFMT) was compared
with PFMT alone (basic PFMT), in terms of clinical effectiveness and cost-effectiveness.
l A process evaluation to identify and investigate the possible mediating factors that affect the effectiveness
of the interventions (including fidelity to intervention delivery and uptake), how these mediating factors
influence effectiveness and whether or not the factors differ between randomised groups.
l A longitudinal qualitative case study to investigate women’s experiences of the trial interventions, to
identify the barriers and facilitators that affect adherence, to explain the process through which they
influence adherence and to identify whether or not these differ between randomised groups.
INTRODUCTION
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Development of the OPAL trial interventions
The OPAL trial interventions (including biofeedback-mediated intensive PFMT and basic PFMT protocols)
were developed by Jean Hay-Smith, Doctor of Philosophy (PhD) (University of Otago, Dunedin, New Zealand);
Sarah G Dean, PhD (University of Exeter, Exeter, UK); Doreen McClurg, PhD [Nursing, Midwifery and Allied
Health Professions Research Unit (NMAHP RU) Research Unit, Glasgow Caledonian University (GCU),
Glasgow, UK]; Suzanne Hagen, PhD (NMAHP RU, GCU, Glasgow UK); Carol Bugge, PhD (University of Stirling,
Stirling, UK); and Joanne Booth, PhD (GCU, Glasgow, UK).
The OPAL trial interventions are essentially behavioural intervention (i.e. an intervention focusing on the
adoption and maintenance of a PFMT programme, with or without use of biofeedback). PFMT adherence
is problematic and often decreases over time.15 PFMT interventions typically include a number of ‘active’
ingredients that ‘interact’ (e.g. in the OPAL trial, the exercise and biofeedback ingredients are presumed to
interact to intensify PFMT) to produce an effect that is potentially greater than the sum of the parts. Thus,
the OPAL interventions had two core characteristics (behavioural difficulty and interacting components)
of a ‘complex’ intervention.16 A further element of complexity was the tailoring components within the
interventions, which allowed flexibility in delivery; these components have been called ‘optional’ in the
intervention protocols.
Four sources were used to develop the intervention:
1. theory consistent with our objective of changing health behaviour: the information motivation
behavioural skills (IMB) model17
2. existing qualitative evidence about women’s experiences of PFMT and why they did or did not adopt
the behaviour to undertake PFMT18
3. the explicit use of BCTs to support adoption and maintenance of the behaviour8
4. the existing PFMT intervention from the Pelvic Organ Prolapse PhysiotherapY (POPPY) trial,19 which
provided the outline for what therapists considered ‘basic’ PFMT in UK clinical practice.
Once developed, the intervention protocols to be delivered were detailed in the intervention manual,
which was given to each therapist. Separate protocols were available for biofeedback-mediated intensive
PFMT (referred to hereafter as biofeedback PFMT) and basic PFMT. In practice, the interventions were
delivered over six appointments with a trial therapist, which the participant attended. Details of the desired
content of each appointment were provided in the intervention manual and in checklist format in the
therapist assessment form (TAF), completed by the therapist at each appointment. This is described in
more detail in Chapter 3.
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Chapter 2 Trial design and methods
Trial design
The OPAL trial was designed to compare biofeedback PFMT with basic PFMT, in terms of long-term
continence severity [see the project web page: www.journalslibrary.nihr.ac.uk/programmes/hta/117103/#/
(accessed 29 July 2019)]. It included a superiority multicentre RCT comparing two treatment groups:
(1) PFMT with EMG biofeedback in clinic and at home (biofeedback PFMT) and (2) PFMT alone (basic PFMT)20
(see Chapter 3).
The main trial was supplemented with a separate economic evaluation (see Chapter 4), a process evaluation
(see Chapter 5) and a longitudinal qualitative case study (see Chapter 6). For a trial overview, see Appendix 1.
A published protocol is available for the process evaluation and case study.21
Ethics approval and research governance
Ethics approval for all aspects of the trial was granted by the West of Scotland Research Ethics Committee
4 on 13 March 2013 [reference number 13/WS/0048; see the project web page: www.journalslibrary.nihr.
ac.uk/programmes/hta/117103/#/ (accessed 29 July 2019)]. Overall research and development (R&D)
approval for the trial from NHS Research Scotland was granted on 24 January 2014 (reference number
NRS13/UR13) and from the National Institute for Health Research (NIHR) Co-ordinated System for gaining
NHS permission on 2 April 2014 (reference number 120377). Local NHS R&D approval for the trial was
granted by 16 different trusts in England, and six local health boards granted R&D approval for seven
centres in Scotland. The trial sponsor was GCU and the OPAL trial office was based in the NMAHP RU
at GCU. The OPAL trial is registered with the International Standard Randomised Controlled Trial
Register (ISRCTN57746448).
Management of the trial
A Project Management Group (PMG), made up of all co-applicants and research staff employed on the trial,
met regularly, face to face or by teleconference, to review the trial’s progress. An independent Trial Steering
Committee (TSC) and Data Monitoring and Ethics Committee (DMEC) met at least yearly to review trial
progress. Patient and public involvement in the trial was ensured by involvement in the development and
delivery of the trial, and membership of the PMG, of a lay person who had experience of treatment for
female UI. A second lay person was a member of the TSC.
Participants and setting
The trial recruited women with SUI or MUI from 23 centres across the UK, comprising hospital outpatient
and community settings.
Inclusion criteria
The trial included women:
l aged ≥ 18 years, presenting with a new episode of SUI or MUI.
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Exclusion criteria
The trial excluded women:
l with urgency UI alone
l who had received formal instruction in PFMT in the previous year
l not able to contract their pelvic floor muscles
l who were pregnant or < 6 months postnatal
l with a prolapse greater than stage II (i.e. > 1 cm below the hymen on valsalva)
l receiving active treatment for pelvic cancer
l with cognitive impairment affecting capacity to give informed consent
l who had the following neurological diseases: multiple sclerosis, Parkinson’s disease, stroke, motor
neurone disease, spinal cord injury
l with a known nickel allergy or sensitivity
l who were already participating in other research relating to UI.
Recruitment procedure
The research team at each centre was responsible for identifying potential participants from women newly
presenting with UI, with urinary leakage as the presenting complaint. A pre-screening process was used
to exclude women who were obviously not eligible and therefore not approached to be formally screened
at a clinic appointment. Screening could take place either at the first clinical presentation or a separate
appointment arranged to assess eligibility. During screening appointments, clinicians assessed women for a
clinical diagnosis of SUI or MUI and performed a vaginal examination to assess other trial eligibility criteria.
With ethics approval, these details, along with contact details, were recorded on the clinical assessment
form [see the project web page: www.journalslibrary.nihr.ac.uk/programmes/hta/117103/#/ (accessed
29 July 2019)]. Each potentially eligible woman was allocated a unique trial identity number that, if the
woman was recruited, was used throughout the trial in all the woman’s trial materials. Centre trial staff
discussed the trial with women who were eligible and willing to take part, provided a patient information
leaflet [see the project web page: www.journalslibrary.nihr.ac.uk/programmes/hta/117103/#/ (accessed
29 July 2019)], answered any questions and provided women with a consent form to complete [see the
project web page: www.journalslibrary.nihr.ac.uk/programmes/hta/117103/#/ (accessed 29 July 2019)].
Informed consent
Informed, written consent was sought after the women had received all trial information and after any
questions about participating had been answered. Copies of the completed consent form were held (1) by
the participating woman, (2) in their general practitioner’s (GP’s) notes, (3) at the centre and (4) at the trial
office. Women were provided with information about the process evaluation audio-recordings and the
linked case study [see the project web page: www.journalslibrary.nihr.ac.uk/programmes/hta/117103/#/
(accessed 29 July 2019)] and given the option of being approached to take part in these additional aspects
of the research (see Chapters 5 and 6).
Randomisation, concealment and blinding
Consenting participants were individually randomised to one of two groups: biofeedback PFMT or basic
PFMT. Group allocation was generated by the web-based randomisation service provided by the Centre
for Healthcare Randomised Trials (CHaRT), a UK Clinical Research Collaboration clinical trials unit, located
in the Health Services Research Unit, University of Aberdeen, Aberdeen, UK. A woman’s group allocation
was relayed by e-mail to the trial office and recruiting member of staff at the centre. Owing to the nature
TRIAL DESIGN AND METHODS
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of the intervention, blinded allocation was not possible for the participants and therapists delivering the
intervention. The data entry staff and statistician were not blinded, as some data collection forms were
intentionally different between groups, and this would be apparent to those staff processing the data.
However, clinicians performing the 6-month pelvic floor muscle assessments were blinded to group
allocation. Group allocation used minimisation based on four variables: UI type (SUI or MUI), recruiting
centre, age (< 50/≥ 50 years) and UI severity [International Consultation on Incontinence Questionnaire
Urinary Incontinence Short Form (ICIQ-UI SF) score of < 13 or ≥ 13].
Therapist training
To ensure consistency of expertise, all therapists received face-to-face training in delivery of both
interventions (biofeedback PFMT and basic PFMT, as described in Treatment group allocation) by OPAL trial
staff. They were also supplied with the OPAL trial intervention manual, providing a background to the
OPAL trial, and the OPAL intervention protocols, describing the health behaviour model adopted to
maximise intervention adherence.
Treatment group allocation
Both trial groups (biofeedback PFMT and basic PFMT)
In both groups, participants completed the basic PFMT protocol over a 16-week period:22 six individual
face-to-face appointments with a therapist were offered at weeks 0, 1, 3, 6, 10 and 15, based on a
previous trial of PFMT.19 At the first appointment the therapist performed a vaginal examination, including
visual inspection and digital assessment of the pelvic floor muscles (the Oxford Classification,23 and the
International Continence Society method24).
During this assessment, all participants were taught how to contract and relax their pelvic floor muscles
and how to pre-contract their pelvic floor muscles prior to (and in expectation of) increases in abdominal
pressure, such as coughing and sneezing (‘the Knack’25).
Based on the findings of the assessment, the therapist and participant agreed a PFMT programme, tailored
according to the woman’s ability and lifestyle, which progressed over time. The PFMT programme focused
on strength and endurance, aiming for three sets of contractions per day, progressed by increasing the
number of repetitions, hold duration and body position modification on progression (i.e. lying, sitting,
standing, squatting).
As per local practice, therapists provided participants with information to support good bladder management
and methods of dealing with urgency and frequency. Therapists also used the BCTs that had been mapped
to, and detailed in, the intervention protocols to encourage participants’ adherence to the PFMT programme.
Participants recorded the PFMT they performed in a diary [see the project web page: www.journalslibrary.
nihr.ac.uk/programmes/hta/117103/#/ (accessed 29 July 2019)].
No EMG biofeedback equipment was used during appointments for the basic PFMT group. Verbal
feedback based on digital vaginal palpation was, however, permitted.
Biofeedback PFMT
In addition to the basic PFMT protocol provided to both groups [see Both trial groups (biofeedback PFMT
and basic PFMT)], women randomised to the biofeedback PFMT group received a biofeedback protocol
during appointments and were provided with a biofeedback unit to use at home. Biofeedback units
were provided by the trial office and the same type of unit was used during appointments and at home
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[NeuroTrac® Simplex single-channel EMG biofeedback unit (Verity Medical Ltd, Romsey, UK)]. The
biofeedback unit displayed participants’ pelvic floor muscle activity, providing audio and visual feedback
on muscle contraction and relaxation. Participants were instructed how to insert, use and clean the
probe, operate the unit and interpret the biofeedback information. Therapists set the parameters of the
biofeedback unit and agreed with participants the frequency for use at home. The units stored data on
home usage and participants also recorded their home use (and PFMT practice) in a diary.
Data collection and management
Baseline characteristics were recorded for each participant, including age, body mass index, number of
births and delivery mode (number of breech, caesarean, forceps, normal vaginal and vacuum deliveries)
and type of UI and severity (normal, mild, moderate, severe). Participants also recorded their urinary
leakage at baseline in a 3-day bladder diary [see the project web page: www.journalslibrary.nihr.ac.uk/
programmes/hta/117103/#/ (accessed 29 July 2019)].
Baseline and 6-, 12- and 24-month data were collected via questionnaire booklets completed by the
participants, containing the primary and secondary outcome measures [see the project web page:
www.journalslibrary.nihr.ac.uk/programmes/hta/117103/#/ (accessed 29 July 2019)]. See Appendix 2
for an overview of the time points of when participant data were collected via questionnaires.
At each appointment, participants were given a diary to record the PFMT carried out (and biofeedback use,
where appropriate), during the intervention period. Participants had the telephone number of their
therapist written on their diary so they could make contact if there were any concerns about the home
exercise programme.
At a participant’s first appointment, therapists recorded demographic information, medical history and
pelvic floor assessment findings in the TAF. At each subsequent appointment the therapist used the TAF
to record pelvic floor assessment findings, the treatment plan, the prescribed PFMT programme and the
participant’s adherence.
Participants attended an appointment at 6 months for a further pelvic floor assessment. This was undertaken
by an assessor who was blinded to the participant’s group allocation and had not been involved in treatment
delivery. Blinding was achieved by instructing participants in their appointment letter not to discuss their
allocated treatment group with the assessor until after the assessment was complete. Assessors were
directed in a trial standard operating procedure to remind participants not to discuss their trial treatment
until after the examination. Assessors also recorded whether or not they had been aware of a participant’s
group when carrying out the examination and, if so, to provide details.
Researchers at the trial office entered the data described above into the trial database, developed by CHaRT.
Participant follow-up
The duration of follow-up was 24 months from date of randomisation. It is important to assess duration of
effect; previous trials typically measured outcomes immediately post treatment or followed up participants
for a maximum of only 1 year. Follow-up questionnaires were sent from the trial office by post or e-mail to
participants, with postal, e-mail and telephone reminders. During telephone reminder calls, participants
could verbally complete a shortened version of follow-up questionnaires, including ICIQ-UI SF, EuroQol-5
Dimensions, three-level version (EQ-5D-3L), and questions about PFMT adherence and UI treatment uptake
[see the project web page: www.journalslibrary.nihr.ac.uk/programmes/hta/117103/#/ (accessed 29 July 2019)].
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The primary outcome was the ICIQ-UI SF score at 24 months. This met with the commissioning brief from the
funder, which highlighted symptom severity as an important outcome and 2 years as the minimum duration
of follow-up. The ICIQ-UI SF26 is a four-item questionnaire (total score ranging from 0 to 21, with higher
scores indicating greater severity), covering frequency of UI (never = 0, once a week = 1, two or three times a
week = 2, once a day = 3, several times a day = 4, all the time = 5), amount of leakage (none = 0, small = 2,
moderate = 4, large = 6), overall impact of UI (not at all = 0, a great deal = 10) and a diagnostic question to
identify type of UI. Responses to the first three questions are summed to give the total score. The maximum
score is 21; the higher the score, the more severe the UI, with a score of ≥ 13 rated as severe.27
Secondary outcomes
Urinary outcomes
The number of women with UI cured and improved was derived from the ICIQ-UI SF (cured = negative
response to both ‘how often do you leak urine?’ and ‘how much urine do you usually leak’; improved = a
reduction in ICIQ-UI SF score of ≥ 3 points).28 The Patient Global Impression of Improvement (PGI-I), which
has been validated for use in females with UI,29 was completed to assess perceptions of improvement in UI.
The PGI-I enabled participants to describe their UI at each time point compared with the start of the trial,
using a 7-point scale from 1 (‘very much better’) to 7 (‘very much worse’). The International Consultation
on Incontinence Questionnaire for Female Lower Urinary Tract Symptoms (ICIQ-FLUTS)30 was completed to
capture other urinary symptoms (nocturia, urgency, frequency, SUI, unexplained UI, bladder pain, diurnal
frequency, hesitancy, straining, intermittency and enuresis), comprising 12 items, each scored 0–4, and
three subscales [filling score (range 0–16), voiding score (range 0–12) and incontinence score (range 0–20)].
Participants completed questions assessing uptake of other treatment and use of services for UI: hospital
admission, outpatient appointment, GP consultation, nurse appointment, physiotherapy appointment,
surgery, medication and other treatment/medical advice.
Quality-of-life outcomes
Condition-specific quality of life was measured using the International Consultation on Incontinence
Questionnaire for Lower Urinary Tract Symptoms Quality of Life (ICIQ-LUTSqol),31 which has 19 items,
each scored from 1 to 4 (range 19–76). General health was measured using the EQ-5D-3L questionnaire32
(range –0.594 to 1) and the EuroQol-5 Dimensions (EQ-5D) visual analogue score (range 0–100).
Pelvic floor-related outcomes
Pelvic floor outcomes were assessed using four different measurements: (1) the pelvic organ prolapse
symptom score (POP-SS), a seven-item questionnaire measuring prolapse symptoms;33 (2) bowel symptoms
were assessed via an unpublished early version of the International Consultation on Incontinence Questionnaire
Bowel Short Form, comprising six items covering frequency and consistency of bowel movement; (3) the
Oxford Classification23 was used by therapists to quantify pelvic floor muscle strength on a 6-point scale,
as well as contraction endurance and repetitions; and (4) therapists also used the International Continence
Society classification for muscle relaxation (absent, partial, complete) and contraction (absent, weak,
normal, strong).24
Self-efficacy for PFMT
Women’s self-efficacy for PFMT was assessed using the PFME self-efficacy scale,34 a 17-item self-report scale
comprising two factors: (1) belief in PFME execution and its benefits (11 items); and (2) belief in performing
PFME as scheduled and despite barriers (six items). Items are scored from 1 (strongly disagree) to 5 (strongly
agree). Higher scores are associated with a woman perceiving that she has greater confidence in her ability
to perform PFMEs.
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Adherence to PFMT
Adherence to performing PFMT and the use of biofeedback was captured through the number of
appointments attended, participants completing PFMT diaries during the 16-week intervention period,
information in the TAFs on whether or not the recommended intervention protocol had been followed and
participants’ responses to questions in the follow-up questionnaires. Additional understanding of perceived
outcomes, self-efficacy and adherence was gained through the process evaluation (see Chapter 5) and
case study (see Chapter 6).
Economic-related outcomes
The primary health economic outcome measure of cost-effectiveness was incremental cost per quality-adjusted
life-year (QALY) at 24 months, based on responses to the EQ-5D-3L. This incremental cost-effectiveness
ratio (ICER) was defined by the difference in cost between two trial interventions, divided by the difference
in their effect.
Secondary outcomes were (1) the cost of resources used by participants, including the use of primary
(GP services) and secondary (outpatient visits, inpatient stay, surgical interventions for incontinence) care
services, and further referral for subsequent additional specialist management; (2) the personal costs to
the participants, including costs of travelling to appointments and work/social restrictions; and (3) QALYs
derived using the ICIQ-LUTSqol responses.
Full cost-effectiveness methods are described in detail in Chapter 4.
Adverse events
The interventions delivered in the trial are well established clinically; therefore, any adverse events (AEs)
may commonly be found in women receiving PFMT and biofeedback. Expected AEs arising from the
interventions were:
l sore pelvic floor muscles
l lower back pain
l vaginal irritation or discomfort
l thrush
l urinary tract infection
l spotting or staining (not linked to menstruation), potentially caused by biofeedback probe insertion
l vaginal itchiness and discomfort (potentially linked to biofeedback probe if nickel sensitivity/allergy)
l psychological distress from vaginal examination and/or use of biofeedback probe (e.g. as a result
of previous abuse or distressing labour).
All AEs (for which the participant sought health-care professional interventions) and serious adverse
events (SAEs) (an untoward medical occurrence in a participant, including death, life-threatening conditions,
hospitalisation or prolonging of existing hospitalisation, persistent or significant disability or incapacity,
a congenital anomaly or birth defect, and any event considered medically significant by the investigator) were
assessed to determine cause, severity and relatedness, and were reported to the relevant regulatory bodies.
Serious adverse events were reported to the main Research Ethics Committee if they occurred within 30 days
of the woman’s previous therapy appointment and were, in the opinion of the chief investigator or the
chairperson of the DMEC, related to trial participation (resulted from the administration of any of the
research procedures) and unexpected (not listed in the protocol as an expected occurrence). In additional,
SAE forms were used to record deaths from any cause during the course of the trial.
TRIAL DESIGN AND METHODS
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Sample size
There were no published long-term outcome data for our primary outcome measure to inform our sample
size calculation; thus, we referred to studies reporting baseline ICIQ-UI SF data for women with SUI/MUI.35,36
These studies indicated a standard deviation (SD) of 5, but we expected that the SD at the 24-month time
point in the trial could possibly be as high as 10. A minimal clinically important difference of 2.5 points on
the ICIQ-UI SF score was assumed (a change in frequency of urine leakage of, e.g., ‘once a day’ to ‘never’),
based on a study of older women available at the time.37 On this basis, a sample size of 234 participants per
group would detect this difference, with 90% power at a significance level of 0.05. Allowing for a 22%
dropout, a target of 300 women per group was set.
Statistical methods
The analysis was based on an intention-to-treat (ITT) principle, in which participants were analysed
according to their randomised group, regardless of the intervention received. All outcomes were described
with the appropriate descriptive statistics: means and SDs for continuous outcomes, counts and percentages
for dichotomous and categorical outcomes.
The analysis of the primary outcome estimated the mean difference [with 95% confidence intervals (CIs)]
in the ICIQ-UI SF score at 24 months between the biofeedback PFMT group and the basic PFMT group,
using a linear mixed model, adjusting for the minimisation covariates of therapist type (physiotherapist or
other type of therapist) and baseline score. Recruiting centre was fitted as a random effect. Assumptions
of linearity and normality of error distributions were examined by inspection of residual plots. Statistical
significance was at the 5% level. Equivalent analyses were conducted for the ICIQ-UI SF score at
6 and 12 months.
The effect of missing ICIQ-UI SF data was investigated under various assumptions in a set of sensitivity
analyses. Multiple imputation and repeated-measures models were analysed under a missing at random
assumption. Pattern mixture models were then used under a missing not at random (MNAR) assumption. In
these analyses, the imputed ICIQ-UI SF scores were first adjusted by adding 2.5 points (the minimal clinically
important difference) and then by subtracting 2.5 points. These adjustments were then repeated in only one
group and repeated again by applying the adjustments in only the other group. A further sensitivity analysis
of the primary outcome was conducted, which took non-compliers into account, using a complier-average
causal effect (CACE) model.
Secondary outcomes were analysed in a similar manner to the analysis of the ICIQ-UI SF, using appropriate
generalised linear models (GLMs) (linear mixed models for continuous outcomes, binary logistic regression
for dichotomous outcomes and ordinal logistic regression for ordered categorical outcomes). When ordinal
models were fitted, the proportional odds assumption was examined using a Brant test. All models adjusted
for minimisation variables, therapist type and, if measured, baseline score.
Subgroup analyses of the primary outcome by type of incontinence (SUI or MUI), type of therapist, participant
age (< 50/≥ 50 years) and UI severity (ICIQ-UI SF score of < 13 or ≥ 13) were also conducted. A stricter level of
statistical significance (1%) was set for the subgroup analyses, reflecting their exploratory nature. Heterogeneity
of treatment effects among subgroups was tested for, using the appropriate subgroup by treatment
group interactions.
The analysis of the trial data were conducted according to the statistical analysis plan [see the project web
page: www.journalslibrary.nihr.ac.uk/programmes/hta/117103/#/ (accessed 29 July 2019)], which was
written by investigators blinded to accruing outcome data and agreed by the DMEC and the TSC. The
DMEC reviewed confidential reports of accumulating data and a single main analysis was performed at
the end of the trial when 24-month follow-up was complete and the database locked. We did not plan
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or conduct any interim analyses of outcome data, based on a decision made at the beginning of the trial
and following discussion with the DMEC. Deviations from the statistical analysis plan are documented [see
the project web page: www.journalslibrary.nihr.ac.uk/programmes/hta/117103/#/ (accessed 29 July 2019)].
Important changes to the project protocol
The original protocol included the following exclusion criterion: women who were pregnant or were < 1 year
postnatal. This was subsequently relaxed to women who were < 6 months postnatal. This recognised that
any natural resolution of postnatal UI would occur within the first 6 months and, therefore, beyond this time
point women should be eligible for inclusion. The original criteria: women who have had formal instruction
in PFMT in the previous 3 years was changed to in the previous year. Memory of PFMT instruction given
more than 1 year ago was thought likely to be poor; therefore, these women would be similar to women
who had not received instruction before. Women taking antimuscarinic medication were originally excluded;
however, this did not reflect current clinical practice, so inclusion criteria were changed to enable women
using this medication to take part. Furthermore, an additional criterion was agreed, excluding women with
a known nickel allergy or sensitivity, as such women, if randomised to the biofeedback PFMT group, might
experience irritation due to the biofeedback probe. A nickel-free probe could have been sourced for these
women, but they were not routinely stocked by the NHS and we did not procure them because of the cost.
The original protocol specified that participants would be asked to complete a 3-day bladder diary at
24 months to quantify urine leakage. This aspect of data collection was stopped because of a poor response
rate and the observation that it was impeding responses to the 24-month questionnaire (which was sent to
participants at the same time) and having a negative impact on the primary outcome data completeness.
All changes to the protocol were approved by the TSC and DMEC, when appropriate, and the Research
Ethics Committee.
TRIAL DESIGN AND METHODS
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Chapter 3 Trial outcomes and results
This chapter reports the results of the trial analysis set out in the statistical analysis plan [see the projectweb page: www.journalslibrary.nihr.ac.uk/programmes/hta/117103/#/ (accessed 29 July 2019)].
Participants
The OPAL trial recruited to target, with 600 participants randomised (300 to each group) between
February 2014 and July 2016 (Figure 1). The trial had planned to recruit to target by November 2015, but
the recruitment phase needed to be extended in order to randomise the required number of participants.
Participants were recruited at 23 centres across the UK (see Appendix 3).
A total of 687 women were formally screened for eligibility, of whom 87 were ineligible or declined
to participate (see Appendix 4 for details of ineligibility). Of the eligible 629 women, 29 consented to
participate but did not attend the subsequent appointment at which they would have been randomised.
These women were therefore excluded from the trial, leaving 600 women who were randomised.
All outcome data were returned and entered by 4 June 2018, the date of agreed database lock.
Questionnaires were completed by 589 participants (98%) at baseline (292 in the biofeedback PFMT group
and 297 in the basic PFMT group). Seven out of 600 participants withdrew consent to their data being used
after randomisation, leaving 295 participants in the biofeedback PFMT group and 298 participants in the
basic PFMT group included in the analysis (although the data for participants who withdrew are included
in the summary of the baseline characteristics). At 6 months, 444 participants (74%) provided follow-up
























































































































































FIGURE 1 Projected and actual recruitment.
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(78%) set out in the sample size calculation was achieved, with 230 (77%) in the biofeedback PFMT group
and 238 (79%) in the basic PFMT group. Of those women who were followed up, the proportions of
participants who completed the full questionnaire (rather than a shortened version over the telephone)
were 82%, 75% and 72% at 6, 12 and 24 months, respectively. The response rates were similar between
the two groups at each follow-up time point, for both methods of response. No participants died during the
course of the trial. The number of participants at each stage of the trial is summarised in the Consolidated
Standards of Reporting Trials (CONSORT) flow diagram (Figure 2).
Baseline characteristics
Table 1 summarises the baseline characteristics of participants. The age of participants ranged from 20
to 83 years, with a mean age of 47 years (48.2 ± 11.6 years in the biofeedback PFMT group and 47.3 ±
11.4 years basic PFMT group); 61.3% of participants in each group had MUI (SUI and urgency UI).
Baseline UI measures are reported in Table 2. The ICIQ-UI SF score (the primary outcome measure) ranged
from 0 to the maximum of 21. Approximately half of the participants (51%) had UI at baseline that could
be classed as severe (ICIQ-UI SF score of ≥ 13).27 For the Patient Global Impression of Severity (PGI-S)
scale, 55% of participants reported a rating of moderate or severe. Baseline pelvic floor measures show
that < 8% of participants had an Oxford Scale score of ≥ 4 for slow contraction strength (Table 3). The
Oxford Scale is measured from 0 to 5, with higher scores indicating stronger muscle function.23 The mean
self-efficacy for PFMT score was 62 (measured on a scale from 17 to 85, with higher scores indicating
stronger beliefs in ability to exercise)34 and 48% reported doing pelvic floor exercises at least one a week
during the month prior to their participation in the trial.
Intervention received
The proportion of participants attending the maximum number of six appointments was 36.9% in the
biofeedback PFMT group and 35.6% in the basic PFMT group (Table 4). The mean number of appointments
was 4.2 ± 1.9 (biofeedback PFMT) and 4.0 ± 2.1 (basic PFMT). Forty-nine out of 593 women (8.3%) did not
attend any appointments [n = 16 (5.4%) biofeedback PFMT; n = 33 (11.1%) basic PFMT].
The majority of participants (84.8%) were treated by only physiotherapists (86.8% biofeedback PFMT,
82.9% basic PFMT), with the remainder mostly being treated by only nurses. In most cases, the participant
was treated by the same therapist throughout. There were 13 participants whose therapist type is classified
as ‘other and mixture’, which included participants treated either by a midwife, a consultant or a mixture
of different therapist types. All therapists participating in the trial were female.
According to our a priori definition, participants were classed as receiving ‘treatment as allocated’ (i.e.
compliant with protocol or ‘on-treatment’) if pelvic floor muscle contractions were taught and feedback
was given (at the first appointment), and a recommended exercise programme was written in the home
exercise diary and given to the participant (during at least one appointment). In addition, participants in the
biofeedback PFMT group were required to be taught insertion and removal of the probe and placement of
the electrode at the first appointment in order to be classed as having treatment as allocated. This protocol
compliance rate was 74.4% (198/266) in the biofeedback PFMT group and 83.3% (230/276) in the basic
PFMT group. In a post hoc analysis, the definition for the biofeedback PFMT group was relaxed to allow
for training in the use of the biofeedback device during either the first or second appointment, which
reflected more accurately the instructions provided to therapists. Mostly, this was because it was not always
possible to fit everything into the first appointment, but sometimes it was a clinical judgement that it was
not appropriate for the participant; thus, therapists were told that biofeedback could be initiated in the
second appointment. This revised definition resulted in a protocol compliance rate of 83.5% (222/266)
TRIAL OUTCOMES AND RESULTS





• Responded, n = 292 (97%)
Appointment 1
• Invited, n = 295
• Attended, n = 279 (95%)
Appointment 2
• Invited, n = 276
• Attended, n = 245 (89%)
Appointment 3
• Invited, n = 255
• Attended, n = 198 (78%)
Appointment 4
• Invited, n = 268
• Attended, n = 185 (69%)
Appointment 5
• Invited, n = 227
• Attended, n = 156 (69%)
Appointment 6
• Invited, n = 224
• Attended, n = 182 (81%)
6-month questionnaire
• Responded, n = 221 (74%)
   (long, n = 184; short, n = 37)
12-month questionnaire
• Responded, n = 250 (83%)
   (long, n = 190; short, n = 60)
24-month questionnaire
• Responded, n = 230 (77%)














• Responded, n = 297 (99%)
Appointment 1
• Invited, n = 298
• Attended, n = 265 (89%)
Appointment 2
• Invited, n = 264
• Attended, n = 235 (89%)
Appointment 3
• Invited, n = 241
• Attended, n = 189 (78%)
Appointment 4
• Invited, n = 254
• Attended, n = 175 (69%)
Appointment 5
• Invited, n = 224
• Attended, n = 166 (74%)
Appointment 6
• Invited, n = 211
• Attended, n = 175 (83%)
6-month questionnaire
• Responded, n = 223 (74%)
   (long, n = 180; short, n = 43)
12-month questionnaire
• Responded, n = 254 (85%)
   (long, n = 187; short, n = 67)
24-month questionnaire
• Responded, n = 238 (79%)
   (long, n = 171; short, n = 67)
Withdrew consent
(n = 2)
FIGURE 2 The CONSORT flow diagram.
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TABLE 1 Baseline characteristics
Variable
Treatment group
Biofeedback PFMT Basic PFMT
Age (years), n, mean (SD) 300, 48.2 (11.6) 300, 47.3 (11.4)
BMI (kg/m2), n, mean (SD) 290, 28.6 (5.9) 287, 28.3 (6.2)
Number of births, n/N (%)
0 21/298 (7.0) 12/289 (4.2)
1 40/298 (13.4) 60/289 (20.8)
2 116/298 (38.9) 122/289 (42.2)
3 83/298 (27.9) 63/289 (21.8)
≥ 4 38/298 (12.8) 32/289 (11.1)
Delivery mode history, n/N (%)
Vaginal deliveries only 163/277 (58.8) 164/266 (61.7)
Caesarean deliveries only 11/277 (4.0) 15/266 (5.6)
Vaginal and caesarean deliveries 31/277 (11.2) 17/266 (6.4)
Any forceps delivery 52/277 (18.8) 55/266 (20.7)
Any vacuum delivery (but no forceps) 20/277 (7.2) 15/266 (5.6)
Type of incontinence, n/N (%)
SUI 116/300 (38.7) 116/300 (38.7)
MUI 184/300 (61.3) 184/300 (61.3)
BMI, body mass index.
TABLE 2 Urinary measures at baseline
Variable
Treatment group
Biofeedback PFMT Basic PFMT
ICIQ-UI SF, n, mean (SD) 291, 12.5 (4.1) 294, 12.3 (3.7)
ICIQ-UI SF severity, n/N (%)
Mild/moderate (score of < 13) 140/291 (48.1) 149/294 (50.7)
Severe (score of ≥ 13) 151/291 (51.9) 145/294 (49.3)
ICIQ-FLUTS filling score, n, mean (SD) 289, 5.0 (2.8) 297, 4.8 (2.6)
ICIQ-FLUTS voiding score, n, mean (SD) 292, 2.0 (2.0) 294, 2.0 (2.1)
ICIQ-FLUTS incontinence score, n, mean (SD) 290, 9.8 (3.6) 294, 9.3 (3.4)
PGI-S scale, n/N (%)
Normal 13/292 (4.5) 23/294 (7.8)
Mild 113/292 (38.7) 115/294 (39.1)
Moderate 137/292 (46.9) 133/294 (45.2)
Severe 29/292 (9.9) 23/294 (7.8)
ICIQ-LUTSqol, n, mean (SD) 292, 43.5 (12.3) 297, 42.3 (12.1)
ICIQ-LUTSqol bother scale, n, mean (SD) 288, 7.4 (2.6) 288, 7.6 (2.5)
PGI-S, Patient Global Impression of Severity.
All the urinary outcomes in this table are measures in which higher scores indicate greater symptom severity. The ICIQ-UI SF
has a possible range from 0 to 21, the ICIQ-FLUTS filling score ranges from 0 to 16, the ICIQ-FLUTS voiding score ranges
from 0 to 12, the ICIQ-FLUTS incontinence score ranges from 0 to 20, the ICIQ-LUTSqol ranges from 19 to 76 and the
ICIQ-LUTSqol bother scale ranges from 0 to 10.
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in the biofeedback PFMT group. There were some participants for whom compliance status could not be
determined due to missing checklist items in the TAFs.
Four participants randomised to the biofeedback PFMT group were given basic PFMT from the outset (in
error). Similarly, one participant was randomised to the basic PFMT group but received biofeedback PFMT.
TABLE 3 Pelvic floor measures at baseline
Variable
Treatment group
Biofeedback PFMT Basic PFMT
Prolapse symptoms: POP-SS, n, mean (SD) 274, 6.4 (5.7) 286, 6.7 (5.6)
Oxford Scale:a slow contraction strength, n/N (%)
0 0/300 (0.0) 0/300 (0.0)
1 34/300 (11.3) 31/300 (10.3)
2 115/300 (38.3) 111/300 (37.0)
3 128/300 (42.7) 134/300 (44.7)
4 22/300 (7.3) 24/300 (8.0)
5 1/300 (0.3) 0/300 (0.0)
Oxford Scale:a fast contraction strength, n/N (%)
0 0/238 (0.0) 0/220 (0.0)
1 11/238 (4.6) 14/220 (6.4)
2 75/238 (31.5) 73/220 (33.2)
3 108/238 (45.4) 102/220 (46.4)
4 38/238 (16.0) 28/220 (12.7)
5 6/238 (2.5) 3/220 (1.4)
Contraction endurance [length of hold (seconds)], n, mean (SD) 264, 6.48 (3.00) 250, 6.35 (3.13)
Number of repetitions slow, n, mean (SD) 263, 6.03 (2.44) 249, 5.77 (2.41)
Number of repetitions fast, n, mean (SD) 248, 8.24 (2.50) 239, 7.81 (2.64)
Self-efficacy scale for PFMT, n, mean (SD)b 280, 62.7 (9.7) 295, 62.2 (8.8)
Belief in PFMT execution 280, 38.9 (7.1) 295, 38.5 (6.3)
Belief in performing PFMT as scheduled 282, 23.8 (3.8) 294, 23.6 (3.8)
Frequency of PFMT in previous month, n/N (%)
None 116/287 (40.4) 119/295 (40.3)
Few times a month 37/287 (12.9) 32/295 (10.8)
Once a week 21/287 (7.3) 14/295 (4.7)
Few times a week 52/287 (18.1) 69/295 (23.4)
Once a day 32/287 (11.1) 32/295 (10.8)
Few times a day 29/287 (10.1) 29/295 (9.8)
a The Oxford scale ranges from 0 to 5; higher scores indicate greater strength.
b The self-efficacy scale has a possible range of 17–85 (with the subscales ranging from 11 to 55 and 6 to 30,
respectively). Higher scores indicate greater self-efficacy.
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The exercise programmes are summarised in Table 5. The mean recommended length of hold increased from
7.0 seconds in the biofeedback PFMT group and 6.8 seconds in the basic PFMT group to 10.4 seconds and
10.6 seconds, respectively, at the final appointment. The mean number of repetitions increased between the first
and last appointment from 7.6 to 8.9 (biofeedback PFMT group) and 6.7 to 9.0 (basic PFMT group). Similarly, the
mean number of fast contractions increased from 9.9 to 13.0 (biofeedback PFMT group) and 8.9 to 12.7 (basic
PFMT group). The recommended levels for endurance and repetitions at the first appointment appear to be
similar to the baseline levels summarised in Table 3. Table 5 also summarises the recommended daily frequency
for carrying out the whole set of exercises, which ranged between three and four times a day in both groups.
Primary outcome measure
The ICIQ-UI SF score at 24 months was the primary outcome measure in the trial (lower scores indicate
lower symptom severity). In the biofeedback PFMT group, the mean score was 8.2 (SD 5.1) compared with
8.5 (SD 4.9) in the basic PFMT group, with a mean difference (adjusted for baseline score and minimisation
covariates) of −0.09 (95% CI −0.92 to 0.75). There was therefore no evidence of a difference between
the groups in terms of UI symptoms. Similar results of no difference between groups were found at the
6- and 12-month time points (Table 6).
Sensitivity analyses
Analyses of the primary outcome to examine data under differing assumptions relating to non-compliance
and missing data all showed very similar results to the primary ITT analysis (Figure 3).
The first sensitivity analysis, which tested non-compliance in a CACE analysis (CACE1), treated participants
with an indeterminable compliance status as being compliant and the second analysis (CACE2) assumed
these participants to be non-compliant. The results of these analyses estimated mean differences of −0.11
(95% CI −1.05 to 0.82) and −0.13 (95% CI −1.20 to 0.95), respectively (see Figure 3).
TABLE 4 Appointment attendance and therapist type
Variable
Treatment group
Biofeedback PFMT Basic PFMT
Number of appointments attended, n/N (%)
0 16/295 (5.4) 33/298 (11.1)
1 20/295 (6.8) 18/298 (6.0)
2 24/295 (8.1) 22/298 (7.4)
3 37/295 (12.5) 33/298 (11.1)
4 33/295 (11.2) 22/298 (7.4)
5 56/295 (19.0) 64/298 (21.5)
6 109/295 (36.9) 106/298 (35.6)
Total number of appointments, n, mean (SD) 295, 4.2 (1.9) 298, 4.0 (2.1)
Type of therapist, n/N (%)
Physiotherapist 256/295 (86.8) 247/298 (82.9)
Nurse 17/295 (5.8) 11/298 (3.7)
Other and mixture 6/295 (2.0) 7/298 (2.3)
No therapist 16/295 (5.4) 33/298 (11.1)
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Biofeedback PFMT Basic PFMT
n Mean SD n Mean SD
Contraction endurance [length of hold
(seconds)]
1 262 7.0 3.9 257 6.8 3.5
2 238 7.7 4.0 230 7.8 4.9
3 186 8.3 3.9 187 9.1 7.8
4 181 9.5 4.5 172 9.6 5.6
5 150 10.1 5.1 158 10.9 9.9
6 176 10.4 6.3 172 10.6 6.8
Number of slow contractions (repetitions) 1 261 7.6 6.6 256 6.7 2.6
2 237 7.9 2.6 228 7.5 2.9
3 185 8.6 3.0 186 8.0 2.7
4 180 9.0 3.4 172 8.4 2.6
5 149 8.9 2.6 159 8.9 2.6
6 177 8.9 2.9 173 9.0 2.5
Number of fast contractions (repetitions) 1 251 9.9 5.8 251 8.9 4.2
2 226 10.7 6.2 220 10.3 5.0
3 173 11.5 6.5 181 11.9 6.3
4 176 12.5 9.3 164 12.6 7.0
5 146 12.6 7.4 154 13.2 10.6
6 174 13.0 10.1 167 12.7 6.6
Number of times per day 1 257 3.2 1.3 255 3.7 1.4
2 232 3.2 1.3 227 3.7 1.0
3 183 3.2 1.2 185 3.7 1.2
4 177 3.1 1.1 171 3.6 1.0
5 149 3.2 1.1 156 3.8 2.4
6 174 3.2 2.1 172 3.2 1.3
TABLE 6 Summary of ICIQ-UI SF responses and analysis of differences between groups (models correct for





Biofeedback PFMT Basic PFMT
n Mean SD n Mean SD
Baseline 291 12.5 4.1 294 12.3 3.7
6 months 221 9.0 5.0 221 8.8 4.5 0.39 –0.33 to 1.12
12 months 249 9.1 4.9 252 8.7 5.0 0.57 –0.17 to 1.31
24 months 225 8.2 5.1 235 8.5 4.9 –0.09 –0.92 to 0.75
Reproduced with permission from Hagen et al.38 This is an Open Access article distributed in accordance with the Creative
Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon
this work non-commercially, and license their derivative works on different terms, provided the original work is properly
cited and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/. The table includes minor
additions and formatting changes to the original table.
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The multiple imputation and the repeated-measures models, which both treat missing data as missing at
random, estimated mean differences of −0.11 (95% CI −0.95 to 0.74) and −0.08 (95% CI −0.86 to 0.70),
respectively (see Figure 3). The repeated-measures model also provided estimates at the intermediate time
points, which showed very similar results to the primary analysis: 0.28 (95% CI −0.51 to 1.07) at 6 months
and 0.57 (95% CI −0.19 to 1.33) at 12 months. None of the sensitivity analyses performed under MNAR
assumptions yielded results that contradicted the primary ITT analysis (see Appendix 5 and Figure 12).
An additional post hoc sensitivity analysis, in which therapist type was removed from the ITT analysis as
a covariate in the model (to address the potential bias of including an independent variable that was
measured post randomisation), gave a very similar result (mean difference −0.18, 95% CI −1.02 to 0.65).
Subgroup analyses
The prespecified subgroup analyses of the primary outcome showed no significant treatment by subgroup
interactions (Figure 4). Full results of the subgroup analysis are included in Appendix 6.
Urinary outcomes
The results of the analysis of the lower urinary tract symptoms data are summarised in Table 7. The outcome
measures used are all International Consultation on Incontinence Questionnaire measures,30,31 in which higher
scores indicate greater symptom severity or impact on quality of life. There were no significant differences
between the groups in any of the outcomes.
Measures of cure and improvement are summarised in Table 8. We defined ‘cure’ as being asymptomatic,
identified as a null response to the first two questions of the ICIQ-UI SF (amount and frequency of leakage).
Using this definition, 7.9% of participants in the biofeedback PFMT group and 8.4% of participants in the
basic PFMT group were asymptomatic at 24 months [odds ratio (OR) 0.90, 95% CI 0.46 to 1.78]. Three
participants in the basic PFMT group were asymptomatic according to this definition at baseline, but they all
reported non-zero scores on the ICIQ-UI SF scale for interference of UI with everyday life.
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FIGURE 3 Sensitivity analyses. MI, multiple imputation model; RMM, repeated-measures model. Reproduced with
permission from Hagen et al.38 This is an Open Access article distributed in accordance with the Creative Commons
Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon
this work non-commercially, and license their derivative works on different terms, provided the original work is
properly cited and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/. The figure includes
minor additions and formatting changes to the original figure.
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at 24 months 95% CI
Biofeedback PFMT Basic PFMT
n Mean SD n Mean SD
ICIQ-FLUTS filling score Baseline 289 5.0 2.8 297 4.8 2.6
6 months 183 3.7 2.7 176 3.4 2.3
12 months 187 3.8 2.7 186 3.6 2.4
24 months 167 3.4 2.6 168 3.5 2.3 –0.19 –0.61 to 0.24
ICIQ-FLUTS voiding score Baseline 292 2.0 2.0 294 2.0 2.1
6 months 182 1.6 1.8 179 1.4 1.8
12 months 188 1.5 1.9 186 1.5 1.8
24 months 165 1.6 1.8 169 1.6 1.8 0.04 –0.30 to 0.38
ICIQ-FLUTS incontinence
score
Baseline 290 9.8 3.6 294 9.3 3.4
6 months 182 7.1 4.0 178 6.6 3.8
12 months 188 7.1 3.9 182 6.6 4.1
24 months 164 7.0 4.3 169 6.5 4.0 0.20 –0.58 to 0.98
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0.28 (– 0.87 to 1.43)
1.03 (– 0.69 to 2.75)
1.15 (– 1.38 to 3.68)
– 0.24 (– 1.12 to 0.64)
– 1.39 (– 4.07 to 1.29)
– 0.09 (– 0.92 to 0.75)
– 0.80 (– 2.13 to 0.53)
0.38 (– 0.69 to 1.45)
1.18 (– 0.53 to 2.89)
FIGURE 4 Subgroup analyses. Reproduced with permission from Hagen et al.38 This is an Open Access article
distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license,
which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their
derivative works on different terms, provided the original work is properly cited and the use is non-commercial.
See: http://creativecommons.org/licenses/by-nc/4.0/. The figure includes minor additions and formatting changes
to the original figure.
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Biofeedback PFMT Basic PFMT
n N % n N %
Asymptomatic (cure) Baseline 0 292 0.0 3 297 1.0
6 months 12 221 5.4 13 223 5.8
12 months 16 250 6.4 22 253 8.7
24 months 18 229 7.9 20 238 8.4 0.90 0.46 to 1.78
Improvement in UI
(≥ 3-point reduction in
ICIQ-UI SF)
6 months 129 221 58.4 133 221 60.2
12 months 148 249 59.4 163 252 64.7
24 months 135 225 60.0 147 235 62.6 0.89 0.61 to 1.32
Very much better or
much better (PGI-I)
6 months 96 219 43.8 85 221 38.5
12 months 101 249 40.6 92 250 36.8
24 months 93 227 41.0 90 236 38.1 1.12 0.76 to 1.63
OR, odds ratio.
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at 24 months 95% CI
Biofeedback PFMT Basic PFMT
n Mean SD n Mean SD
ICIQ-LUTSqol Baseline 292 43.5 12.3 297 42.3 12.1
6 months 183 36.2 13.2 176 35.7 11.9
12 months 189 35.7 13.3 184 34.7 12.1
24 months 164 34.3 12.4 169 34.3 12.5 –0.81 –3.03 to 1.41
ICIQ-LUTSqol bother scale Baseline 288 7.4 2.6 288 7.6 2.5
6 months 183 4.3 3.1 177 4.3 2.8
12 months 189 4.0 3.1 184 3.9 3.0
24 months 163 3.8 3.1 169 3.7 2.9 0.26 –0.33 to 0.85
Reproduced with permission from Hagen et al.38 This is an Open Access article distributed in accordance with the Creative
Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon
this work non-commercially, and license their derivative works on different terms, provided the original work is properly
cited and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/. The table includes minor
additions and formatting changes to the original table.
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In terms of improvement, 60.0% of participants in the biofeedback PFMT group and 62.6% of participants
in the basic PFMT group (OR 0.89, 95% CI 0.61 to 1.32) had a reduction in their ICIQ-UI SF score between
baseline and 24 months by a margin of ≥ 3 points (equivalent to the estimated minimum clinically important
difference of ≥ 2.5 points).28 Comparing the PGI-I in UI (ordinal scale)29 also shows no difference between
groups at 24 months (OR 1.14, 95% CI 0.75 to 1.72). Full descriptive summaries of the PGI-I data are
reported (see Appendix 7). As a post hoc analysis, data from a dichotomous version of this scale were
compared between groups (see Table 8). At 24 months, 41.0% of participants in the biofeedback PFMT
group and 38.1% of participants in the basic PFMT group reported being much better or very much better
(OR 1.12, 95% CI 0.76 to 1.63), which resulted in a very similar effect estimate to the analysis of the full
ordinal PGI-I data (OR 1.14, 95% CI 0.75 to 1.72). When tested, the proportional odds assumption held in
the ordinal analysis.
Further treatment for urinary incontinence
Participants who accessed other treatments for UI (including surgery) were able to remain in the trial. Table 9
summarises the rates of surgical and non-surgical treatment for UI reported by participants. In the first 6 months
post randomisation, 1.2% of women in the biofeedback PFMT group and 1.8% of women in the basic PFMT
group had continence surgery (OR 0.56, 95% CI 0.09 to 3.53). This increased to 3.9% and 5.2%, respectively,
in the second 6 months (OR 0.63, 95% CI 0.23 to 1.69) and to 5.2% and 7.4%, respectively, during the second
year of follow-up (OR 0.62, 95% CI 0.24 to 1.65). The cumulative rate for UI surgery over the whole 2 years was
12.3% in the biofeedback PFMT group and 9.3% in the basic PFMT group (OR 1.25, 95% CI 0.35 to 4.46).
Rates of non-surgical treatments did not increase over the course of follow-up. There were high cumulative
rates of uptake over the 2-year follow-up period in both groups (81.7%, biofeedback PFMT; 79.7%, basic
PFMT, OR 1.35, 95% CI 0.54 to 3.41), although this measure includes a broad range of health-care use
for the treatment of UI, some resources of which were accessed frequently. For example, appointments
with either a continence nurse in secondary care or a physiotherapist were attended by 60.6% in the
biofeedback PFMT group and 53.8% in the basic PFMT group (Table 10).




Biofeedback PFMT Basic PFMT
n N % n N %
Surgery 0–6 months 2 172 1.2 3 164 1.8 0.56 0.09 to 3.53
6–12 months 8 204 3.9 11 210 5.2 0.63 0.23 to 1.69
12–24 months 8 154 5.2 12 162 7.4 0.62 0.24 to 1.65
0–24 months 10 81 12.3 8 86 9.3 1.25 0.35 to 4.46
Non-surgical treatment 0–6 months 96 146 65.8 107 149 71.8 0.77 0.46 to 1.28
6–12 months 70 164 42.7 74 159 46.5 0.90 0.56 to 1.42
12–24 months 40 105 38.1 42 119 35.3 0.65 0.65 to 2.03
0–24 months 49 60 81.7 55 69 79.7 1.35 0.54 to 3.41
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Pelvic floor outcomes
When self-efficacy for PFMT34 was compared, there was a small and statistically significant difference in favour
of the biofeedback PFMT group in the overall score (mean difference 2.36, 95% CI 0.04 to 4.68) (Table 11).
This difference appeared to be attributed more to the subscale for belief in PFMT and its execution, in which
there was also a small and statistically significant difference (mean difference 1.54, 95% CI 0.03 to 3.06).
There was no significant difference in the subscale for belief in performing PFMT as scheduled and despite
barriers (mean difference 0.71, 95% CI −0.31 to 1.72).
TABLE 10 Hospital admissions and non-surgical treatment for UI
Treatment Time point
Treatment group
Biofeedback PFMT Basic PFMT
Admitted to hospital, n/N (%) 0–6 months 3/180 (1.7) 2/179 (1.1)
6–12 months 4/180 (2.2) 4/175 (2.3)
12–24 months 3/111 (2.7) 1/130 (0.8)
0–24 months 6/84 (7.1) 3/94 (3.2)
Number of nights in hospital, n, mean (SD) 0–6 months 180, 0.02 (0.13) 179, 0.01 (0.11)
6–12 months 180, 0.06 (0.54) 175, 0.03 (0.26)
12–24 months 111, 0.04 (0.23) 130, 0.01 (0.09)
0–24 months 84, 0.16 (0.81) 94, 0.05 (0.34)
Hospital doctor appointment, n/N (%) 0–6 months 43/156 (27.6) 46/163 (28.2)
6–12 months 27/185 (14.6) 35/181 (19.3)
12–24 months 18/124 (14.5) 20/131 (15.3)
0–24 months 35/83 (42.2) 34/89 (38.2)
GP appointment, n/N (%) 0–6 months 46/183 (25.1) 65/183 (35.5)
6–12 months 32/187 (17.1) 29/186 (15.6)
12–24 months 18/125 (14.4) 21/132 (15.9)
0–24 months 37/99 (37.4) 48/100 (48.0)
GP nurse appointment, n/N (%) 0–6 months 13/180 (7.2) 6/180 (3.3)
6–12 months 16/178 (9.0) 11/183 (6.0)
12–24 months 8/127 (6.3) 6/128 (4.7)
0–24 months 14/96 (14.6) 10/94 (10.6)
Hospital nurse/physiotherapist appointment, n/N (%) 0–6 months 62/177 (35.0) 57/179 (31.8)
6–12 months 51/181 (28.2) 49/181 (27.1)
12–24 months 14/124 (11.3) 21/129 (16.3)
0–24 months 57/94 (60.6) 50/93 (53.8)
Medication, n/N (%) 0–6 months 32/209 (15.3) 34/204 (16.7)
6–12 months 32/234 (13.7) 38/232 (16.4)
12–24 months 30/168 (17.9) 28/174 (16.1)
0–24 months 35/125 (28.0) 36/128 (28.1)
Other treatment/advice, n/N (%) 0–6 months 25/208 (12.0) 29/201 (14.4)
6–12 months 22/229 (9.6) 27/232 (11.6)
12–24 months 12/208 (5.8) 15/221 (6.8)
0–24 months 35/157 (22.3) 35/162 (21.6)
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The results from the 6-month blinded pelvic floor muscle assessment are summarised in Table 12. At baseline,
there was only one participant who achieved the maximum score of 5 on the Oxford Scale for slow contraction
strength. At 6 months, there were 13 participants (8.5%) in the biofeedback PFMT group and 10 (6.0%) in
the basic PFMT group with a score of 5. There was no difference between the groups when the Oxford Scale
at 6 months was compared (OR 1.28, 95% CI 0.86 to 1.89; p = 0.22). The proportional odds assumption,
however, did not hold in this ordinal analysis.







Biofeedback PFMT Basic PFMT
n Mean SD n Mean SD
Self-efficacy scale for PFMT Baseline 280 62.7 9.7 295 62.2 8.8
6 months 172 65.6 10.2 165 65.7 10.1
12 months 178 63.7 11.0 180 64.1 10.2
24 months 154 63.1 11.6 161 60.9 12.0 2.36 0.04 to 4.68
Belief in PFMT execution
subscale
Baseline 280 38.9 7.1 295 38.5 6.3
6 months 173 42.7 7.0 166 42.3 6.8
12 months 179 41.7 7.3 180 41.6 6.6
24 months 156 41.3 7.8 162 39.8 7.9 1.54 0.03 to 3.06
Belief in performing PFMT as
scheduled subscale
Baseline 282 23.8 3.8 294 23.6 3.8
6 months 178 23.0 4.3 172 23.5 4.3
12 months 183 21.9 4.9 179 22.6 4.8
24 months 156 21.6 4.9 164 21.0 5.0 0.71 –0.31 to 1.72





Biofeedback PFMT Basic PFMT
Oxford scale: slow contraction strength, n/N (%) Baseline 0 0/300 (0.0) 0/300 (0.0)
1 34/300 (11.3) 31/300 (10.3)
2 115/300 (38.3) 111/300 (37.0)
3 128/300 (42.7) 134/300 (44.7)
4 22/300 (7.3) 24/300 (8.0)
5 1/300 (0.3) 0/300 (0.0)
6 months 0 0/153 (0.0) 0/166 (0.0)
1 4/153 (2.6) 3/166 (1.8)
2 25/153 (16.3) 23/166 (13.9)
3 57/153 (37.3) 74/166 (44.6)
4 54/153 (35.3) 56/166 (33.7)
5 13/153 (8.5) 10/166 (6.0)
continued
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For endurance and repetitions, the results at 6 months appear to be similar between groups and appear
to be slightly higher than baseline in both groups, although it should be noted that nearly half of the
participants did not attend the 6-month pelvic floor muscle appointment. Furthermore, at 6 months, the
observed results for endurance and repetitions appear to be slightly lower than the prescribed programme
at the end of the intervention period (see Tables 5 and 12).
Bowel and prolapse symptoms are summarised at each time point (see Appendix 8). No validated measure
for bowel symptoms was available, but the results are summarised for each question asked individually
(see Table 35). There was no evidence of any effect on prolapse symptoms with no difference between
groups in the POP-SS (mean difference −0.60, 95% CI −1.51 to 0.30) (see Table 36).
Adherence
Our prespecified definitions for adherence are described in the statistical analysis plan [see the project
web page: www.journalslibrary.nihr.ac.uk/programmes/hta/117103/#/ (accessed 29 July 2019)]. Table 13
summarises the levels of adherence to separate aspects of the intervention; there were no differences between
groups. Adherence to introductory teaching of PFMT and introduction to biofeedback (as appropriate) by
the therapist was 88% in each group (OR 0.69, 95% CI 0.33 to 1.42). Adherence to practising PFMT and
biofeedback use during appointments was just under 80% in each group (OR 0.89, 95% CI 0.63 to 1.25).
Adherence by participants to the recommended programme at home between appointments was also around
80% in each group (OR 0.71, 95% CI 0.43 to 1.16). Table 13 also summarises the frequency of appointments






Biofeedback PFMT Basic PFMT
Oxford scale: fast contraction strength, n/N (%) Baseline 0 0/238 (0.0) 0/220 (0.0)
1 11/238 (4.6) 14/220 (6.4)
2 75/238 (31.5) 73/220 (33.2)
3 108/238 (45.4) 102/220 (46.4)
4 38/238 (16.0) 28/220 (12.7)
5 6/238 (2.5) 3/220 (1.4)
6 months 0 1/133 (0.8) 0/152 (0.0)
1 2/133 (1.5) 2/152 (1.3)
2 30/133 (22.6) 22/152 (14.5)
3 49/133 (36.8) 66/152 (43.4)
4 39/133 (29.3) 49/152 (32.2)
5 12/133 (9.0) 13/152 (8.6)
Contraction endurance [length of hold (seconds)], n,
mean (SD)
Baseline 264, 6.48 (3.00) 250, 6.35 (3.13)
6 months 152, 8.72 (2.26) 166, 8.54 (2.48)
Number of slow contractions (repetitions), n, mean (SD) Baseline 263, 6.03 (2.44) 249, 5.77 (2.41)
6 months 151, 7.42 (2.62) 165, 7.55 (2.59)
Number of fast contractions (repetitions), n, mean (SD) Baseline 248, 8.24 (2.50) 239, 7.81 (2.64)
6 months 149, 8.94 (2.14) 164, 9.50 (1.50)
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with intervention adherence (subsequent to the first appointment) and the frequency of adherence at home
(between appointments). There were some participants for whom adherence status could be determined,
but the frequency of adherence could not be determined as a result of partially missing checklist data in the
TAFs. There was also one participant in the biofeedback PFMT group and four in the basic PFMT group who,
at 24 months, reported using a biofeedback device at home after the OPAL trial intervention had completed.
The frequency of PFMT being undertaken, as reported by participants across the different post-intervention
time points, is summarised in Table 14. At 24 months, the proportion of participants exercising at least
once a week was 52.0% in the biofeedback PFMT group and 46.3% in the basic PFMT group.
Adverse events
There were no suspected unexpected serious adverse reactions reported by participants in the trial. There
were eight SAEs (six in the biofeedback PFMT group and two in the basic PFMT group), all of which were
unrelated to the intervention received (e.g. two participants had atrial fibrillation).
In addition to the SAEs, there were 48 participants for whom at least one AE was reported (34 in the
biofeedback PFMT group and 14 in the basic PFMT group), but none of these complications was classified
as a SAE. Of these participants, 23 (21, biofeedback PFMT; 2, basic PFMT) had a complication related or
possibly related to one of the interventions. Only one of these complications was definitely related to the
intervention, when a participant randomised to the biofeedback PFMT group was found to have a nickel
allergy and did not continue with the intervention.
TABLE 13 Therapists’ adherence to intervention delivery protocol at appointments and women’s adherence to




Biofeedback PFMT Basic PFMT
n N % n N %
Adherence during clinic appointment
Introductory teaching (as appropriate to group) 254 288 88.2 259 293 88.4 0.69 0.33 to 1.42
Any adherence in clinic 231 290 79.7 231 292 79.1 0.89 0.63 to 1.25
Frequency of adherence to intervention protocol at clinic appointments (subsequent to initial appointment)
One appointment or more 218 277 78.7 200 261 76.6
Two appointments or more 175 277 63.2 167 261 64.0
Three appointments or more 130 277 46.9 121 261 46.4
Four appointments or more 86 277 31.0 89 261 34.1
All five appointments 39 277 14.1 40 261 15.3
Adherence at home
Any adherence at home 220 281 78.3 241 297 81.1 0.71 0.43 to 1.16
Frequency of adherence to intervention protocol at home (number of appointments with adherence since previous appointment)
Once or more 196 257 76.3 177 233 76.0
Twice or more 155 257 60.3 156 233 67.0
Three times or more 115 257 44.7 125 233 53.6
Four times or more 75 257 29.2 105 233 45.1
All five times 34 257 13.2 52 233 22.3
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TABLE 14 Participant-reported frequency of PFMEs
Time point Time frame Frequency
Treatment group
Biofeedback PFMT Basic PFMT
At 6 months Yesterday, n/N (%) None 47/167 (28.1) 46/166 (27.7)
A little 47/167 (28.1) 42166 (25.3)
Now and then 32/167 (19.2) 17166 (10.2)
Regularly 41/167 (24.6) 61166 (36.7)
In previous 7 days, n, mean (SD) Number of days 168, 4.5 (2.0) 167, 5 (2.0)
Over previous month, n/N (%) None 19/183 (10.4) 10/172 (5.8)
A few times a month 11/183 (6.0) 10/172 (5.8)
Once a week 12/183 (6.6) 8/172 (4.7)
A few times a week 36/183 (19.7) 24/172 (14.0)
Once a day 31/183 (16.9) 39/172 (22.7)
A few times a day 74/183 (40.4) 81/172 (47.1)
At 12 months Yesterday, n/N (%) None 59/147 (40.1) 59/156 (37.8)
A little 47/147 (32.0) 51/156 (32.7)
Now and then 19/147 (12.9) 21/156 (13.5)
Regularly 22/147 (15.0) 25/156 (16.0)
In previous 7 days, n, mean (SD) Number of days 145, 4 (2.2) 153, 4.1 (2.3)
Over previous month, n/N (%) None 52/197 (26.4) 40/195 (20.5)
A few times a month 20/197 (10.2) 24/195 (12.3)
Once a week 12/197 (6.1) 11/195 (5.6)
A few times a week 51/197 (25.9) 41/195 (21.0)
Once a day 27/197 (13.7) 43/195 (22.1)
A few times a day 35/197 (17.8) 36/195 (18.5)
At 24 months Yesterday, n/N (%) None 64/132 (48.5) 70/128 (54.7)
A little 39/132 (29.5) 31/128 (24.2)
Now and then 12/132 (9.1) 10/128 (7.8)
Regularly 17/132 (12.9) 17/128 (13.3)
In previous 7 days, n, mean (SD) Number of days 133, 3.5 (2.3) 129, 3.5 (2.4)
Over previous month, n/N (%) None 47/173 (27.2) 63/188 (33.5)
A few times a month 36/173 (20.8) 38/188 (20.2)
Once a week 5/173 (2.9) 7/188 (3.7)
A few times a week 45/173 (26.0) 31/188 (16.5)
Once a day 17/173 (9.8) 27/188 (14.4)
A few times a day 23/173 (13.3) 22/188 (11.7)
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Chapter 4 Health economic evaluation
Methods
The principal research question being addressed in the economic analysis concerns the cost-effectiveness
of a policy of biofeedback PFMT compared with basic PFMT. The main economic evaluation was based on data
collected alongside the RCT. There was a plan to undertake an additional modelling analysis that considered a
longer time horizon, to provide additional information for policy-makers, if relevant. However, the evidence
indicated that there were no statistical or clinically meaningful differences in either the clinical or the economic
outcomes to warrant further extrapolation of the data. Therefore, no modelling was conducted and this
chapter focusses on the within-trial analysis. The trial population were women presenting with SUI or MUI.
The base-case trial analysis assessed the costs and cost-effectiveness of the interventions from the perspective
of the NHS. A further analysis included a societal perspective that considered the cost to the participants and
their families. The costs were in Great British pounds (GBP) and the cost year was 2017. All analyses were
prespecified in the health economic analysis plan [see the project web page: www.journalslibrary.nihr.ac.uk/
programmes/hta/117103/#/ (accessed 29 July 2019)] and were reported following the Consolidated Health
Economic Evaluation Reporting Standards (CHEERS) recommendations [URL: www.equator-network.org/
reporting-guidelines/cheers/ (accessed 29 July 2019)]. The methods are summarised below.
Data collection
Resource utilisation was measured over four time points (baseline and 6, 12 and 24 months) using TAFs and
participant-completed questionnaires, which included health-care utilisation questions. The second year costs
and benefits were discounted using the National Institute for Health and Care Excellence (NICE) recommended
3.5%.39 Intervention resource use included the number of appointments with the therapists as captured on
the TAF. Although the first appointment was expected to last for 1 hour and each follow-up appointment to
last for 30 minutes, data on the length of each appointment were also recorded on the TAF. The biofeedback
PFMT group had the additional resource of biofeedback in the clinic and a portable biofeedback unit for home
use. Information on the biofeedback units, such as type of units, type and number of electrodes, internal
probes, laptops, software and licences for laptops, printers and cables, was sourced from the trial office.
Further resource use relating to UI was recorded retrospectively for every woman in the trial. These
data were collected at 6, 12 and 24 months, using participant-completed questionnaires and included
the use of primary (GP services) and secondary (outpatient appointments, inpatient stay and surgical
interventions for incontinence) health care. Health service costs refer to those incurred directly by the NHS,
such as related surgery, additional appointments and procedures. As physiotherapist appointments were
part of the trial interventions, it was probable that participant-reported appointments in the 6-month
questionnaire included some or all of the trial-related appointments and would introduce the chance of
double-counting number and cost. Therefore, the numbers of trial appointments and participant-reported
incontinence-related appointments were compared to establish a clear pattern in the latter, in an attempt to
exclude any already captured in the intervention costing. It was assumed that a one-appointment difference
in participant-reported appointments was most probably due to patient recall bias. It was assumed that
these participants had no additional appointments, other than the trial appointments, and incurred no
additional cost. Those women who reported more than one appointment in addition to their trial
appointments incurred the cost of the difference in participant-reported and trial appointments. Resource
use incurred at personal cost to the participants (such as purchase of pads, medication) was collected using
the participant-reported 24-month questionnaire.
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Intervention costs
The cost of the biofeedback unit was calculated on a per-participant basis and was estimated based on the
following assumptions: the cost of biofeedback units and equipment (laptops, printers, cables) obtained from
the trial office was spread out over 5 years, reflecting the expected lifespan of all equipment (Amanda Tombs,
Verity Medical Ltd, 2018, personal communication). It was assumed that, on average, three women would use
the unit every year to allow for the 16-week intervention period and time for units to be returned to the centres.
The cost of consumables (two packets of electrodes and a probe) was also included. As the biofeedback units
and consumables were purchased across several years, the Hospital and Community Health Service (HCHS)
index40 was used to bring all costs to the same year. The cost of the biofeedback unit per user was then
annuitised, using an annual rate of 3.5% over its lifespan of 5 years. This produced a per-participant unit cost
of biofeedback of £37.40 for the 16-week intervention period (see Appendix 9 for details on the costing).
Medication costs
The incontinence care pathway suggests that, before women progress to the severity level, when surgery
is needed, treatment with medications for UI and overactive bladder is recommended.10 Incontinence
medications have a very low unit cost; Mirabegron (Betmiga; Astellas Pharma Inc., Tokyo, Japan) and
Solifenacin (Vesicare; Astellas Pharma Inc.) are the most frequently reported and have the highest unit cost
(see Appendix 10). As participant-reported medication data were available only at distinct time points
(from 6-, 12- and 24-month follow-up questionnaires), an assumption was made that participants started
their treatment halfway between the follow-up points.
Unit costs
Unit costs and prices were obtained using published estimates from the British National Formulary for
medications,41 NHS Reference Costs 2016/1742 for secondary care resource use and the Personal Social Services
Research Unit’s Unit Costs of Health and Social Care 201740 for primary care resource use, as outlined in Table 15.
TABLE 15 Average NHS unit costs
Area of resource





115 Trial office Average cost of biofeedback units
purchased in 2013–15 and inflated
to 2017 prices using HCHS
Electrodes 8 Trial office Average cost of electrodes purchased
for the trial in 2013–14 and inflated
to 2017 prices using HCHS
Probe 13 Trial office Average cost of internal probes
purchased for the trial in 2013–15




37 Estimated cost Based on information outlined in






2 Curtis and Burns
201740
Per-minute cost. Based on average
cost per hour of patient contact of
band 6 and band 7 hospital-based
scientific and professional staff
Primary care GP appointment 31 (37) Curtis and Burns
201740
Cost per surgery consultation lasting
9.22 minutes, including qualifications




9 (11) Curtis and Burns
201740
Surgery consultation based on the
2006/7 UK general practice survey is
15.5 minutes (including qualifications
given in brackets)
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Estimation of participant costs
For each area of resource use, estimates of resource utilisation were multiplied by unit costs to derive total
costs for each item of resource use and each participant. These data were averaged to provide estimates
of the average cost per participant for each item of resource use. These costs were summed to produce
a total cost for each participant and an average total cost per participant in each intervention group.
Participant- and companion-incurred costs and indirect costs
Personal costs to the participants (such as costs of travelling to appointments and work/social restrictions) were
also investigated. Participant resource utilisation comprised three main elements: (1) self-purchased health care;
(2) travel costs for making return appointment(s) to receive NHS health care (such as petrol, public transport
and parking); and (3) time costs of travelling and attending NHS health care (such as time involved away from
usual activities or work). The self-purchased health-care items included in the investigations were services,
medications and pads paid for by participants for the treatment or management of UI symptoms, and time and
travel costs related to time spent travelling to, and attending, hospital or primary care providers in relation to
UI. Estimation of travel costs included information from participants about the number of appointments with,
TABLE 15 Average NHS unit costs (continued )
Area of resource
























Weighted average for non-elective
short-term stay (0/1 nights), for UI
without interventions across all
severity scores (HRG codes LB16G-K)
1724 Reference Costs
2016/1742
Weighted average for non-elective
long-term stay (2/3 nights) for UI
without interventions across all
severity scores (HRG codes LB16G-K)
278 Reference Costs
2016/1742
Excess bed-days (≥ 4 nights) for UI
without interventions across all
severity scores (HRG codes LB16G-K)
Participant
resource use
Medications Various British National
Formulary41






A weighted average of HRG4 codes








procedures (HRG code LB14Z)
Private care Doctor (GP) 70 Bupa 201843 Based on 15-minute appointment





Physiotherapist 51 (42) Bupa 201843 Initial consultation (follow-up
consultations in brackets),
pay-as-you-go appointments
CC, complication or comorbidity; HRG, Healthcare Resource Group; TVT, tension-free vaginal tape.
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for example, their GP or physiotherapist (estimated from the health-care utilisation questions at the various
follow-up questionnaire time points) and the unit cost of making a return journey to each type of health-care
provider (from the participant time and travel cost questions collected at 24 months). The cost of participant
time was estimated in a similar manner. The participant was asked how long they had spent travelling to,
and attending, their previous appointment with each type of health-care provider. Information was sought on
the activity they would have been undertaking (e.g. paid work, leisure, housework) had they not attended the
health-care provider. They were also asked if they were accompanied by a friend or a relative and their time
and travel costs were also incorporated into the analysis. These data were presented in their natural units
(e.g. hours) and also costed using standard economic conventions, using the Department for Transport44
estimates for the value of work and leisure time. These unit time costs were combined with the number of
health-care contacts derived from the health-care utilisation questions, to elicit a total time and travel cost
from a participant perspective. Details of unit costs applied to the various activities are included in Table 16.
Quality-of-life measures
A generic instrument, the EQ-5D-3L, was used to measure the participants’ quality of life. The EQ-5D-3L
was completed at baseline and at 6, 12 and 24 months post randomisation. The responses to the EQ-5D-3L
questionnaires were valued using UK general population tariffs, based on the time trade-off technique
to generate a utility score for every participant in the trial.47 QALYs were calculated by combining utility
with health state duration, using an area beneath the curve approach, assuming linear interpolation of
utility between time points. Quality-of-life data were also collected using items from the condition-specific
tool ICIQ-LUTSqol for comparison. This tool was included as it was anticipated that the generic measure
(EQ-5D-3L) may not be sensitive enough to pick up the continence-related factors that influence quality
of life for these participants, such as impact on personal relationship and sleep.48 The ICIQ-LUTSqol is
a 21-item, condition-specific measure of health for urinary incontinent participants, developed in a UK
population similar to that in this trial. This instrument was revised into a five-dimensional health state
classification amenable to valuation, using items selected using psychometric evidence. Forty-nine states
were valued using standard gamble by a representative sample of patients with UI attending UK hospital
outpatient clinics. These data were converted into a utility index using a published algorithm6 and used as
an alternative utility value for condition-specific QALY calculation.
TABLE 16 Participant time and travel unit cost
Activity Unit cost (£) Source and notes
Unit costs applied to participant and companion travel
Cost per mile travelled by car 0.45 HMRC45
Car parking charges Various As reported by participants
Cost of public transport (bus, train, taxi) Various As reported by participants
Unit costs applied to participant and companion time
Paid work 15.28 ONS annual survey of hours and earnings46
Housework 8.58 ONS annual survey of hours and earnings46
Child care 15.28 ONS annual survey of hours and earnings (as paid work)46
Caring for a friend/family member 15.28 ONS annual survey of hours and earnings (as paid work)46
Voluntary work 15.28 ONS annual survey of hours and earnings (as paid work)46
Retired 5.93 Department for Transport44
Leisure 5.93 Department for Transport44
Unemployed 5.93 Department for Transport44
Private doctor appointments 70.00 Bupa 201843
Private appointments with nurse/
physiotherapist
51.00 Bupa 201843
HMRC, HM Revenue and Customs; ONS, Office for National Statistics.
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Data analysis
The economic analysis was undertaken on the ITT principle. All components of costs were described with
the appropriate descriptive statistics: mean and SD for continuous and count outcomes; numbers and
percentages for dichotomous and categorical outcomes (e.g. numbers reporting problems on EQ-5D-3L).
All analyses were conducted using Stata® version 14.1 software (StataCorp LP, College Station, TX, USA).
Investigations were carried out for skewed cost data (i.e. a small proportion of participants incurring very
high costs), using GLMs to test alternative model specifications for appropriate fit to the data. The GLM
allowed for heteroscedasticity by selecting and specifying an appropriate distributional family and link
function for the data. This family offered alternative specifications to reflect the relationship between the
mean and variance of the estimates under consideration.49,50 Two diagnostic actions were performed to
identify the most appropriate distributional family: (1) a modified Park test and (2) the Akaike information
criterion were consulted. The best model fit for analysing cost data appeared to be the gamma distribution
with an identity link. The Gaussian distribution with an identity link was chosen for the QALY analysis.
The appropriate link to characterise the relation between the linear combination of predictors and the
prediction was selected based on the results from the Pearson correlation, Pregibon link and the modified
Hosmer–Lemeshow tests (see Appendix 12).
Both cost and QALY difference analyses were adjusted for baseline prognostic factors (all of which were
minimisation covariates plus the type of therapist and baseline EQ-5D-3L utility score):
l centre number
l age in years
l type of UI
l UI severity
l type of therapist (physiotherapist/nurse)
l baseline EQ-5D-3L utility score.
The first five factors are in line with the clinical effectiveness analyses and the baseline EQ-5D-3L was
included for the economic analysis. Standard parametric tests for differences in costs were performed, with
the robustness of the parametric tests confirmed using bias-corrected, non-parametric bootstrapping.51
Missing data
Missing data are a frequent problem in economic evaluations undertaken in a RCT setting. There are several
possible methods that can be employed to account for such missing data, including mean or multiple imputation.
Multiple imputation analysis was conducted for the base-case analysis, as > 5% of the quality-of-life and cost
data needed were missing for the primary analysis. Components of cost data were imputed, based on linear
regression models that were adjusted for minimisation variables, baseline utility and intervention allocation
group. Missing utility values were imputed using predictive mean matching (the mean of five nearest values).
Chained equations were used for the imputations; 20 imputations were considered sufficient to generate
stable and reliable estimates for analysis. Imputed data were then analysed using the appropriately specified
GLMs described in Data analysis.
Incremental cost per quality-adjusted life-year gained
Incremental cost-effectiveness ratios were computed using the imputed data. Differences in costs were
based on resource utilisation costs over the 24-month follow-up period. The difference in effectiveness
was expressed in terms of QALYs at 24-month follow-up. The economic results were reported using a
cost–utility analysis framework, with the ICER representing the incremental cost per QALY gained.








in which Ci and Cj are the mean costs among participants in the biofeedback PFMT and basic PFMT group,
respectively. Similarly, Ei and Ej are the mean QALYs in the biofeedback PFMT and basic PFMT groups,
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respectively. The ICER was assessed against the NICE-recommended cost-effectiveness threshold of
£20,000–30,000 per QALY gained.
Measures of variance for NHS costs and QALYs were derived using non-parametric bootstrapping. From the
results of the bootstrapping, cost-effectiveness acceptability curves (CEACs) were created. CEACs are used
to display the inherent uncertainty surrounding cost-effectiveness at various threshold values for society’s
willingness to pay (WTP) for an additional QALY. CEACs present results when the analysis follows a net
benefit approach. This approach utilises a straightforward rearrangement of the cost-effectiveness decision
rule used when calculating ICERs to create the net monetary benefit (NMB) for each bootstrapped iteration
at increasing values of WTP per QALY:
NMB = λ ×ΔE−ΔC>0, (2)
in which λ represents a decision-maker’s WTP for incontinence avoided or a QALY gained. If the above
expression holds true for a given iteration and threshold WTP value (λ), then the intervention is considered
cost-effective for that iteration. As society’s WTP is unknown, the NMB will be calculated for a number of
possible λ values, including the usual £20,000–30,000 range often adopted by policy-makers in the NHS.39
A balance sheet approach was used to report the costs and QALYs of women who are or are not incontinent.
Sensitivity and subgroup analyses
Sensitivity analyses were performed to gauge the impact of varying key assumptions and/or parameter
values in the base-case analysis. Sensitivity analyses in relation to the assumptions made in the cost of the
intervention were performed. The base-case analysis utilised number of minutes recorded by therapists for each
appointment, to estimate the average cost per intervention. The first sensitivity analysis performed was based on
the recommended time of appointments of 1 hour for the first appointment and 30 minutes for the following
five appointments.1 The base-case analysis in terms of utilities was adjusted for baseline EQ-5D-3L values to
account for variability that may be present among the intervention groups. An unadjusted analysis was also
performed as a sensitivity analysis to highlight the importance of this base-case assumption. An analysis
exploring the impact of changing the discount rate used for second-year costs and QALYs in accordance with
NICE best-practice recommendations, varying the discount rate from 0% to 6% per annum, was undertaken.1
A subgroup analysis similar to that described in the statistical analysis plan was undertaken. This was based on:
l type of incontinence (SUI or MUI)
l age (< 50/≥ 50 years)
l UI severity (ICIQ-UI SF score of < 13 or ≥ 13).
A subgroup analysis on the type of therapist was not performed, as almost all participants were seen by a
physiotherapist.
Sensitivity analysis was also performed to assess the impact of the assumption that data were MNAR.
Several methods have been proposed in the statistical literature to conduct analyses under MNAR.52
The analysis was conducted using pattern mixture models to capture how the distribution of missing
values could differ from the conditional distribution based on the observed data. Several scenarios were
considered. It was supposed that women who did not complete the questionnaires were in a poorer
health state and possibly incurred higher costs. We assumed that the health state could have been 10%
lower and costs would have been 10% higher than the missing at random setting. These assumptions
were applied to two different settings, that (1) they were missing at the same value for both groups and
(2) they were missing for one group only each time. In total, seven scenarios were considered.
Results
The aim of the following sections is to present the within-trial cost-effectiveness analysis.
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Missing data
Data on intervention resource use and costs were missing for participants who withdrew consent, but their
baseline data were still usable (five in the biofeedback PFMT group and two in the basic PFMT group). Details
of missing participant-reported data on resource use in the primary and secondary care trial intervention are
reported in Table 17. The proportions of missing data for cost and utility outcomes were equally distributed
between the two groups. Complete total cost data were available for only 78 participants: 40 participants
(13%) in the biofeedback PFMT group and 38 participants (13%) in the basic PFMT group. Utility data were
available for 174 (biofeedback PFMT) and 158 (basic PFMT) participants. A summary of missing data for each
cost variable, first year and total QALY is presented in Table 17 (see Appendices 13 and 14).
As described in Methods, missing data are a significant issue for the calculation of complete-case cost and
QALY pairs. This is a common issue in cost-effectiveness analyses alongside trials, in which data can be
missing at an individual and item non-response level. It was therefore necessary to impute to address the
significant missing data in the base-case cost-effectiveness analysis.
Resource use
Table 18 presents the resource use associated with the intervention and follow-up care in the biofeedback
PFMT and basic PFMT groups.
Intervention
Overall, 264 out of 300 (88%) participants randomised to biofeedback PFMT received a home unit. Sixteen
(44%) of those participants who did not get a biofeedback unit did not receive any intervention within the
trial, five (14%) withdrew consent, seven (19%) withdrew after their first appointment, four (11%) received
basic PFMT in error and the reason why the four (11%) remaining participants did not receive a home unit
was unclear. One participant in the basic PFMT group was given a home biofeedback PFMT unit in error.
Participants in both trial groups attended an average of four out of their six scheduled appointments, but the
overall time spent at appointments was, on average, 26 minutes longer (95% CI 16.21 to 35.42 minutes) for
those participants in the biofeedback PFMT group.
TABLE 17 Missing resource use/cost and QALY data
Variable
Treatment group, n missing/total N (%)
Biofeedback PFMT Basic PFMT
Cost
Intervention cost 5/300 (2) 2/300 (1)
Total GP appointments 201/300 (67) 200/300 (6)
Total nurse appointments 204/300 (68) 206/300 (69)
Total hospital doctor appointments 217/300 (72) 211/300 (70)
Total nurse/physiotherapist appointments 206/300 (69) 207/300(69)
Total hospital stay 216/300 (72) 206/300 (69)
Total surgical interventions 219/300 (73) 214/300 (71)
Total medications 175/300 (58) 172/300 (57)
Total cost (intervention and follow-up) 260/300 (87) 262/300 (87)
Utility data (QALYs) 174/300 (58) 158/300 (53)
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Follow-up care
Overall, the two trial groups had very similar levels of resource use in the follow-up period. Full details
of all follow-up care resource use reported in the trial are provided in Table 18. The numbers of general
practice doctor and nurse appointments were similar for both groups. The differences for both types
of appointments were not statistically significant.
Although the biofeedback PFMT group had higher resource use for UI symptom management in secondary
care (visits to hospital doctor, nurse or physiotherapist, and inpatient stay) than the basic PFMT group, the
differences in resource use were not statistically significantly different. Furthermore, there was no significant
difference in the number of surgical interventions (tension-free vaginal tape, bulking agents) or medications.





(N= 300) Basic PFMT (N= 300)
n Mean SD n Mean SD
Intervention
Biofeedback units (number of
home units)
295 0.89 0.31 298 0.00 0.06 0.90b 0.86 to 0.95
Number of scheduled trial
appointments attended
295 4.19 1.88 298 4.05 2.09 0.23 –0.05 to 0.50
Trial appointments’ duration
(minutes)
295 176.06 84.20 298 151.70 78.51 25.81b 16.21 to 35.42
Primary care (number of appointments)
GP at the surgery 99 0.98 2.17 100 1.01 1.57 –0.10 –0.59 to 0.40
Practice nurse at the surgery 96 0.34 1.22 94 0.14 0.45 0.17 –0.17 to 0.50
Secondary care
Hospital doctor 83 1.11 2.20 89 0.97 1.60 0.14 –0.42 to 0.70
Hospital nurse/physiotherapist 94 2.02 2.88 93 1.96 3.59 0.33 –1.83 to .49
Inpatient stay (number of nights)c 84 0.15 0.81 94 0.05 0.05 0.08 –0.01 to 0.17
Surgical interventions for the treatment of SUI
6 months 172 0.01 0.11 164 0.02 0.13 –0.01 –0.10 to 0.03
12 months 204 0.04 0.19 210 0.05 0.22 –0.01 –0.06 to 0.04
24 months 154 0.05 0.22 162 0.07 0.26 –0.02 –0.08 to 0.03
Total 81 0.15 0.45 86 0.14 0.49 0.02 –0.09 to 0.13
Prescribed medications
6 months 209 0.18 0.46 204 0.19 0.46 –0.03 –0.14 to 0.08
12 months 229 0.15 0.39 229 0.19 0.44 –0.05 –0.13 to 0.02
24 months 168 0.20 0.46 174 0.17 0.41 0.02 –0.05 to 0.08
Total 125 0.58 1.14 128 0.63 1.17 –0.10 –0.41 to 0.21
a Differences have been adjusted for minimisation covariates and baseline EQ-5D-3L scores.
b Statistically significant.
c Non-surgery-related overnight hospital stay.
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Intervention and follow-up costs
The differences in costs mirror the differences reported in resource use. Details of the cost results are
reported in Table 19. As expected, the cost of biofeedback units was £33.76 (95% CI £31.99 to £35.52)
higher in the biofeedback PFMT group. The cost of the appointments was also £53.12 (95% CI £34.20 to
£72.05) higher in the biofeedback PFMT group. Both of these costs were statistically significantly higher.
Therefore, the total cost of the within-trial intervention was significantly higher (£86.43, 95% CI £67.09 to
£105.76) in the biofeedback PFMT group than in the basic PFMT group. The remaining cost differences
were not statistically significantly different between the groups. Overall, the total cost was higher in the
biofeedback PFMT group, but not statistically significant (difference was £120.97, 95% CI –£409.08 to
£651.02). These findings are based on a complete-case analysis and it is notable that full-cost profile data
were available for only 40 out of 300 (13%) participants and 38 out of 300 (13%) participants in the
biofeedback PFMT and basic PFMT groups, respectively.
Generic and condition-specific quality-of-life measures
Results of EQ-5D-3L scores and adjusted differences between the groups are presented in Table 20.
Participants randomised to the biofeedback PFMT group reported significantly lower EQ-5D-3L utility scores
at baseline (mean difference biofeedback PFMT vs. basic PFMT –0.048, 95% CI –0.085 to –0.01). None of
the follow-up scores was statistically significant between groups. The biofeedback PFMT group had lower
QALYs (1.571) overall than the basic PFMT group (1.619) at 2 years, driven by the EQ-5D-3L imbalance in
the baseline score. When adjusted for baseline differences, the incremental QALY (biofeedback PFMT vs.
basic PFMT) was –0.041 (95% CI –0.121 to 0.039), which was not statistically significant.




(£)a 95% CI (£)
Biofeedback PFMT
(N= 300) Basic PFMT (N= 300)
n Mean (£) SD (£) n Mean (£) SD (£)
Biofeedback units 295 33.47 11.49 298 0.13 2.17 33.76b 31.99 to 35.52
Within-trial
appointments
259 353.89 169.23 298 304.92 157.80 53.12b 34.20 to 72.05
Total intervention cost 295 387.36 175.62 298 305.05 157.88 86.43b 67.09 to 105.76
Primary care
GP at the surgery 99 36.25 80.16 100 37.37 57.97 –3.57 –21.90 to 14.76
Practice nurse at
the surgery
96 3.73 13.25 94 1.50 4.93 0.17 –0.17 to 0.50
Secondary care
Hospital doctor 83 130.43 242.20 89 117.12 189.60 12.81 –50.36 to 75.97
Hospital nurse/
physiotherapist
94 166.81 237.82 93 160.90 291.97 27.82 –145.41 to 201.05




81 225.09 716.30 86 195.23 661.02 42.18 –103.07 to 187.43
Prescribed
medications
125 49.95 113.15 128 58.11 165.32 –8.53 –56.25 to 39.19
Total overall cost 40 1261.42 1333.21 38 1118.26 1294.36 120.97 –409.08 to 651.02
a Differences adjusted for baseline EQ-5D-3L score and minimisation covariates.
b Statistically significant.
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The proportion of trial participants who reported problems in the domains of the EQ-5D-3L were equally
distributed between the two groups (Figure 5). Pain/discomfort and anxiety/depression was the dimensions
associated with most problems. Details of the number of participants are reported (see Appendix 15).
The mean ICIQ-LUTSqol scores at baseline and at each follow-up time point, as well as the differences
between the two trial groups, are presented in Table 21. None of the differences in ICIQ-LUTSqol was
statistically significant across the groups.
The proportion of participants in each trial group who reported any issues on each domain of the
ICIQ-LUTSqol utility measure are reported in Figure 6 (see Appendix 16). The problems reported by the
highest proportion of participants were with physical activities, such as travelling, walking, running
(between 79% and 97%), followed by emotional distress associated with their incontinence (between 60%
and 83%) and limitations associated with their job or normal daily activities in and outside their household
(between 53% and 84%), over the different time periods. The largest reduction in the proportion of
participants reporting problems was observed between baseline and 6 months, and this occurred in both
trial groups. The proportion of participants who reported issues remained stable for the rest of the follow-up
(see Figure 6).
Costs incurred by and quality-adjusted life-years of cured and incontinent participants
At 24 months, the total cost of those participants who were reported as cured according to the primary
clinical outcome (ICIQ-UI SF score) was £1032 (SD £942). The mean total cost for those who were still
incontinent at the end of the follow-up period was £1203 (SD £1333). The mean total QALY for participants
who were cured was 1.85 (SD 0.17), whereas it was 1.57 (SD 0.48) for those who were still incontinent.
These results are based on only those who had complete data.




Biofeedback PFMT (N= 300) Basic PFMT (N= 300)
n Mean SD n Mean SD
EQ-5D-3L scores
Baseline 287 0.788 0.288 295 0.836 0.240 –0.048b –0.085 to –0.010
6 months 225 0.785 0.300 229 0.823 0.256 –0.014 –0.055 to 0.026
12 months 235 0.769 0.320 241 0.811 0.267 –0.014 –0.056 to 0.028
24 months 166 0.810 0.284 171 0.808 0.264 0.003 –0.035 to 0.041
Visual analogue scale
Baseline 280 73.74 19.39 285 73.90 19.65 1.10 –2.299 to 4.503
6 months 209 74.36 18.52 221 75.72 17.39 –1.68 –5.331 to 1.969
12 months 236 72.67 22.70 241 74.72 17.07 –2.09 –5.496 to 1.313
24 months 163 74.62 18.78 163 73.21 20.73 1.39 –3.171 to 5.951
QALYs
First-year QALY 192 0.783 0.280 202 0.826 0.230 –0.02 –0.044 to 0.013
Second-year QALYc 126 1.571 0.492 142 1.619 0.455 –0.041 –0.121 to 0.039
a All differences adjusted for minimisation covariates and baseline EQ-5D-3L score using ordinary least square regressions.
b Significant at 5%.
c Second year discounted at 3.5%.
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Costs directly incurred by participants and carers and indirect costs of time and
productivity lost due to urinary incontinence
There were no statistically significant differences in personal costs to the participants between the two
groups (Table 22). The number of participants who reported the need to take full days off work because
of incontinence was low (n = 16). Among those who required time off from usual activities in the follow-up
period, the average number of days off in the basic PFMT group was 12.5 and the average number of days
off in the biofeedback PFMT group was 10. The differences between groups were not statistically significant.
The cost of self-purchased incontinence products (pads) constituted the highest annual cost to the participants:
£806 for the biofeedback PFMT group and £862 for the basic PFMT group; however, the difference between
the groups was not statistically significant. Only five participants reported self-purchasing other incontinence
products, such as biofeedback units, vaginal cones or pessaries, in the follow-up period. The time and travel
cost to the participant and carer (if applicable) of attending outpatient appointments was the second highest
cost (on average, £200 for the biofeedback PFMT group and £303 for the basic PFMT group). Only very few
participants (six in the basic PFMT group and eight in the biofeedback PFMT group) reported use of private
secondary care (appointments to private doctors, nurses and physiotherapists). The total participant perspective
cost difference (biofeedback PFMT vs. basic PFMT) was –£74.21 (95% CI –£201.21 to £52.78), but this was
not statistically significant.
Base-case cost-effectiveness analysis
As described in Missing data, missing data were a significant issue for the calculation of complete-case cost
and QALY pairs. This is a common issue in cost-effectiveness analyses alongside trials, in which data can be
missing at an individual and item non-response level. Therefore, the remaining results (base-case and all
sensitivity analyses) refer to analyses conducted on the multiply imputed data set, following best practice
economic evaluation methodology. Results of the base-case analysis based on the reported intervention
time indicated that, on average, the biofeedback PFMT group was £50 more costly than and had almost
equivalent (+0.0009) QALYs to the basic PFMT group. The QALY differences are exceptionally small over a
2-year time horizon and equate to only 8 hours or 0.33 days improvement in quality of life over the trial time
horizon. The base-case ICER was £56,617. The probability that biofeedback PFMT would be cost-effective
was 48% and 49% at £20,000 and £30,000 WTP for a QALY thresholds, respectively (Table 23). The
probability of being cost-effective remains unchanged at much higher WTP thresholds, as illustrated by the
CEAC (Figure 7). The uncertainty is further illustrated by the scatterplots of incremental costs and incremental
QALYs (Figure 8).









n Mean SD n Mean SD
ICIQ-LUTSqol score at baseline 292 0.954 0.024 297 0.957 0.023 –0.003 –0.006 to 0.0001
ICIQ-LUTSqol score at 6 months 186 0.966 0.026 180 0.968 0.021 –0.003 –0.008 to 0.002
ICIQ-LUTSqol score at 12 months 189 0.967 0.026 184 0.969 0.022 –0.002 –0.007 to 0.003
ICIQ-LUTSqol score at 24 months 128 0.970 0.025 135 0.968 0.025 0.001 –0.006 to 0.008
First-year QALY 160 0.964 0.024 153 0.967 0.019 –0.000 –0.004 to 0.003
Second-year QALY (discounted) 98 1.900 0.046 100 1.903 0.038 –0.001 –0.011 to 0.008
a All differences are adjusted for baseline minimisation covariates and ICIQ-LUTSqol score (except the difference in
baseline ICIQ-LUTSqol itself) using ordinary least square regressions.
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Recommended appointment time was based on the assumptions that there was no difference in the
duration of the appointments and that both biofeedback PFMT and basic PFMT appointments were similar
(1 hour for the first appointment and 30 minutes for each subsequent appointment). The results indicate
that, on average, the biofeedback PFMT group’s costs were £23 higher than the costs of basic PFMT
group, but the biofeedback PFMT group had 0.004 fewer QALYs than the basic PFMT group (Table 24).
Biofeedback PFMT group was dominated by the basic PFMT group, as it cost more and was less effective.
The probability that biofeedback PFMT was cost-effective was 42% at the £20,000 WTP threshold and
43% at the £30,000 WTP threshold (Figures 9 and 10).
TABLE 22 Direct and indirect costs to participants and carers (complete-case data)
Cost
Treatment group
Difference (£)a 95% CI (£)
Biofeedback PFMT
(N= 300) Basic PFMT (N= 300)
n Mean (£) SD (£) n Mean (£) SD (£)
Time/travel (inpatient stay) 66 52 216 78 19 80 29 –28 to 86
Time/travel (outpatient appointments) 73 200 196 73 303 539 –66 –163 to 32
Time and travel (general practice) 84 21 44 92 22 38 –4 –11 to 3
Self-purchased UI products 52 806 666 56 862 825 –127 –326 to 72
Private care 87 3 17 90 5 38 2b –3 to 6
Total cost 43 353 331 52 417 544 –74 –201 to 53
a Differences adjusted for baseline EQ-5D-3L and minimisation covariates.
b Adjusted differences using ordinary least squares regression due to GLM regressions not converging.
TABLE 23 Base-case cost-effectiveness results: therapist-reported duration of appointment (imputed data set)
Treatment group Mean cost (£)
Difference
in costs (£) Mean QALYs
Difference




Basic PFMT 906 1.567 51.8 50.7








































FIGURE 7 Cost-effectiveness acceptability curves: therapist-reported duration of appointment (imputed data set).
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Subgroup analysis
The results of the sensitivity analyses exploring the cost-effectiveness of biofeedback PFMT compared
with basic PFMT for different subgroups are detailed in Table 25. The results of those participants with
SUI were similar to those of the base-case analysis (for sensitivity analyses CEACs and ICER scatterplots,























FIGURE 8 Scatterplot of incremental costs and QALYs for biofeedback PFMT vs. basic PFMT: therapist-reported
duration of appointment (imputed data set).





costs (£) Mean QALYs
Difference




Basic PFMT 885 1.570 58.2 57.4








































FIGURE 9 Cost-effectiveness acceptability curves: recommended appointment time (3.5 hours for six appointments).
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FIGURE 10 Scatterplot of incremental costs and QALYs for biofeedback PFMT vs. basic PFMT: recommended
appointment time (3.5 hours for six appointments).









SUI (n = 235)
Basic PFMT 815 1.596 61.3 56.2
Biofeedback PFMT 976 162 1.599 0.003 57,936 38.7 43.8
MUI (stress and urgency) (n = 365)
Biofeedback PFMT 939 1.551 53.2 52.1
Basic PFMT 993 54 1.550 –0.001 Dominated 46.8 47.9
Aged < 50 years (n = 360)
Basic PFMT 890 1.573 88.8 88.4
Biofeedback PFMT 919 29 1.540 –0.034 Dominated 11.2 11.6
Aged ≥ 50 years (n = 240)
Basic PFMT 951 1.560 8.0 7.1
Biofeedback PFMT 1033 82 1.618 0.058 1417 92.0 92.9
Lower severity level (ICIQ-UI SF score of < 13) (n = 250)
Basic PFMT 827 1.603 19.4 20.1
Biofeedback PFMT 863 36 1.629 0.026 1397 80.6 79.9
Higher severity level (ICIQ-UI SF score of ≥ 13) (n = 350)
Basic PFMT 977 1.543 68.2 67.8
Biofeedback PFMT 1036 59 1.529 –0.014 Dominated 31.8 32.2
Using ICIQ-LUTSqoL scores as a utility measure
Basic PFMT 906 1.896 46.2 42.9
Biofeedback PFMT 956 50 1.896 0.000 177,668 53.8 57.1
Undiscounted costs and QALYs
Basic PFMT 897 1.595 54.3% 53.4%
Biofeedback PFMT 948 51 1.594 –0.001 Dominated 45.7% 46.6%
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Type of incontinence
On average, the biofeedback PFMT intervention cost £152 more and was more effective than basic PFMT.
The ICER was £57,936 and the probability that biofeedback PFMT would be considered to be cost-effective
was 39% at society’s £20,000 WTP threshold and 44% at the £30,000 threshold. The results of those
participants with MUI differed from the base-case results. On average, the biofeedback PFMT intervention cost
less and was more effective than basic PFMT. Biofeedback PFMT dominated basic PFMT. The probability that
biofeedback PFMT would be considered to be cost-effective was 53% at society’s £20,000 WTP threshold and
52% at the £30,000 threshold.









Discounted costs and QALYs at 6%
Basic PFMT 886.07 1.550 55.3% 54.1%
Biofeedback PFMT 938.22 52.16 1.549 –0.001 Dominated 44.7% 45.9%
Unadjusted costs and QALYs
Basic PFMT 904.36 1.602 96.9 96.9
Biofeedback PFMT 953.31 48.95 1.532 –0.070 Dominated 3.1 3.1
Same MNAR parameters in two groups
–10% quality of life in both groups
Basic PFMT 906 1.508 55.9 54.9
Biofeedback PFMT 956 50 1.507 –0.001 Dominated 44.1 45.1
+10% cost in both arms
Basic PFMT 980 1.567 51.6 50.0
Biofeedback PFMT 1033 55 1.568 0.001 61,855 48.4 50.0
–10% quality of life and + 10% cost
Basic PFMT 980 1.508 56.3 54.7
Biofeedback PFMT 1033 55 1.507 –0.001 Dominated 43.7 45.3
Different MNAR in the two groups
–10% quality of life in biofeedback PFMT group
Basic PFMT 906 1.567 99.6 99.6
Biofeedback PFMT 956 50 1.507 –0.060 Dominated 0.4 0.4
–10% quality of life in basic PFMT group
Basic PFMT 906 1.507 0.8 0.7
Biofeedback PFMT 956 50 1.568 0.060 843 99.2 99.3
+10% cost in biofeedback group
Basic PFMT 906 1.567 57.9 55.2
Biofeedback PFMT 1033 124 1.568 0.001 140,278 42.1 44.8
+10% cost in basic PFMT group
Biofeedback PFMT 956 1.568 45.3 45.4
Basic PFMT 980 –19 1.567 0.001 Dominated 54.7 54.6
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Age
The results of those participants aged < 50 years were also different from the base-case analysis. On average,
the biofeedback PFMT intervention cost more and was less effective than basic PFMT. Biofeedback PFMT was
dominated by basic PFMT. The probability that biofeedback PFMT would be considered to be cost-effective
was 11% at society’s £20,000 WTP threshold and 12% at the £30,000 threshold. For participants aged
≥ 50 years, biofeedback PFMT cost, on average, £82 more than basic PFMT, and the difference in QALYs was
0.058 (vs. 0.0009 in the base-case analysis). The ICER was £1417. The probability that biofeedback PFMT
would be considered to be cost-effective was 92% at society’s £20,000 WTP threshold and 93% at the
£30,000 threshold.
Severity of incontinence
The results for those participants with a lower-severity ICIQ-UI SF score (< 13) indicated that, on average,
biofeedback PFMT cost £29 more and was 0.026 QALYs more effective than basic PFMT. The ICER was
£1397. The probability that biofeedback PFMT would be considered to be cost-effective was 81% at
society’s £20,000 WTP threshold and 80% at the £30,000 threshold. The results for those participants
with a higher-severity ICIQ-UI SF score (≥ 13) indicated that, on average, biofeedback PFMT cost £59 more
and was 0.014 QALYs less effective than basic PFMT. The biofeedback PFMT group was dominated by the
basic PFMT group. The probability that biofeedback PFMT would be considered to be cost-effective was
11% society’s £20,000 WTP threshold and 12% at the £30,000 threshold.
Quality-of-life scores
The results of the analysis using the ICIQ-LUTSqol were similar to those of the base-case analysis.
On average, biofeedback PFMT cost £50 more and was more effective than basic PFMT. The ICER was
£177,668 and the probability that biofeedback PFMT would be considered to be cost-effective was 54%
at society’s £20,000 WTP threshold and 57% at the £30,000 threshold.
Discounting and unadjusted costs and quality-adjusted life-years
The results of the discounting and unadjusted analyses differ from the base-case analysis. On average,
biofeedback PFMT cost more and was less effective than basic PFMT; therefore, biofeedback PFMT was
dominated, although the differences were not statistically significant. The change in results is mainly
because the baseline imbalance was maintained, as the data were not adjusted to take into account
this difference.
Assuming that data were missing not at random
As shown in Table 25 (also see Appendix 17), this assumption has an impact on the results, in which the
missing quality-of-life data are 10% lower in the biofeedback PFMT group only and the QALY difference
is statistically significantly lower –0.060 (95% CI –0.117 to –0.003) for the biofeedback PFMT group.
Biofeedback PFMT is dominated by basic PFMT as it costs more and is less effective, and the probability
that biofeedback PFMT would be considered to be cost-effective was 0.4% at society’s £20,000 WTP for
a QALY threshold and 0.4% at the £30,000 WTP threshold. The results are reversed when we assume
a reduction of 10% in the missing of quality-of-life data in the basic PFMT group only, as the QALY is
statistically significantly higher (0.060, 95% CI –0.04 to –0.115) for the biofeedback PFMT group. The ICER
for the biofeedback PFMT group is £843, as it costs more and is more effective, and the probability that
biofeedback PFMT would be considered to be cost-effective was 99% at society’s £20,000 WTP for a
QALY threshold and 99% at the £30,000 WTP threshold. The rest of the scenario results were the same as
those reported when it was assumed that data were missing at random.
Discussion
The base-case results indicate that biofeedback PFMT, on average, cost more than basic PFMT and generated
more QALYs. However, none of these results was statistically significant. Although, on average, the total
number of appointments attended was similar in both groups, the total duration of the biofeedback PFMT
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appointments was 26 minutes longer than the basic PFMT appointment. The difference in the intervention
cost was driven by the cost of the biofeedback PFMT units and the duration of the appointments. The
difference in appointment duration was attributed to information technology (IT) problems encountered
by therapists during appointments and the extra time associated with setting up the biofeedback PFMT
equipment. However, over the 24-month follow-up period, this cost difference was reduced, as there were
no statistically significant differences in primary and secondary care resource use and costs between the
two groups.
At baseline, the EQ-5D-3L score was statistically significantly higher for the basic PFMT group than for the
biofeedback PFMT group; therefore, all the analyses conducted were adjusted for the baseline EQ-5D-3L
utility scores. This difference decreased and was not statistically significant at any time point during the
follow-up period. The adjusted mean QALY difference (biofeedback PFMT vs. basic PFMT) was negligible,
at 0.0009. Over the 2-year follow-up period, this would equate to 8 hours’ improvement in quality of life,
which may not be meaningful. The ICER for analysis based on the reported duration of appointments was
£56,617, which is higher than the £20,000–30,000 WTP threshold typically used in the UK.39 Therefore,
biofeedback PFMT would not be considered to be cost-effective. The probability that biofeedback PFMT
was cost-effective if society were willing to pay £20,000 for an additional QALY was 48% and did not
increase above 55% at higher WTP thresholds. However, some subgroup analyses led to changes in the
base-case cost-effectiveness conclusions. This could be because the trial was not powered to undertake
these analyses.
Deterministic sensitivity analyses were conducted to address areas of uncertainty in assumptions and data
collection. The conclusions of the cost-effectiveness analysis that addressed the uncertainty in the cost
and QALY data were similar to those of the base case. The first analysis assumed that there were no
differences in the duration of the appointments. As expected, this analysis reduced the magnitude of
incremental costs, but the resultant ICER remained highly uncertain and the probability of biofeedback
PFMT being cost-effective increased by only 1%. This uncertainty is depicted by the distribution of the
simulations in all quadrants of the cost-effectiveness plane.
The number of participants who reported full days off work as a result of incontinence was low. Among
those who required time off their usual activities in the follow-up period, the average number of days off
in the basic PFMT group was 12.5 and in the biofeedback PFMT group was 10. The differences were not
statistically significant.
The amount of uncertainty around the final cost and QALY increments was found to vary, with point estimates
being highly unstable and changing sign and magnitude with every attempt at multiple imputation using
chained equations. This shows that the two interventions for UI are very similar in terms of cost-effectiveness.
As indicated in the base-case analysis, the main driver of the costs was the biofeedback units, as the
subsequent costs were, on average, similar in the two groups. Thus, there was an additional cost associated
with the biofeedback PFMT intervention but no difference in QALYs.
One of the challenges for the cost-effectiveness analysis was the number of missing data. The analysis
of complete-case QALY data at 12 and 24 months ignored important individual-level information for
participants who reported no or partially complete EQ-5D-3L data at any time point. However, missing
data were evenly distributed between the two trial groups at all time points, with 98 out of 300 (33%)
and 108 out of 300 (36%) having missing 12-month QALY data in the basic PFMT and the biofeedback
PFMT group, respectively, and this increased to > 50% in both groups: 53% and 58%, respectively.
This challenge was addressed by imputing cost and QALY outcomes. The base-case analysis was based
on multiple imputation. The conclusions of the imputed analysis were similar to those of complete-case
analysis. Analyses assuming a 10% reduction in the missing quality-of-life data led to changes in the
overall results, as both treatments had higher probability of being cost-effective when the other group
had the reduction attached to their values. This can be attributed to the fact that there was a very small
difference in the QALYs in the base-case analysis (0.0009) and a reduction in one group could favour the
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other group. Analyses that assume that cost data were MNAR did not change the overall conclusions,
as the QALY difference remained low, and, taking into account the results from the clinical effectiveness
analysis, we do not have any reason to believe that the pattern of missing cost and QALY data was
significantly different across treatment arms, or can be explained by factors for which we are unable
to control in our regression models.
One of the key strengths of the cost-effectiveness analysis is that it was conducted alongside a multicentre
trial, adding to the generalisability of the results. A detailed costing of the intervention was undertaken and
participants were followed up over 24 months. The quality-of-life data were collected using both generic and
condition-specific instruments at several time points to ensure that the impact on quality of life was captured.
As the trial was not powered to detect differences in economic outcomes, conclusions from the economic
evaluation have to be based on the consideration of the balance of probabilities.
Conclusion
The base-case analysis showed that biofeedback PFMT was not significantly more expensive than basic
PFMT and did not generate significantly higher QALYs. The ICER (£56,617) is greater than society’s WTP
threshold of £30,000. Biofeedback PFMT was associated with a 49% chance of being cost-effective if
society is willing to pay £30,000 for a QALY. The difference in intervention costs was driven by the cost
of the biofeedback units and longer duration of biofeedback PFMT appointments. A sensitivity analysis
assuming that the duration of appointments was the same for both groups indicated a reduction in the
cost difference. Biofeedback PFMT was dominated by basic PFMT, as it cost more but was less effective.
The chance that biofeedback PFMT would be considered cost-effective at the £30,000 threshold for
society’s WTP for a QALY reduced to 48%. These results have to be interpreted taking into account the
uncertainty surrounding the estimates of cost and QALYs.
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Chapter 5 Process evaluation
Introduction
This chapter summarises the OPAL trial process evaluation, addressing the third research aim (see Chapter 1,
Aims and objectives), and is in line with guidance for evaluating complex interventions.16,53 The two OPAL
trial interventions are described in Chapter 2 and their development was underpinned by the IMB model,17
the BCT taxonomy8 and self-efficacy theory54 (see also Chapter 1 and the trial protocols20,21).
The aim was to:
l identify and investigate the possible mediating factors that affect the effectiveness of the intervention
(including fidelity to intervention delivery and uptake), how these mediating factors influence
effectiveness and whether or not the factors differ between randomised groups.
The process evaluation was conducted in parallel with the main trial and comprised analysis of multiple
data sets generated throughout the trial, including:
1. therapist-completed TAF checklists
2. audio-recorded appointments
3. interviews with therapists
4. PFMT exercise diaries
5. patient-completed trial baseline and follow-up questionnaires.
This chapter presents the research methods and results from the first four data sources, reporting findings
from the intervention period.
Methods
This mixed-methods process evaluation had a concurrent design. For intervention delivery, we assessed the
‘fidelity of form’55 for the core components of the two interventions (i.e. the core components that were to
be used for all participants and not individualised). We also assessed ‘fidelity of function’55 for individualised
or optional components, as therapists were given the intervention protocols to follow, with the expectation
that they would tailor some components to individual participants (in terms of the exact exercise prescription,
lifestyle advice, etc.). The main data sources for assessing intervention delivery were therapist-completed TAF
checklists, audio-recordings of appointments and therapist interviews.
Although participants’ fidelity to the intervention, with respect to their experiences of receiving treatment
in clinic and how they engaged with PFMT at home, was mainly covered by the longitudinal qualitative
case study (see Chapter 6), we also evaluated this using the audio-recording of appointments, therapist
interviews and the free-text responses in participants’ exercise diaries.
Process evaluation sampling, recruitment strategy and data collection
Appointment checklists
A protocolised checklist (basic PFMT group or biofeedback PFMT group) was completed by all therapists
for each appointment (for examples of core and optional components for each group, see Appendix 18).
These checklists were embedded in the TAF completed at each appointment [see the project web page:
www.journalslibrary.nihr.ac.uk/programmes/hta/117103/#/ (accessed 29 July 2019)]. Each checklist
contained the core and optional intervention components for the appointment, and varied by appointment
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number (1–6) and by group. For each appointment, the biofeedback PFMT checklists had all the core basic
PFMT components and additional biofeedback-related components. Therapists ticked yes or no for each
component to allow assessment of fidelity. At the end of the tick-box section, an open-text space enabled
therapists to explain the clinical reasoning for any omissions or additions to tailor the intervention based on
a participant’s needs.
Appointment audio-recordings
Audio-recordings were planned to obtain a deliberately heterogeneous purposive sample of 100 appointments
from across both basic PFMT and biofeedback PFMT groups; from the different appointment time point (1–6);
centres and UI type and severity; and different therapist type (physiotherapist/nurse). Challenges with arranging
recordings and the increase in the number of centres meant that we subsequently focused sampling on the
first and last appointments, as a result of our a priori hypothesis that treatment delivery may be more intensive
and concentrated in these appointments. The first appointment was scheduled to be longer (1 hour) and
involved assessment (including assessment of correct contraction), education and teaching for participants
on how to properly perform PFMEs, use of clinic biofeedback and teaching use of home biofeedback (for
the biofeedback PFMT group only) and explanation of any recommended changes to lifestyle. However,
as occurs in clinical practice, some of these elements could be deferred to the second appointment based
on the individual needs of the woman. The last appointment (30 minutes scheduled) was important because
supervised therapy was ending and participants were being given important information to allow them to
self-care, such as instructions regarding the maintenance PFMT dose. Appointments 2–5 were also 30 minutes
in duration and component content was mostly similar (i.e. repeated) across these four appointments.
If participants had signed on their consent form that they were willing to have an appointment audio-recorded,
the researcher purposively selected participants and telephoned them to ask if they were willing to have a
specific appointment recorded, answer any questions they had and obtain verbal consent. Therapists were then
informed which participants and appointments to record, using a centre-specific password-protected digital
audio-recorder; these were returned to the researcher at regular intervals for downloading data. Recordings
were anonymised and transcribed verbatim.
Therapist interviews
Semistructured telephone interviews were undertaken with staff at the end of their centre’s participation
in the delivery of the trial interventions. Initially, we planned to interview at least one therapist from
each centre; however, for various reasons this was not possible and a decision was taken by the process
evaluation team to widen recruitment to include at least one person from each centre, but extending the
sample to administrative support staff and nurses involved only in recruiting women. In the first instance,
the interview researcher e-mailed the therapist(s) at each centre, informing them about the interview
purpose and inviting them to participate. Their reply, with a suitable date and time, was accepted as
consent to be interviewed. A topic guide was developed from the literature, from issues arising during
delivery of the trial interventions and from case study participant interviews. The resultant broad categories
of questions were delivery of the interventions to participants; response of participants; maintenance of
PFMT; and aspects of theory underlying the intervention. In these categories, the interviewer deliberately
sought therapist perspectives on their protocol adherence and participants’ PFMT adherence. Interviews
were audio-recorded, anonymised and transcribed verbatim then uploaded to NVivo 11 (QSR International,
Warrington UK) for coding.
PFMT exercise diaries
Exercise diaries were provided to each participant at appointments 1–5, to be completed as a record of PFMT
undertaken at home and returned at the following appointment. Therapists wrote the agreed PFMT (and
biofeedback use) to be followed (the ‘dose’) in the diary and participants were asked to sign their agreement
(a BCT called ‘commitment’) to undertake home PFMT and, if allocated, home biofeedback PFMT. At the
following appointment, exercise diaries were collected, progress reviewed and a new diary issued. Diaries
provided space for participants to record, on a daily basis, the number of sets of exercises undertaken and,
if allocated, their use of biofeedback PFMT, along with any free-text comments about their homework.
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Process evaluation analysis
In this chapter, the analysis of each individual data source, undertaken to reach separate conclusions,
is presented.
Appointment checklists
The number of available checklists (i.e. a checklist for all appointments attended) for participants in both
groups was compared with the potential number. In each appointment, the number of components
checked ‘yes’ were summarised descriptively (means, modes and interquartile ranges) to report the extent
to which therapists delivered the core and optional components of each appointment in each group.
Therapist free-text comments about intervention omissions, additions and tailoring were coded using a
framework developed following content analysis of a 10% representative sample of appointments.
Appointment audio-recordings
A quantitative coding scheme was developed based on the appointment checklists. The coding scheme for
each appointment contained explicit guidance for assessing whether or not the protocol components (core
and optional) were delivered (yes/no), followed by an assessment of the quality of delivery. The reliability
of the coding scheme was checked by comparing the codes independently assigned by three members
of the research team to a sample of audio-recordings. Following discussion of differences in coding, the
agreed coding scheme was finalised. Using both the audio-recordings and the transcribed audio-recordings,
the coding was completed and entered into IBM SPSS Statistics 25 (IBM Corporation, Armonk, NY, USA) for
data management. Coded data were summarised descriptively by appointment and by group.
Therapist interviews
Using a general inductive and descriptive qualitative approach, analysis began with familiarisation with
the data. A thematic framework56 was developed by one researcher from initial coding of 10 interviews;
a second researcher then independently coded four transcripts, and a third researcher cross-checked and
agreed the final set of codes. This coding framework was then applied across the data set. Findings are
reported in alignment with the sequence of issues discussed in the interviews, with a focus on the
therapists’ perspectives on the barriers to and facilitators of intervention fidelity, and participants’
engagement and adherence, to demonstrate variation over time.
PFMT exercise diaries
Content analysis was used to summarise free-text entries made by participants, checking for similarities
and differences between groups and appointments. This analysis took place prior to the main trial results
being known. Subsequent to knowing the results, we examined the returned diaries for completion of the
therapist- and participant-signed PFMT agreement. This BCT was a core component in both trial interventions
and was summarised by appointment and by group as a proportion of those attending each appointment.
Results
We present results according to the four main process evaluation data sources.
Appointment checklists
The potential maximum number of checklists was 3600 (600 participants, six appointments each). The
number of available checklists by group and by appointment is summarised in Table 26, and does not
necessarily reflect how well the checklists were completed by the therapist. Missing checklists include
participants who withdrew, participants who did not attend a specific appointment, non-submission
of a checklist by a therapist (some forgot to complete it) or a missing TAF. There were no clear differences
between groups in the proportion of available checklists, either by specific appointment or over time.
There was a steadily decreasing trend from appointment 1 (91% submitted) to 6 (60% submitted).
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On the checklists, therapists ticked ‘yes’ or ‘no’ to delivery of each core component for each appointment
[for examples, see the project web page: www.journalslibrary.nihr.ac.uk/programmes/hta/117103/#/
(accessed 29 July 2019)]. Table 27 summarises the number of core components ticked ‘yes’, by group
and by appointment. Between the two groups, there were no observed differences in the number of
basic core components (i.e. components that were the same in both groups and ticked ‘yes’ by therapists
per appointment). Therapists most often ticked either a full complement of core components or just one
less than a full complement; this was the case for every appointment apart from appointment 5 in the
biofeedback PFMT group, when the mode was only 15 of a possible 18 ticks. The interquartile ranges
reveal a skewed data distribution in favour of a high number of basic PFMT core components being ticked
‘yes’ for all appointments and for both groups (see Table 27, columns 2 and 3).
In the biofeedback PFMT group only, therapists most often ticked ‘yes’ to either all the biofeedback core
components or one less than a full complement. In all but the last biofeedback PFMT appointment,
at least 75% of the checklists had more than half of the core components ticked ‘yes’ (see Table 27,
column 4). When combining the basic and biofeedback core components (see Table 27, column 5), it can
be seen that the biofeedback PFMT group received more ‘yes’ ticks overall than the basic PFMT group.
For example, in appointment 1, the median number of ticks was 18 for the basic PFMT group (out of a
possible 19, see Table 27, column 2) and for the biofeedback PFMT group, the median was 26 (out of a
possible 28, see Table 27, column 5). This pattern was similar for all appointments, indicating that, based
on therapist reporting, the biofeedback PFMT group did have more core components delivered during
appointments, consistent with the intervention protocol.
A similar summary for the optional intervention components [see the project web page: www.journalslibrary.
nihr.ac.uk/programmes/hta/117103/#/ (accessed 29 July 2019)] revealed a very different pattern: very few were
ticked ‘yes’ in any appointment, for either group (Table 28). The mode is consistently zero for all appointments
in both groups; the interquartile range is much larger and in only appointment 6 does the median reach half
the number of available basic optional components. The optional component pattern is consistent across the
appointments and between the groups for the basic PFMT components. The biofeedback PFMT group did
receive some additional biofeedback-specific optional components, but relatively few compared with those
available on the checklist (see Table 28, column 3).
Appointment audio-recordings
As described in Methods, collecting the full intended sample of audio-recordings was challenging because
therapists were unfamiliar with equipment, declined to do their quota because of staff shortages or forgot
to record or identify the patient/appointment number, or because participants failed to attend the selected
appointment or withdrew from the trial. Table 29 demonstrates our decision to focus on collecting data
from appointments 1–6, as appointments 2–5 were designed to repeat intervention content from previous











1 265 (83) 279 (93) 544 (91)
2 235 (78) 245 (81) 480 (80)
3 189 (63) 198 (66) 387 (65)
4 175 (58) 185 (62) 360 (60)
5 166 (53) 156 (52) 322 (54)
6 175 (58) 182 (61) 357 (60)
Total 1205 (67) 1245 (69) 2450 (68)
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TABLE 27 Summary of checklist core components ticked for each appointment by group: differentiating between
basic PFMT core components and biofeedback-specific PFMT core components
Appointment
Treatment group










Potential range 0–19 0–19 0–9 0–28
n 265 279 279 279
Median 18 18 8 26
Mode 18 18 9 27
IQR 17–19 15–18 5–9 20–27
Appointment 2
Potential range 0–20 0–20 0–13 0–33
n 235 245 245 245
Median 18 18 11 29
Mode 19 19 12 31
IQR 17–19 16–19 9–12 25–31
Appointment 3
Potential range 0–18 0–18 0–14 0–32
n 189 198 198 198
Median 16 16 12 28
Mode 17 17 13 30
IQR 15–17 13–17 10–13 24–30
Appointment 4
Potential range 0–19 0–19 0–13 0–32
n 175 185 185 185
Median 17 16 11 27
Mode 18 18 12 30
IQR 14–18 14–18 9–12 22–30
Appointment 5
Potential range 0–17 0–17 0–13 0–30
n 166 156 156 156
Median 15 14 12 26
Mode 17 16 13 26
IQR 12–16 12–16 10–13 21–28
Appointment 6
Potential range 0–19 0–19 0–8 0–27
n 175 182 182 182
Median 18 17 6 22
Mode 18 18 6 25
IQR 15–18 13–18 3–6 17–24
IQR, interquartile range.
Notes
n = number of available checklists.
Remaining data summarise number of components ticked ‘yes’.
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TABLE 28 Summary of checklist optional components ticked for each appointment by group: differentiating
between basic PFMT optional components and biofeedback-specific PFMT optional components
Appointment
Treatment group










Potential range 0–11 0–11 0–6 0–17
n 265 279 279 279
Median 3 3 3 6
Mode 0 0 0 0
IQR 0–7 0–6 0–4 0–10
Appointment 2
Potential range 0–18 0–17 (1 omitted in error) 0–12 0–29
n 235 245 245 245
Median 8 5 5 10
Mode 0 0 0 0
IQR 4–12 1–9 0–8 2–17
Appointment 3
Potential range 0–15 0–14 (1 omitted in error) 0–12 0–26
n 189 198 198 198
Median 6 4 4 9
Mode 0 0 0 0
IQR 3–10 0–8 0–8 0–16
Appointment 4
Potential range 0–13 0–13 0–8 0–21
n 175 185 185 185
Median 6 3 2 6
Mode 0 0 0 0
IQR 2–9 0–7 0–5 2–12
Appointment 5
Potential range 0–15 0–13 (2 omitted in error) 0–9 0–22
n 166 156 156 156
Median 6 3 2 6
Mode 0 0 0 0
IQR 2–10 0–8 0–4 0–11
Appointment 6
Potential range 0–16 0–12 (4 omitted in error) 0–10 0–22
n 175 182 182 182
Median 8 6 1 7
Mode 0 0 0 0
IQR 4–12 2–9 0–3 3–11
IQR, interquartile range.
Notes
n = number of available checklists.
Remaining data summarise number of components ticked ‘yes’.
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appointments, and, although appointment 2 in the biofeedback group could be when the device was first
introduced, it was not feasible to know this in advance when arranging the appointments to be audio-
recorded. Although we achieved more recordings in appointments 1 and 6, recruiting to appointment 1
remained difficult, but we achieved a reasonably balanced sample across groups (see Table 29). Overall,
the number of audio-recordings made was 88% of the original target.
The number of basic PFMT and biofeedback PFMT core components that were heard being delivered are
summarised in Table 30. We agreed that some components were unlikely to be heard and these were not
coded; hence, the potential range of components differs from the checklist summaries.
Therapists were heard to use fewer core components, overall, than the number that were potentially
audible for coding. This was the case for both groups and across all appointments. The biofeedback PFMT
group received more core components (basic and biofeedback combined, see Table 30, column 5) than
the basic PFMT group. No participant in the biofeedback PFMT group started biofeedback for the first time
in session 2.
A similar summary of audio-recording data was not undertaken for the optional intervention components,
given that we knew from the checklist data that therapists were not reporting the use of many of these
optional components.
Therapist interviews
We were able to recruit from 21 of 23 centres, obtaining 30 interviews from 26 physiotherapists, one nurse
continence specialist (total of 27 therapists delivering the interventions), two nurses and one administrator
involved in a variety of tasks, including participant recruitment, obtaining consent and dealing with IT issues.
We report therapist perceptions of recruitment and delivering the trial overall, their perceptions of both
basic and biofeedback PFMT interventions and any differences between them. We pay particular attention
to therapists’ perspectives on (1) their protocol fidelity and (2) participants’ intervention adherence.
Recruitment of trial centres and participants
Therapists said that the financial incentive was important during recruitment of their centre to the trial and
for supporting them in continuing in the trial. Management were more likely to agree if there was funding
associated with participation and the larger English centres with research experience knew this enabled
management buy-in:
I think that was, that was important, if it was just me doing extra work and the department not
making money out of it, they probably wouldn’t have been as supportive, ‘cause they rely on that
money kinda coming in for different research projects.
Therapist 4
TABLE 29 Summary of audio-recordings made by appointment and by group
Treatment group
Appointment (n)
Total (n)1 2 3 4 5 6
Basic PFMT 7 6 8 6 8 11 46
Biofeedback PFMT 8 6 5 6 5 12 42
Total 15 12 13 12 13 23 88
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TABLE 30 Summary of audio-recorded evidence of delivery of core components by group and by appointment
Appointment
Treatment group










Potential range 0–17 0–17 0–7 0–24
n (audios) 7 8 8 8
Median 11 8.5 3 11.5
Mode 10 8 2 and 3 15
Range 9–14 5–12 0–7 7–18
Appointment 2
Potential range 0–15 0–15 0–11 0–26
n (audios) 6 6 6 6
Median 7.5 6.5 4.5 10.5
Mode 10 7 4 and 5 9
Range 6–10 3–8 3–8 7–15
Appointment 3
Potential range 0–16 0–16 0–9 0–25
n (audios) 8 5 5 5
Median 7 9 4 11
Mode 5, 7 and 8 6 and 9 0 Multiple
Range 3–12 6–11 0–7 6–16
Appointment 4
Potential range 0–17 0–17 0–10 0–27
n (audios) 6 6 6 6
Median 6 6.6 5.5 11.5
Mode 5 4 and 7 6 10 and 13
Range 4–10 4–8 3–7 7–14
Appointment 5
Potential range 0–14 0–14 0–10 0–24
n (audios) 8 5 5 5
Median 8.5 6 6 12
Mode 9 6 6 12
Range 4–11 1–8 1–6 2–14
Appointment 6
Potential range 0–16 0–16 0–5 0–21
n (audios) 11 12 12 12
Median 7 7.5 3 11
Mode 7 8 2 and 3 10.5
Range 5–9 2–10 1–5 5–13
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Some centres retained trial monies to use for staff training and development, whereas sometimes the
hospital or trust kept the money; however, all centres kept their laptop and biofeedback units at the end
of the trial. One centre’s IT department required them to buy their own laptop at £1000 (the OPAL trial
contributed the value of the trial laptop) and the therapist from this centre noted that the subsequent
per-patient-recruited payment helped them cover OPAL trial set-up costs. The remaining therapists were not
motivated by the payment but by the research, a desire to know the outcome and acquiring biofeedback
units (or extra units) in the department, or the staff training and development:
I mean, obviously, what I’m hoping is that this is going to show that biofeedback is better than no
biofeedback, because so many of my patients find it, they just love it, they absolutely love it, it just
changes the way they see their appointments, and it also, I, I just feel it empowers patients to do
things for themselves.
Therapist 13
. . . we don’t actually have any [biofeedback units] in the department; we tend to suggest that patients
go and purchase their own, we don’t have a pool of them, so that’ll change now.
Therapist 5
Across all centres, those involved in recruitment reported that some participants refused because they
could not commit to six appointments. Others were reported to join for altruistic reasons or because they
wanted the ‘new’ therapy, even though the therapist made it clear they had only a 50% chance of being
randomised to the biofeedback PFMT group.
Delivering the trial
Therapists were positive about the intervention delivery training. A main concern was insufficient hands-on
experience with the biofeedback units, including connecting it to the laptop; this was true even for
therapists with experience of biofeedback devices from other manufacturers. It was recommended
that therapists practised with the units after the training and, although some did do this, many of the
interviewed therapists would have been willing to try the units on each other as part of their training.
Another concern was the delay between training and starting trial intervention delivery. Therapists would
have liked more timely training or a refresher nearer the start of the trial on biofeedback, IT and paperwork,
and such refreshers were offered and received by many. The trial website was reported to be easy to use
and navigate.
All centres experienced delays (a few months to 1 year) in being able to commence intervention delivery, as
the OPAL trial-supplied laptop was taken away by their IT departments for NHS security software installation
(one centre had to procure an alternative laptop). Therapists spent considerable time chasing IT departments
to get trial laptops back. Once ready to start, a variety of further IT set-up problems were experienced by
most centres, at least initially, while they got familiar with the equipment. Problems included the software
installed by NHS IT and faulty equipment: biofeedback units, vaginal probes, fibre optics and dongles. Often
the therapists who experienced these issues had to address these IT problems by themselves. They reported
that a lot of time was spent going between the trial team, their IT department and the manufacturers to
get to the bottom of their problem. Although the trial team support by telephone was perceived as good,
for those working on their own, this was a frustrating and lonely experience, and these IT problems were
the leading reason why one centre withdrew from the trial.
All therapists found the trial paperwork lengthy, time-consuming and repetitive, particularly the checklists.
Some said they could not complete the paperwork within the allocated time and some tried to complete
everything and realised later some elements (e.g. optional components) were not necessarily meant to be
repeated at every appointment. Some therapists felt that the paperwork did not ask for a subjective history,
which they would normally cover in their routine clinical work, especially before vaginal examination.
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However, there was free-text space for them to add anything. ‘Protocolised’ TAFs and checklists were
sometimes counterintuitive to the holistic, tailored approach therapists typically used:
I try and have quite a holistic approach to things, and I don’t always feel like the pelvic floor exercises
are the first thing that I would tackle, so sometimes I might, you know, talk to people about you
know, more like fluid management stuff and it would be that I wouldn’t even get started on the pelvic
floor stuff until I’d sorted out whether or not they have an overactive bladder for example.
Therapist 3
Although two centres bought extra therapist time to cover additional OPAL trial work, most centres had
to absorb this into existing workloads, even though they were not being asked to see additional patients.
Three centres withdrew from the trial, as the therapists did not have capacity to deliver the trial or they
found the demands of trial delivery overwhelming and lost motivation to take part. A combination of
factors contributed: difficulties recruiting women, IT or biofeedback device problems, paperwork issues,
changes or loss of key staff and delays between centre training and the centre being ready to deliver the
trial. Three further centres stayed in the trial but struggled to recruit because of caseload mix (few eligible
referrals and complex clinical presentations taking trial-designated therapists away from trial-eligible
patients), lack of staff continuity (e.g. rotational junior staff, maternity leave, staff leaving) or IT issues
(which delayed start of recruitment).
Delivering the basic PFMT and biofeedback PFMT interventions
All therapists liked the basic PFMT intervention, describing it as their ‘bread and butter’ (therapist 12) and
‘what we would have been doing anyway’ (therapist 1), although several said that the number of
appointments was more than they would routinely offer:
. . . we probably saw them more often, because we were seeing them the six times, so, on average,
I’d probably see a patient probably two to three times, so they probably were getting more contact
with us, which I think, from a motivational point of view, probably is better.
Therapist 27
The basic PFMT intervention was delivered within the allocated time and some said they struggled to fill
the six appointments or participants were not sure why they had to keep attending. Some therapists thought
components related to dietary advice and fluid intake were more often delivered in the basic PFMT intervention.
All therapists also liked the biofeedback PFMT intervention, but it was more problematic to fit it into the
scheduled time because there were additional activities (e.g. downloading biofeedback data, showing
participants how they had improved and adjusting the unit). Many therapists experienced problems initially
in the delivery of biofeedback, particularly connecting the biofeedback unit with the laptop. Already
feeling under time pressure in a biofeedback consultation, this caused additional stress and these early trial
consultations ran late:
Very stressful; my heart used to sink a little bit if they were randomised to the EMG group, I just knew
that that was going to be a lot more work and a lot more paperwork and it probably would be
appointments that would run over time . . .
Therapist 12
Although many technical problems resolved over time, having prior experience of using biofeedback was
useful. Some centres routinely used similar hand-held biofeedback units, whereas others had only one
hand-held unit for the whole department or a larger clinic-only machine. Previous and/or regular experience
of using hand-held units gave therapist’s confidence in delivering the OPAL trial biofeedback intervention,
which they continued to use post trial. In contrast, confidence was usually lower in those without previous
experience and, although encouraged to practice with their routine patients (prior to the trial), the less
experienced still wanted more time to practice before delivering biofeedback to trial participants.
PROCESS EVALUATION
NIHR Journals Library www.journalslibrary.nihr.ac.uk
58
Although the basic PFMT intervention was similar to usual practice, the biofeedback protocol was different
for many:
. . . it very much differed from my usual care . . . in as far as I wouldn’t, I have, I haven’t given any
equipment to aid the patient’s compliance before.
Therapist 26
The trial protocol required therapists to introduce biofeedback in clinic at appointments 1 or 2, then at every
subsequent appointment, and prescribe home biofeedback. In contrast, therapists who previously used
biofeedback said that they would typically use it more selectively, for instance they would not usually start a
patient on biofeedback immediately but start with PFMT, or would introduce biofeedback only to patients
who struggled to contract the pelvic floor muscles, or only once patients had good PFMT technique to check
that they were not using accessory muscles (albeit with different units to those used in the OPAL trial).
Delivering treatment beyond the trial
Some therapists delivered treatment to participants beyond the 6-month blind assessment date, explaining
that more improvement was possible. Two interviewed therapists extended treatment (after the six OPAL
trial appointments) for participants in the basic PFMT group, to include biofeedback. Therapists also
referred participants for further treatment or investigation according to their clinical judgement.
Therapists were more confident using biofeedback in their everyday practice post trial. They were also
using it for a wider range of patients:
I probably used it a bit more often, so the OPAL randomisation maybe made me use it with people
that I wouldn’t usually have used it with.
Therapist 14
The randomised allocation required therapists to use biofeedback with some patients they might not
usually have offered it to and their assumptions about who might find it acceptable had changed. For
example, they had typically thought younger women would like the technology and older women would
not, whereas it became apparent during the trial that younger participants (often working mothers) did
not have the time or privacy to use the biofeedback at home, whereas older participants did and the
technology in itself was not a barrier to them.
Therapist perceptions of participants’ intervention fidelity and adherence
Therapists made a number of theoretical propositions about participants’ engagement in treatment and
adherence. One observation was that symptoms prompt participants to undertake PFMT and that
participants forgot to do PFMT as their symptoms improved.
A second observation was that participants’ levels of motivation and commitment to the intervention
influenced engagement and, ultimately, outcome. For instance, the importance of patient motivation
and buy-in was linked to participants’ health priorities (many participants in the trial had comorbidities
and their UI symptoms were not their top health priority) and whether or not participants could find
energy and time for PFMT. Another example was that therapists thought that if participants expected the
biofeedback to stimulate their muscles for them, they were disappointed and somewhat demotivated.
Alternatively:
. . . if they need motivation or they’re very motivated, and particularly if they’re very young and they
have less complex problems, if it’s just the pelvic floor issue then you’ve got more time and energy to
focus on, right, pelvic floor, biofeedback, whereas if it’s, you know, you’ve got to be dealing with their
constipation, their diet, their depression, or a million other things, you’re less likely to give up a whole
half-an-hour appointment just for the pelvic floor.
Therapist 8
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Therapists also saw buy-in change over time, with participants withdrawing from the trial because of personal
circumstances (such as ill health or ill health of a family member), rather than because of the research or the
interventions. These participants prioritised their other health conditions or the health of their family member
over their continence.
Accountability was also thought important. Therapists mentioned that participants compared treatment
to weight loss classes; regular attendance and knowing they were going to be assessed meant that
participants worked harder than they would have done had they been on their own. The therapists
wondered, but were not sure, if accountability was felt more strongly in the biofeedback PFMT group,
as part of the appointment included the therapist downloading the participant’s data.
Therapists noticed how many participants struggled to fit biofeedback into their daily routine, especially
those who were time-constrained and working mothers:
. . . how do I fit this into my daily life? – that’s the big issue, and you know, we had quite a few
conversations about that.
Therapist 21
Therapists wondered if biofeedback would work better if it was used only in the clinical setting rather than
at home, or if home biofeedback was the key, or if biofeedback would be appropriate only for those women
who struggle to do PFMT because of very weak pelvic floor muscles or a lack of contraction sensation. The
majority of interviewed therapists hypothesised that biofeedback was more suited to goal-orientated women
who have the time and privacy at home to use the equipment:
I did also probably feel that maybe more active sporty ladies who had quite high demand on their
pelvic floor and quite a high demand from treatment wanted, you know they, they seemed to be
better with the biofeedback, I definitely felt like it’s a motivational tool and made ladies feel like they
were achieving something, and made them work harder probably.
Therapist 30
Participant diaries
Although the number of returned diaries dropped from appointment 2 to 6, in much the same way
appointment attendance dropped (see Table 30), there were no apparent differences in the pattern
between the two groups (Figure 11). Nor were there apparent differences in the proportion that were




































FIGURE 11 Proportion of exercise diaries signed (by participant and therapist) and returned by appointment and
by group (in respect to the total number attending that appointment in that group).
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In free-text diary entries from participants, the most frequent reasons for being unable to exercise were
time (biofeedback PFMT = 13 comments, basic PFMT = 33 comments), forgetting (biofeedback PFMT = 7
comments, basic PFMT = 24 comments) and other physical health reasons (biofeedback PFMT = 25
comments, basic PFMT = 13 comments), with menstruation featuring more frequently in the biofeedback
PFMT (14 comments) than the basic PFMT group (6 comments) (participants were not expected to use
biofeedback during this time).
Discussion
Discussion is structured according to the source data, covering key findings and interpretation, as well as
the strengths and limitations.
The appointment checklist data show that therapists said (ticked ‘yes’) they had delivered most of the core
components per appointment; therefore, the between-group differences in delivery were as designed: the
biofeedback PFMT group received more core components (specific to biofeedback) without necessarily
compromising the number of basic PFMT core components the participants were meant to get. This
suggests that, overall, the therapists delivered the interventions with fidelity to the form of the protocol
for both groups and that the biofeedback PFMT group did receive an intensified intervention. It was clear
that the optional components were seldom used. The strength of the checklist data set is that it may offer
a comprehensive assessment of appointment content. The main limitation is that it relies on accurate
therapist recording. Other data sources indicate that therapists were clearly time pressed (see Therapist
interviews), so reporting accuracy may have been compromised and in the much smaller sample of
audio-recorded appointments less was heard to be done. However, there was no suggestion that fidelity
was lower in one group than the other.
The audio-recording data verified that the biofeedback PFMT group did receive more components
(biofeedback specific) overall, and there was no obvious imbalance in number of basic PFMT core components
between groups, suggesting, again, that the biofeedback PFMT group received an intensified intervention.
We plan to compare individual audio-recorded appointments with their corresponding checklist to verify
fidelity. This is a potential strength of the audio-recordings, yet they have limits as a gold-standard method
of assessing fidelity; we cannot be sure that we coded every component of an appointment as some could
have been completed in silence, outside the clinic room or after the recorder was turned off. Coding was
complicated because therapists did not necessarily use the language or specifics detailed in the intervention
manual or BCT taxonomy, and there was general conversation between the therapist and the participant
(e.g. for establishing the therapeutic relationship) to ‘sift’ through. The resources required to obtain the
audio-recordings, transcribe and analyse them was a further limitation. However, they may provide a rich
data source of anonymised composite examples for future training to help therapists refine their use of BCTs.
The therapist interviews provided extensive material regarding the challenges of trial delivery and how
this had an impact initially; they also offer further insights into intervention delivery fidelity and therapists’
ideas about what has an impact on patient adherence. Several of the challenges expressed by therapists
were to do with the research (IT issues, paperwork) and these would not be an issue if either of the trial
interventions were implemented into routine practice. It was clear that some therapists were overwhelmed
by the logistics of getting ready for the trial and there were gaps in support locally, highlighting how
difficult it can be to establish research ‘readiness’, especially in centres where levels of research experience
are low. Many therapist comments related to their confidence in delivery of good basic PFMT in contrast
with their concerns about confident and competent use of biofeedback PFMT, at least initially (e.g. the
‘heart sink’ some experienced if a participant was randomised to biofeedback). Much of this concern
related to IT issues and the time pressure imposed by trying to fit all biofeedback components in the first
two appointments, rather than a dislike or lack of belief in the use of biofeedback PFMT or, indeed, the
biofeedback protocol. Nevertheless, the therapists did manage to deliver an intensified intervention to the
biofeedback PFMT group.
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In contrast, therapists reported that both they and the participants felt that the basic PFMT intervention
lacked content, with some participants querying why they needed to attend all six appointments. Checklist
data show that few optional intervention components were used in either group. This is important,
suggesting that the trial was a fair test of PFMT intensified by biofeedback and we can be clear that the
null result is unlikely to be confounded by more use of ‘extra’ therapy (the optional components) in the
basic PFMT group. However, from a clinical perspective, it is perhaps a missed opportunity when there
were further optional components that could have been used to promote participants’ adherence, or to
overcome barriers to adherence. This raises the question of how well the therapists understood and
adopted the theory underpinning the intervention protocol; they clearly distinguished between the basic
and the biofeedback PFMT interventions, but it was less apparent that they had assimilated into their
practice all of the underlying theoretical components (IMB and BCTs) for enhancing participant adherence
to treatment. This suggests an opportunity for further refinement to the training manual (and more time
for training) for promoting PFMT adherence. We do, however, commend the trial therapists for delivering
the core components of a highly protocolised evidence-based basic PFMT intervention with such commitment.
It may be that this excellent basic PFMT meant that the biofeedback had to add a lot extra to obtain
additional effect on outcomes.
Therapists hypothesised that many of the influences on participants’ PFMT (non-) adherence related to
the complex context of participants’ lives, similar to findings of Hyland et al.57 These theoretical propositions
can be explored in further analyses in which we link main trial, case study and process evaluation data sets
and attempt to identify any key characteristics about the participants, their therapist or the intervention they
received that influence outcome (see Chapter 7).
The exercise diary data indicate that one of the BCTs (commitment, indicated by participant and therapist
signature) designed for promoting adherence was utilised consistently for both groups. Therapist interviews
suggested that this was seen as a useful addition to the therapist ‘tool box’ and therapists attending the
post-trial collaborators’ event described continuing to use this BCT in their current practice (and that they
had found the protocolised checklists useful reminders). The participants’ free-text comments in the diaries
confirmed some of the difficulties experienced when using vaginal probes; other physical health problems
and menstruation appeared to affect biofeedback use more than on undertaking basic PFMT. However,
time and forgetting were more frequently reported reasons for non-adherence in the basic PFMT group and
a possible interpretation here is that having a biofeedback unit at home (whether used or not) meant that
fewer participants forgot to exercise.
Conclusion
The process evaluation offers two key findings concerning fidelity of delivery and receipt. Together,
they indicate that the OPAL trial did achieve what it set out to do: a fair test of whether or not a PFMT
intervention intensified by biofeedback could improve participant outcomes. First, therapists did deliver an
intervention to the biofeedback PFMT group that was more intensive than that delivered to the basic PFMT
group; this was despite therapists being time pressed to complete the biofeedback intervention delivery
and all the trial requirements. Second, most participants did receive core components of basic PFMT and
this was the case for both groups. Few optional intervention components were used by therapists in either
group and there was no inadvertent ‘intensification’ of the basic PFMT group intervention through an
imbalance in the amount of optional components used, even though therapists reported that they
sometimes struggled to fill appointments in the basic PFMT arm.
This embedded and comprehensive theoretically informed mixed-methods process evaluation is unique to
the trials conducted so far in the field of PFMT. To the best of our knowledge, only one trial11 has reported a
process evaluation and this was a single-method (qualitative) approach; one new trial is planning a mixed-
method evaluation58 and an earlier trial reported plans for a process evaluation.59 The multiple data sources
in the OPAL trial bring a richness to our understanding of trial processes and experiences of the therapists
PROCESS EVALUATION
NIHR Journals Library www.journalslibrary.nihr.ac.uk
62
and women involved, providing an opportunity to explore factors having an impact on adherence to PFMT,
and other contextual factors that may explain variations in treatment delivery and effectiveness across and
between the trial groups.
The work is not without limitations in terms of data quality, analytical volume and complexity; a programme
of further more nuanced analytical work is being prepared to ensure that we fully explore the opportunities
for learning from these data sets. In summary, we have demonstrated robust assessment of intervention
fidelity assisting in interpretation of the trial outcomes (as the null result is a clinically important message)
and indicated potential transferability of these findings into clinical practice and further research.
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Chapter 6 Longitudinal qualitative case study
Introduction
This chapter reports the methods and findings from the longitudinal qualitative case study. In line with
contemporary process evaluation guidance, this is an in-depth, pre-planned and theoretically driven
longitudinal, comparative, qualitative case study to support understanding of two complex interventions
that aim to reduce UI in women.53 In this chapter, we refer to the interview participants as women, in
recognition of the fact that this chapter is based on women’s interview accounts (rather than using the
term ‘participants’ as elsewhere in the report).
In this chapter, the longitudinal qualitative comparative case study will be referred to as the case study.
Given the link between this study and the main OPAL trial, the same conventions in terms of referral to
group allocation will be adhered to: specifically, when referring to the basic PFMT group we are referring
to women allocated to basic PFMT group (ITT), whether or not the women adhered to treatment or
crossed over treatment group; similarly, when referring to the biofeedback PFMT group, we are referring
to women allocated to the biofeedback PFMT group.
When quotations are presented, they are followed by the case number of the woman, the interview
(0M for baseline, 6M for 6 months, 12M for 12 months and 24M for 24 months) and the woman’s
group allocation.
This chapter addresses one aim from the OPAL trial, namely to:
l investigate women’s experiences of the interventions, identify the barriers and facilitators that affect
adherence in the short and long term, to explain the process through which they influence adherence
and to identify whether or not these differ between randomised groups.
Methods
A longitudinal, qualitative, two-tailed case study design60 was employed, in which the tails were the
biofeedback PFMT and basic PFMT trial groups. A detailed protocol has been published.21 A sample of
women from both groups took part in semistructured interviews. The two-tailed case study design
complemented the trial design in its comparative focus, with the analysis set up to explore group
differences. In this chapter, we will hereafter refer to groups rather than tails, in line with the terminology
used in the trial. Case study design supports robust group comparison in a qualitative way;61 therefore,
conclusions of similarity and difference should be read as qualitative comparison as opposed to
quantitative (statistical) comparison.
Sampling and recruitment
Forty randomised women (20 in each group) were purposively sampled for variance in centre type, women’s
type of UI and therapist type. Each recruited woman was one case. Women were asked to consent to the
case study specifically (having already consented to take part in the trial). The women were given an additional
invitation letter [see the project web page: www.journalslibrary.nihr.ac.uk/programmes/hta/117103/#/
(accessed 29 July 2019)] and patient information leaflet [see the project web page: www.journalslibrary.nihr.
ac.uk/programmes/hta/117103/#/ (accessed 29 July 2019)]. Women who remained interested were contacted
by telephone approximately 1 week later to ask if they would like to participate. Written consent was obtained
at the time of the first interview [see the project web page: www.journalslibrary.nihr.ac.uk/programmes/hta/
117103/#/ (accessed 29 July 2019)].
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Case study data collection
Data were collected by a series of semistructured interviews [see the project web page: www.journals
library.nihr.ac.uk/programmes/hta/117103/#/ (accessed 29 July 2019)]. Each interview had a specific focus:
l Baseline pre-treatment interviews (face to face) explored the woman’s experience of UI, the social
contexts within which she experienced UI and her expectations of treatment.
l A 6-month post-treatment interview (face to face) explored the woman’s experience of the trial
intervention, her adherence to therapy appointments and the prescribed programme, factors that
affected that adherence and her perceptions of treatment outcome.
l 12- and 24-month interviews (telephone) explored, at each time point, the woman’s experience of
UI post intervention, the intervention, factors that influence ongoing PFMT adherence and
treatment outcome.
Interview data were, with consent, collected using a password-protected audio digital recorder. Interview
audio-recordings were anonymised, transcribed verbatim and entered into NVivo software to support analysis.
Case study data analysis
Analysis was guided by the OPAL trial protocol [see the project web page: www.journalslibrary.nihr.ac.uk/
programmes/hta/117103/#/ (accessed 29 July 2019)] and the OPAL qualitative study and process evaluation
analysis plan [see the project web page: www.journalslibrary.nihr.ac.uk/programmes/hta/117103/#/
(accessed 29 July 2019)]. Three different researchers have worked on the OPAL case study (Anne Taylor,
Aileen Grant and Marija Kovandzic), alongside the responsible grant holders (Carol Bugge, Jean Hay-Smith
and Sarah Dean). By the nature of qualitative analysis, each analyst had a different approach to data
analysis. This was encouraged by the grant holders, within the confines of the protocol, to maximise the
insights into the data. Sources that were drawn on to support that analysis included Yin,60,61 Alvesson and
Sköldberg,62 Grant et al.,63 Kovandžić et al.,64 Stake65 and Ritchie et al.66
Overall, analysis was iterative with data collection. Analysis occurred on four interacting levels to facilitate
within- and cross-case comparisons.
At the level of the individual interview
An initial a priori coding scheme was developed and initially applied, focusing on core areas of interest:
UI experience, PFMT ± biofeedback experience, factors that influenced adherence in the short and long
term and perceptions of treatment outcome. The coding was developed through team discussions,
iterative coding and multiple analysts’ perceptions. The analytic purpose was to identify barriers and
facilitators that influenced adherence and patient-reported UI outcomes.
At the level of the case (woman)
Case summaries in narrative and tabular form were written with a focus on understanding a woman’s
experience of UI, the treatment, adherence, treatment outcome and how these factors interacted. Analysis
focused on identifying issues relating to changes over time and in developing rival explanations (additional
theoretical propositions) that guided subsequent analysis.60 Theoretical propositions and rival explanations
are analytic strategies drawn from case study design.61 The theoretical propositions used in the OPAL trial
were drawn from the original research questions and the rival explanations arose from working with
the data.
At the level of the trial group
Using case summaries and matrices from the framework approach,66 the cases for one trial group were
arranged together and consistencies and inconsistencies searched for. The aim of analysis was to identify
the core barriers and facilitators within the trial group, the detailed explanations for them and interactions
between them.
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At the group comparison level
The biofeedback PFMT and basic PFMT groups were compared using the theoretical propositions in order
to identify similarities and differences in barriers and facilitators between the trial groups.
After the trial result was known, an additional analysis was undertaken that aimed to explore who
biofeedback works for and why. This analysis is not presented in this report, but may be helpful in
understanding subgroups of women for whom biofeedback is more useful.
Management and governance
Ethics approval for the case study was gained within the main trial approvals (see Chapter 2).
The case study and process evaluation team had a management group with the required mix of clinical,
qualitative, quantitative and theoretical skills and experience. The group met regularly to discuss the
research management and emerging findings. The case study was carried out at a separate academic
institution to the main trial. The case study team participated in trial meetings to understand how the trial
was progressing, but the case study and process evaluation team meetings were closed. Data were not
shared from the case study and process evaluation group with the main trial group until the final PMG
meeting in September 2018.
Findings
Sample
Forty women, 20 per group, were recruited to the case study, as planned. Twenty-five women completed all
four interviews, but, owing to the technical problems with the audio-recorder, a full data set was available for
only 24 women (10 biofeedback PFMT and 14 basic PFMT). The total data set consisted of 125 interviews,
including 24 complete cases (96 interviews). The total number of minutes of recorded interviews per case
ranged from 15 minutes to 126 minutes, with a total of 2856 minutes of recorded interview data. There
were 40 baseline interviews (20 biofeedback PFMT and 20 basic PFMT), 32 interviews at 6 months
(16 biofeedback PFMT and 16 basic PFMT), 28 interviews at 12 months (13 biofeedback PFMT and
15 basic PFMT) and 25 interviews at 24 months (11 biofeedback PFMT and 14 basic PFMT).
The age of women in the case study ranged from 20 to 76 years, with both the biofeedback PFMT and
the basic PFMT groups including women with a wide age range (Table 31). In the main trial, women
ranged in age from 20 to 83 years (22–83 years in the biofeedback PFMT group and 20–78 years in the
TABLE 31 Characteristics of women in the case study by group allocation
Variable
Treatment group
Overall case study sampleBasic PFMT Biofeedback PFMT
Age (years), range 20–76 25–69 20–76
UI type, n
SUI 6 5 11
MUI 14 15 29
Centre type, n
Community 2 4 6
University 9 7 16
DGH 9 9 18
Therapist type, n
Physiotherapist 18 18 36
Nurse 2 2 4
DGH, district general hospital.
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basic PFMT group); thus, the women in the case study were comparable in age to the main trial sample.
From the total case study sample, 11 women had SUI and 29 MUI; the proportions were similar within
groups. Six women in the sample were treated in community clinics, 16 in university hospitals and 18 in
district general hospitals; again, there were similar proportions in the groups. The vast majority of women
were treated by physiotherapists (n = 36) and four women were treated by nurses.
Women’s adherence to the interventions
Women’s adherence to the interventions was analysed in two phases: active treatment and maintenance.
‘Active treatment’ refers to the time when women were attending appointments and receiving the OPAL
trial interventions delivered by a trained therapist. It is the proxy for shorter-term adherence – the uptake and
adoption phase of PFMT – including women’s attendance at appointments, receiving biofeedback-mediated
PFMT or basic PFMT in the clinic and then undertaking their prescribed programme (biofeedback PFMT or
basic PFMT) at home between appointments. The ‘maintenance’ phase is when long-term adherence is
demonstrated and is the period of time after the active treatment has ended when women were asked to
continue PFMT themselves at home without therapist supervision, including relapse management, up to their
final follow-up at 24 months.
Table 32 shows examples of the variation in women’s adherence to PFMT. These examples illustrate that
there are no obvious group differences in adherence in the case study sample in terms of the frequency
with which they undertook biofeedback PFMT or basic PFMT.
Facilitators of adherence during the active treatment phase
There was greater similarity than difference in facilitators of adherence in the active treatment phase when
the trial groups were compared. Two key themes, among the many that were identified, focused on UI
symptoms and factors related to the OPAL trial therapist.
Urinary incontinence symptoms acted as a facilitator in several ways. One way was through the mechanism
of women wanting to eliminate or reduce their UI, so that they could get on with their lives and improve
their quality of life:
Case 27, 0M, biofeedback: Well I’m hoping that it’ll help the leaking and it’ll, it might never stop,
but it won’t be as bad as it’s been . . . that’s what I’m hoping.
Researcher: Yeah. Is there a goal; do you have, like, a personal goal that you would like?
Case 27, 0M, biofeedback: Just that really, just . . . to stop the leaking, maybe be able to go back to
yoga and not feel like I’m worrying about leaking or whatever.
TABLE 32 Case study examples of variation in adherence to treatment by allocated treatment group and across time
Adherence
Active treatment Maintenance
Biofeedback PFMT Basic PFMT Biofeedback PFMT Basic PFMT
Good
adherence
Case 27: uses biofeedback











Case 39: very good
adherence for first couple of




Case 1: tried for three times a day
but does not always manage –











Case 32: does not do PFMT at all Case 15: does not
do PFMT at all
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I’m not that old that I, I’m ready to kind of hang up my dancing shoes.
Case 26, 0M, basic
Women also wanted to prevent a deterioration in their UI symptoms and to avoid surgery. Seeing an
improvement in UI during the active treatment phase motivated women to adhere because they felt that
their treatment, and their skill to undertake the exercise, was working:
Doing the exercises [was most helpful about treatment] and noticing that there was a change,
do you know what I mean? And then realising myself that that was, there had been a change . . .
Case 24, 6M, basic
For women from both groups who had a break in their regular biofeedback PFMT or basic PFMT practice,
a deterioration in symptoms (after a period of improvement) provided proof of PFMT effectiveness and
acted as a facilitator to use the skills that they had learned to overcome the symptomatic deterioration.
Many women from both groups talked at length about the positive impact of the therapist. Women talked
about their therapist as an important and credible source of information, as a motivator and as someone
who taught them the exercise, lifestyle and behavioural skills needed to undertake biofeedback PFMT or
basic PFMT (in line with theoretical model underlying the interventions).17 All of these factors influenced
adherence in the active treatment phase in both groups. However, possibly the most important element of
the interventions in each trial group was the instruction on how to perform PFMEs, given by the therapist
during the vaginal examination (digital assessment). Given the sensitivity of the topic, vaginal examination
was not easy to talk about during the research interviews and, consequently, not an easy finding to capture
in the analysis. Yet there was a consistent observation of the importance of the therapist-mediated vaginal
feedback as being one of two distinctive and valuable forms of vaginal feedback in PFMT (therapist mediated
and EMG mediated). The findings from the case study point to the therapist-mediated feedback as being the
priority and as one of the most important therapist-related facilitators in gaining confidence in PFMT skills
and adhering to treatment.
The quotation below provides an illustration of the difficulties of articulating experience of PFME
instructions during the vaginal examination, as well as the importance of these instructions, which included
feedback (as exemplified in the quotation, a part of the feedback loop was the act of the therapist feeling
the difference in muscular activity during the examination):
That was quite good actually, having somebody there, and I think when you’re doing exercises and
then being able tae feel that it was working, do you know that way when you would get your
assessment . . . and you did have to do them, the exercises, and she could feel the, the difference
[ . . . ] I felt [ . . . ] that was good, u-uuh, just to know that you were doing it properly [ . . . ] ’cause
you do those exercises and you really don’t know one way or another if you are doing it right.
Case 30, 6M, biofeedback
Another important therapist-related factor that had an impact on adherence was the rapport created
between the therapist and the woman. The conditions for creating rapport require further analysis. It is
possible that the above-mentioned therapist-mediated vaginal feedback plays a role, but at this point of
analysis it is certain that having dedicated space and time (secured by OPAL trial intervention design) to
build understanding and trust through repeated appointments with the same therapist acted as a
motivator to adhere to the treatment, if not being a therapeutic agent on its own:
And it’s very motivating . . . you know, seeing someone who’s interested in you, who wants to help
you is terribly motivating . . . ‘cause otherwise you’re just on your own, ‘cause you don’t chat to your
friends about it . . . the only person I’ve ever really spoken to about this [UI] is [OPAL therapist] and the
nurse specialist.
Case 32, 6M, biofeedback
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[ . . . ] it was good having a one to one with someone who kind of constantly, you were able to talk to
about your symptoms and how to improve it and I think just knowing that em that they were there
and they were able to tell you, you know, ‘if you work on this, it will improve’ and I think that was a
big help, even right at the end there, it was a really good for her to tell me, the physio[therapist] to tell
me, like, what exercises it’s best for you to do, what’s not good for you to do and if you keep going
wi’ this it’s going to continue to improve, I think that will help me. [ . . . ] you know, psychologically,
even if it wasn’t physically, you know, I mean it eventually will be physically, but em, you know, even
psychologically I think that was good.
Case 15, 6M, basic
Other therapist-related facilitators included education provided by the therapist, being treated by an
accommodating and skilful therapist, being treated by a therapist who adjusted the treatment protocol
based on individual needs and feeling accountable to the therapist:
I think it was the, the, eh what’s the, what’s the best way to describe it, the actual having to report
back to [therapist], because then you knew, you know, you can’t, well you can’t just sort of, you
know, sit there and say ‘right, OK I didn’t do it,’ and she would know herself when we did the sort
of, the few, even, you know, not the internal examination, when we did the actual work, you know,
when she was there and she could tell from my posture, you know, if I was doing it right or not,
she was like ‘right, you’re slacking’ . . .
Case 3, 24M, basic
Beyond the symptom- and therapist-related facilitators summarised above, women identified other
facilitators of adherence that included the following:
l Service structure, framing and physical environment. Having regular appointments; ease and flexibility
of making appointments; feeling positive about the physical environment of the treatment facilities;
feeling that the intervention was within the framework of womanhood; or the woman finding the
treatment as a whole a novelty were all facilitators of adherence.
l Ownership and agency in the intervention. In terms of ownership and agency, the following were seen
as facilitators of adherence: the woman feeling accountable to herself; having a new focus on herself
through starting a new lifestyle routine; developing a sense of embodiment and empowerment as
starting to feel (and control) her own pelvic floor muscles; and through their own personal
characteristics, such as ‘strong will’, commitment and altruism:
I was so determined though, I mean the thing is you’ve got to want to, to help yourself I think [ . . . ]
you know, it’s just not going to, just taking a note of what somebody says to do, you’ve got to want
to do it as well [ . . . ] you’ve got to want to, you’ve got to need to do it as well, you know.
Case 20, 24M, basic
l Support from relevant others. Their partner, participation in the trial and a sense of accountability to the
trial team were all facilitators of adherence.
l The intervention. In terms of the intervention, the following were seen as facilitators of adherence:
making use of the exercise diary; a woman gaining knowledge about her anatomy, UI and PFMT;
learning the skills to undertake biofeedback PFMT or basic PFMT; learning routines for biofeedback
PFMT or basic PFMT (such as keeping the biofeedback unit next to her bed) or doing PFMT while
watching TV; and learning that PFMT exercise was easy and could be performed at any place and
any time:
. . . so the education was eh the principal thing, when you learn how to do and why it’s wrong,
what is wrong . . . and then you can do your, do good for your body.
Case 13, 6M, biofeedback
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. . . it’s probably the easiest form o’ exercise you could do, I mean you don’t even need tae go tae a
gym, it’s so easy.
Case 34, 12M, basic
There were facilitators that were specific to biofeedback. Some women reported liking the biofeedback device
and having confidence that, by using biofeedback PFMT, they were more likely to achieve symptomatic
improvement than if they were doing PFMT alone. In developing the OPAL trial intervention, the research
team hypothesised that visualisation of the pelvic floor muscle contraction via biofeedback PFMT would
support self-efficacy for performing the correct contraction, leading to improved adherence and better
outcomes. Some women in the biofeedback PFMT group did report that visualisation was important for them
for two main reasons: (1) they could see if they were doing the pelvic floor muscle contraction correctly and
(2) they could see improvement in their pelvic floor muscle contraction ability over time. Women valued the
opportunity to be able to discuss the visualised contraction with their therapist.
Other features of biofeedback PFMT that women valued were biofeedback supporting women being
competitive with themselves; having a new ‘toy’ to play with; the physical presence of the unit acting as a
reminder; getting instruction from the biofeedback device in terms of counting of repetitions and pace of
PFMT; and an awareness that the data on the biofeedback device would be looked at by and discussed
with the therapist:
I thought it was quite positive that when you were actually using it you could see, and I think it did
make you try, it definitely made me try harder, and also I felt that I was doing it for longer, like it,
you know, a 10-second hold I think when you haven’t got the biofeedback is probably, in reality, an
8-second hold, because you count quite quickly . . . whereas with the biofeedback I felt that you were
doing it properly and I was definitely trying harder because I was seeing it and I was thinking ‘right,
I want’ it’s that sort of slightly competitive side to human nature, you’re thinking ‘right, I want to get,
I want to get it higher’.
Case 8, 6M, biofeedback
In summary, although some group differences were noted, there were more similarities in facilitators of
adherence than differences. There were many facilitators of adherence in the active treatment phase, with
being motivated to improve symptoms and the effect of the therapist being clear facilitators in both groups.
Barriers to intervention adherence during active treatment phase
There were more similarities across barriers than there were differences between the groups. Time and
contextual factors in a woman’s life (such as daily routines) were two of the themes that could be seen to
act as barriers to adherence.
Women talked about having a lack of time for themselves; hence, finding time for appointments and to
exercise was difficult. Women reported a lack of time to attend appointments in general and frequent
appointments in particular, to focus on practising PFMT, either with or without biofeedback; biofeedback
was even more time-demanding and, as such, a potentially greater barrier in the biofeedback group:
I don’t know who supplied the physio[therapist] with the dates, but she kinda had a calendar, at the
end o’ my appointment she could tell me the time frame when I was due back . . . and I would look at
my diary and was like ‘oh, that’s only like 2 weeks’ time’, so I don’t know, maybe even once every 5,
6 weeks or something, em but that, again, that’s just because I’m a working mum and I don’t always
have the child care, so em it wasn’t always easy for me to, to get the kids watched, . . .
Case 16, 6M, biofeedback
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Lack of time was compounded by having a generally busy life that included being a working mother,
having unpredictable work patterns and going on holiday. For several women, their UI, and its treatment,
was not a priority given the array of other things that were competing for their time. Illness – theirs, or in
family members – was a particular barrier to adherence:
Em . . . most of the time I’m OK now, as I say I still do my pelvic floor exercise at the moment, eh it’s
not always OK, but [most of them are?], em [sighs] that’s nothing to do wi’ the machine [?] that I
dropped out [of treatment], I took, mum took no’ well and I took really bad depression and I
would’nae get out the bed.
Case 17, 6M, biofeedback
Other contextual factors that acted to diminish adherence included not having a routine (or hook) for
doing PFMT, lack of privacy at home, lack of support from their partner and simply forgetting (in the array
of other things to do).
Several other barriers could also be identified, these included the following:
l A lack of sufficient, or sufficiently quick, improvement in the UI symptoms. This led to a drop in
motivation to adhere. Despite this drop in motivation, many women were still inclined to
continue treatment.
l There were service factors that acted as a barrier to adherence, some of which were OPAL trial-specific and
others which were not. These included general transport or parking problems; the treatment facilities being
unappealing or inappropriate; a lack of suitable appointments; and, although uncommon, a feeling that
staff were being difficult, ‘one of the receptionists at the [clinic] is an absolutely [sic] dragon’ (Case 14, 6M,
basic). Women also reported anxiety and/or embarrassment about having to undergo vaginal examination;
being put off by other trial requirements, such as completion of the bladder diaries; not being randomised
to their preferred group; and, in a few cases, there were indications of rapport and/or satisfaction with the
therapist not being as good as for the majority of other women. Some women commented that there was
repetition between the visits and that this made them unsure about the value of continued appointments:
Yeah, there seemed to be quite a lot, you know, I seemed to have a lot of appointments, em . . .
my husband’s going ‘oh you’re not going there again, what are you going for, what on earth are
you going for this time?’ . . . Em maybe the odd time I did feel a bit like that ‘cause I felt, u-uuh,
at times I thought ‘oh God here, we’re just going to talk about exercises’ [ . . . ] the odd time I did
feel ‘gosh, maybe that was a bit of a waste of time’ [slight laugh] . . .
Case 15, 6M, basic
l A few women in both groups felt that they did not learn the correct PFMT technique in the clinic or how
and when it should be applied, which could manifest as a lack of confidence about doing the exercises
correctly. It is possible that this lack of confidence is linked to not receiving enough therapist-mediated
vaginal feedback:
I thought there would be, I thought there would maybe be more em involved in helping support
you doing the actual . . . exercises; not that they were difficult or anything like that, I just, I, I think
I just felt, you know, you get told what to do, you’re advised about what, how to do them, they
don’t, [sighs] I’ve only once been checked to make sure I was doing them right, em so my feeling
kinda was am I doing these right? Are they really effective?, and it was a bit hit and miss I felt . . .
to how well I was doing; . . .
Case 26, 6M, basic
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There were some barriers that were specific to the biofeedback PFMT group. Some women found the
biofeedback device intrusive or painful to use and others found it inconvenient (e.g. having to set it up,
or to clean it):
I found it intrusive and painful to be honest [ . . . ] if I had of [sic] found it less uncomfortable it
possibly would have made me notice what I was doing more, but I, I just couldn’t put up [with] the,
the pain of it, so I couldn’t be bothered with it.
Case 5, 24M, biofeedback
Women reported that they needed to find even more time to undertake PFMT supported by biofeedback.
Some women also reported embarrassment and a lack of privacy about using biofeedback:
I think it was quite a good idea, but I don’t think it worked for me, for my personal circumstances,
I found it too footery [fiddly] to do, and I just found it quite difficult to have that kind of privacy . . .
just to do it, because I found it easier if I was lying down in the bedroom but then, you know, the kids
were always like in and out, running around and obviously I didn’t want them to see it, and I just felt
it took quite a lot of time and I just felt I didn’t really have the privacy to do it properly, em, so I don’t
think it really worked for me, I felt it was too footery; but on the other hand I think it had lots of
advantages, ‘cause I think it was quite useful to see, to see what was actually happening.
Case 8, 24M, biofeedback
Other issues with the biofeedback included one woman reporting that she got thrush from using the
biofeedback unit; the biofeedback unit could be framed as externalising the movement of the pelvic floor
muscles and a distraction to embodiment of PFMT; and practical problems with the biofeedback unit that
hampered ability to use it:
I thought I was doing super, then one day it died and it, I knew it had a brand new battery so that
shouldn’t have happened . . . it died, so I rang them up and I took it in and we got a new battery,
then I came back and it happened again, it kept doing weird things, and then I bought batteries up
the road in the end, so, . . . And then I realised that by looking at the machine I was distracted from
doing the exercises.
Case 32, 6M, biofeedback
In summary, there were more similarities than differences in barriers to adherence in the active treatment
phase; there were also additional barriers in the biofeedback PFMT group. A lack of time and many
contextual factors were the key barriers to adherence to biofeedback PFMT and basic PFMT.
Facilitators of women’s adherence in the maintenance phase
None of the women in the biofeedback PFMT group reported using biofeedback after the end of
treatment in the trial. None of the interviewed women reported buying biofeedback equipment; some
therapists did give women the probe to keep and use, yet none of the women reported using it, even
though some reported intention to use it. Thus, the data below relate to women, from both groups,
undertaking basic PFMT in the maintenance phase.
Women in both groups reported a change in their adherence from the active treatment phase. PFMT
maintenance was not consistent over time in either group and there were no differences (from qualitative
comparison) between the groups in their adherence. The inconsistency in adherence between women
can be seen in Table 32, in which, at the extremes, some women undertook PFMT in a regular and daily
manner, whereas others did not do PFMT at all. In between these extremes were women who undertook
PFMT with varying degrees of regularity. As well as the inconsistency between different women, there
were fluctuations in adherence for individual women over the time period with, for example, other health
concerns taking over and diminishing adherence at some points in time.
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Many of the facilitators that applied when women were in the active phase of treatment also applied in
the maintenance phase.
Similar to the active treatment phase, women’s desire to lessen UI symptoms supported adherence to
PFMT in the maintenance phase. If women perceived symptom deterioration or recurrence and associated
this with PFMT as a mechanism to improve symptoms, adherence was facilitated. The interpretation of the
data would suggest that symptoms may only act as a prompt to undertake PFMT in the maintenance
phase if the woman perceived that there was an improvement in symptoms as a consequence of doing
PFMT during the active treatment:
Not really no [been doing PFMT], but quite often in the last week, ‘cause I’ve noticed a difference that’s
why I’ve sort of started to try and do it again, ‘cause I have noticed a difference in not doing it . . .
Case 8, 6M, biofeedback
Oh yes, I always will [exercise] now, that’s it . . . that’s it, because I know it, I know it’s, you know how
much it’s helped.
Case 20, 24M, basic
There were multiple factors that seemed to influence women’s confidence (self-efficacy) to continue, or
feel able to restart, PFMT in the maintenance phase. Many women reported feeling that they had good
levels of knowledge and skill to undertake PFMT correctly. Beliefs in their skills and knowledge could be
attributed to women feeling they had mastery of PFMT; having memories of the support they received
from the therapist during active treatment; recalling information imparted by the therapist; using the
resources given by the therapist (such as information leaflets); keeping a record of PFMT like an exercise
diary; and recalling the sense of hope given during treatment and the control they gained:
I don’t feel like I need to go back and see a doctor or, you know, see a nurse or anything, I feel like if
it got bad again I could, you know, I’ve got these exercises to fall back on.
Case 27, 24M, biofeedback
I remember the girl who, or the nurse that, the lady, you know the . . . pelvic floor . . . in [location],
and I remember her, she was very good, gave me a lot of confidence in myself, you know and . . .
it was really good, she was very, very helpful, and I can remember, I can remember the improvement, . . .
Case 20, 24M, basic
In the biofeedback PFMT group some women related having good skills and knowledge of PFMT directly
to biofeedback during active treatment. Women in the basic group also felt that they had good skills and
knowledge of PFMT acquired from teaching by, and feedback from, therapists. Therefore, biofeedback
was not a necessary prerequisite for having skills and knowledge for PFMT maintenance:
[I remember] learning to use the machine properly . . . knowing I was doing it right and . . . yeah, and
just generally being made more aware of the muscles that you need to squeeze and . . . when you’re,
and you know you do one at a time and then you hold them all . . . so yeah . . . being taught how
to do pelvic floor . . . muscle training . . . yeah, being taught that properly, yeah, . . . made a big
difference.
Case 23, 24M, biofeedback
Other factors that facilitated adherence in the maintenance phase included the following:
l A supportive home environment.
l Establishing the intervention as part of life: being able to find time for themselves; helpful work
patterns (e.g. working from home or time spent commuting); making use of available time to do
exercises (e.g. sitting and waiting time such as while commuting, or watching television).
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l Development of routines or ‘hooks’ that continued to supported continued PFMT. In the example below
the woman refers to keeping note of her exercising (like in an exercise diary):
I don’t think so, I mean I know what to do, I mean it’s . . . I, I, aye, I know what tae dae and I know
what I should be doing but it’s just the getting intae it, so . . . maybe I should start up a wee book
kinda thing again, I done that the last time and I was dain’ wee [unclear word] like when, how
many I had done, do you know, how many kinda exercises I’d done that day, and eh, do you know
what I mean, I think I should start that, when it’s doon in black and white sometimes that kinda,
kinda motivates you oan . . .
Case 24, 12M, basic
l Ownership and agency in the intervention – motivation and determination; cognitive features, such as
remembering to do PFMT; and framing PFMT as ‘control’ (e.g. PFMT as a tool to control her body,
or PFMT and the control over UI it gives being the only part of her life she can regain control of):
Oh probably [doing PFMT] daily, ‘cause I do sort o’ try to keep it going . . . ‘cause I’ve got to keep
control o’ something, I can’nae control everything else [that I’ve got?] . . . [I was more?] conscious
of it then, but, as I said, it’s one thing I’m sort of trying to keep control of . . . so I’ll try and keep
that bit going.
Case 17, 24M, biofeedback
l Trial-specific factors – research interviews acting as a trigger to undertake PFMT, interviews providing a
space for reflection on a woman’s own PFMT practice, attending the 6-month pelvic floor assessment
and wanting to demonstrate that the therapist had done an excellent job. These factors occurred in
both groups.
l Women in both groups reported using an application on their phone that supported doing/
remembering to do PFMT:
I [got] the squeeze App on my phone and that was really good . . . you know, it helps you, you
obviously train yourself to hold for longer [kind of thing], that was good.
Case 19, 24M, basic
In summary, adherence did change in the maintenance phase from the active treatment phase. There was
considerable variance, in individual women and between women, in adherence in the longer term. Many
of the facilitators that supported women in adhering in the active treatment phase continued to facilitate
adherence in the maintenance phase.
Barriers to women’s adherence in the maintenance phase
One barrier to adherence that was unique to the maintenance phase was the loss of therapist support, and
accountability to the therapist, when the active treatment phase ended. Some women felt ‘alone’ in their
efforts to improve their UI. Others expressed the view that, because they were no longer accountable to the
therapist, there was no longer that prompt to exercise. Other women said that they got out of the habit
of writing their exercises down (as they would have done in the exercise diary during active treatment):
I thought, you know when the nurse did it with me, you know, did it, that helped me a lot, really it
did, if I could keep going to the physiotherapist and if she kept checking me, because I think, you
think you’re doing it right and then I could be doing it wrong and that, you know what I mean,
I mightn’t be feeling . . . Yeah, I mean I would have liked then to be able to phone up, you know,
the physio[therapist] and say ‘look, can I have another appointment?’, rather than the length of time
between each, and then of course it stopped for so many months . . .
Case 6, 12M, basic
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Otherwise, the main barriers for women in maintaining PFMT, whether allocated to the biofeedback PFMT
or basic PFMT group, were similar to those found in the active treatment phase. First, some women’s UI
had improved to such an extent that they had no symptoms to act as a reminder to exercise:
. . . as I said my symptoms have reduced so there’s not so much of a physical reminder that ‘oh, I need
to do them’ [PFMT].
Case 28, 12M, biofeedback
The second key barrier was the loss of motivation or loss of the habit of doing PFMT due to life events
taking over, even if this was contrary to the intent they had at the end of active treatment. Women spoke
of various contextual factors in their lives that prevented them from maintaining a PFMT regime, such as
having too many other things to do, work commitments or work changes getting in the way, or more
generally feeling that they lacked support. Commonly, women talked of having other non-UI health
problems that overshadowed their focus on UI and/or on their attention being more on the needs of
others (commonly immediate family). In keeping with the active treatment phase, the findings suggest an
interaction between a lack of time (e.g. as shown below, women not having time for themselves) and the
multiple other contextual factors that get in the way of life:
Well I’ve had a lot o’ other health issues so it’s kinda been, that’s [PFMT] been the least o’ my worries
[UI] tae be honest wi’ yae [slight laugh].
Case 10, 24M, basic
Case 32, 12M, biofeedback: . . . it really is down to me . . . I expect you hear that from a lot of women
. . . And it’s very hard to put yourself at the top of your own time agenda . . .
Researcher: As women . . .
Case 32, 12M, biofeedback: Yeah, yeah [talks about her husband exercising every day no matter
what] . . . So, but with me something seems to come up, [then it’s?] all my stuff goes to pot on my
own agenda . . ., I suppose it’s just, [he’s] not easily distracted but there are more pressures on me . . .
and I think it’s probably the same for women generally.
Other factors that acted as barriers to adherence in the maintenance phase were as follows:
l Not establishing PFMT as part of life. Some women found maintaining a PFMT exercise programme to
be difficult because they had no routine in life generally, or for PFMT specifically, or that routine
changed (e.g. going on holiday).
l Not feeling confident in their PFMT technique and when to use it after treatment had stopped. This
seemed to manifest as a lack of confidence in (1) their ability to undertake PFMT generally or (2) how to
get restarted after a break in PFMT. Various reasons can be identified for this lack of confidence in the
maintenance phase: forgetting what they were taught, not feeling that PFMT was going to work, not
perceiving that their UI was caused by pelvic floor weakness (it was caused by something else) or
because they had not seen symptomatic improvement during active treatment. However, there was a
stronger pattern for women to feel confident about continuing PFMT than not having the confidence
to continue.
l Ownership and agency in PFMT. Some women talked about a lack of motivation and willpower, they
talked about forgetting to exercise (sometimes or always), and PFMT lost the novelty factor and priority
over time.
In summary, large-scale systematic differences between the biofeedback PFMT and basic PFMT groups in
barriers to PFMT maintenance were not evident from the data set. Key barriers to maintaining PFMT lay in
loss of support following the active treatment phase and busy lives.
LONGITUDINAL QUALITATIVE CASE STUDY
NIHR Journals Library www.journalslibrary.nihr.ac.uk
76
Women’s urinary incontinence outcomes in the short and long term
The case study did not set out to explore outcome, but women discussed outcome as part of their experience.
Given the longitudinal case study design, and the core aim of the trial, it was useful to consider women’s views
of outcome in this chapter in relation to UI symptoms. However, interviewed women reported outcomes that
were considerably broader than UI symptoms alone. For example, the women talked about changes they made
to their lifestyle, changes to their feelings about UI and about a myriad of things they had learned from being
part of the trial. These additional outcomes will be documented in more detail in future publications.
At 24 months (when the primary outcome was measured in the trial) there was no obvious difference
between the groups in UI severity from qualitative comparison; rather, there were women in both groups
with varying outcomes (Table 33).
In both the biofeedback PFMT and basic PFMT groups there were more women talking about positive
outcomes in relation to their UI symptoms at 24 months than there were talking about poor outcomes
(i.e. from baseline it seemed as if women tended to be better than they were before they entered the
trial). This information, however, needs to be considered with caution, as qualitative studies do not aim to
statistically generalise:
I was just going to say well no, thank you for the opportunity because I’ve seen a massive, you know,
improvement and because I’ve got a prolapse and obviously, I’m quite young, I’m only 38, it was
making me sort of anxious about [?] and you know, everything has improved, my bladder control
and my prolapse symptoms have improved, I’m not getting as many em, I used to get sort of quite a
lot of dragging sort of tummy ache [muscle, or little,?] and I don’t get that any more, so, you know,
and I know that that is definitely all down to the trial, if I wouldn’t have been involved in that, then
I know that I’d still be having the problems and still be anxious, you know, if I went out walking or if
I went, went running, or to the gym or whatever, so, so I’d like to say thank you to you guys as well.
Case 28, 24M, biofeedback
In terms of short-term outcomes, in both groups there was a pattern that suggested that women were
likely to have better UI outcomes at 6 months (immediately post-active treatment phase) than at 24 months.
For example, case 13 (biofeedback PFMT) reported symptomatic improvement at 6 and 12 months, but at
24 months reported that her symptoms were the same or a little worse than when she started the trial.
There was, however, variance between individuals. For example, for case 32 (biofeedback PFMT), there was
no improvement noted at 6 months and at 24 months her symptoms were worse than when she started
the trial. There were other cases when improvements occurred beyond 6 months (i.e. 6 months was not the
best outcome point). For example, case 36 (basic PFMT) reported good improvement at 6 months, further
improvement at 12 months and yet further improvement at 24 months.
TABLE 33 Case study examples of variance in UI outcomes at 24 months by allocated treatment group
Nature of outcome
Treatment group
Biofeedback PFMT Basic PFMT
Good outcome Case 27 was almost cured with few SUI
symptoms at 24 months, some occasional
urgency persisted
Case 20 was almost cured; her stress symptoms
were gone completely and urgency occurred
only occasionally
Intermediate outcome Case 17’s symptoms were not gone but were
much improved (e.g. she makes it to the toilet
with UI most of the time)
Case 36 continued to have UI symptoms, but
they were better than before she started with
the OPAL trial (e.g. she had more time to get
to the toilet)
Poor outcome Case 32’s UI symptoms were worse at
24 months than when she started in the trial
Case 24’s symptoms were the same or worse at
24 months than when she started in the trial
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In summary, there were no obvious differences in UI outcome between the trial groups.
Theoretical propositions
Two theoretical propositions and one rival explanation were considered. The theoretical propositions were
driven by the theory that supported the hypothesised mechanism of action (propositions 1 and 2) and one
rival explanation that arose from analysis of the data (proposition 3).
Proposition 1: biofeedback PFMT will improve (1) women’s adherence and (2) women’s
urinary incontinence outcomes more than basic PFMT in the short and long term
This proposition was the main hypothesis of the trial. There was no clear evidence that biofeedback PFMT
improved adherence over basic PFMT in the short or long term, nor any clear evidence of greater improvement
of outcomes in either the short or the long term. Therefore, the theoretical proposition was not supported.
Proposition 2: the factors that influence women’s adherence and women’s urinary
incontinence outcomes change over time
This proposition arose from the long-term nature of the follow-up that was part of the commissioning
brief and was based in our understanding of the influence of context (e.g. Wells et al.67). This proposition
was supported in that it was clear that the factors that influence adherence and outcome for an individual
woman do change over time. For example, there were women who were diagnosed with other conditions
during the trial that, for them, took precedence in their quest for good health. However, the hypothesis
aimed to identify if there were factors that arose at specific time points for a group of women. It does not
seem that there were factors that occurred at the same time point in specific groups of women (other than
the removal of support when treatment finished); however, this will be the subject of further analysis.
Proposition 3: factors other than biofeedback PFMT or basic PFMT will influence
adherence and urinary incontinence outcome in the short and long term
This proposition arose from rival explanations (to biofeedback PFMT or basic PFMT directly linking to
adherence and outcome) being identified iteratively in data analysis. Although there were factors other than
the interventions that influenced adherence and outcome, there were considerably more similarities in the
factors than differences between the groups. The notion of life events taking over encapsulates this well.
However, for some women with multiple other life events, there was still adherence and a symptomatic
improvement (i.e. these factors did not always act to diminish adherence or outcome, but they often did).
Discussion
Women reported positive experiences of both the biofeedback PFMT and basic PFMT interventions; in
particular, women were clear about the benefit of therapist input. There were no major differences, based
on qualitative comparison, in adherence to PFMT or UI outcome between the biofeedback PFMT and basic
PFMT groups, with wide variation in adherence and outcome in both groups. Adherence in the short and
long term was facilitated by women’s desire to improve or cure their UI symptoms and by factors related to
the therapists, which included feedback given through vaginal examination and rapport. A lack of time and
life taking over were key barriers to adherence in both the short and long term. Adherence did change over
time, but there were no clear differences between the groups. Although UI outcome did not appear to
differ between the groups, there was a trend towards improved outcomes at 2 years when compared with
baseline. There were features of biofeedback PFMT that worked as anticipated (such as visualisation), but
there were also drawbacks to biofeedback (such as it taking more time than PFMT alone).
Strengths and limitations of the case study
A key strength of the case study, and qualitative research linked to trials in general, is that it facilitated the
voice of those whom the intervention aimed to help to be heard and represented. The longitudinal nature
of the case study, with detailed follow-up at the same time points as the trial, and the purposeful searching
for expansion on emerging ideas at subsequent interviews, allowed consideration of women’s expressions
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of adherence to PFMT over time. Studies of long-term adherence in UI are rare (only one other longitudinal
study,68 with women who have UI, has been identified), but are important as reduced adherence is a
common explanation for why treatment effect is not sustained over time.69 The two-tailed case study design
offers a robust, qualitative means of comparison that supports the comparison in the trial.
The process evaluation and case study drew on a contemporary published framework in further developing
the work and developing the analysis plan.63 That framework proposes multiple candidate approaches to
understanding various features of the trial and its effects. However, one weakness was that data were not
gathered on all the candidate approaches.63 However, data were gathered on several candidate approaches
that were central to the research questions, such as maintenance. Another potential weakness of the case
study in relation to the trial is that the interviews may have acted as a co-intervention to promote adherence,
for example women reflected that they undertook PFMT because they knew that an interview was coming
up. However, the case study recruited women from both the biofeedback PFMT and basic PFMT groups and
any effect of the interviews on adherence potentially occurred equally in both groups.
Comparison of findings to existing literature
The evidence from the case study is consistent with the trial finding that biofeedback PFMT did not
improve UI outcomes more than basic PFMT. Insights from the case study are helpful in explaining the
main trial finding. The qualitative data demonstrated that biofeedback could work as anticipated, with
women reporting the benefits of being able to visualise the contraction and know that they were doing
the contraction correctly, alongside their learning in partnership with the therapist. However, women in
the basic PFMT group also had confidence in their ability to undertake PFMT. For these women, this was
based on learning in partnership with the therapist. A possible conclusion is, therefore, that biofeedback
does not need to be added to a strong basic PFMT programme in order for women to achieve self-efficacy
for and adherence to PFMT; good therapist input can also provide self-efficacy and adherence.
Aspects that are central to this conclusion are that the OPAL trial basic PFMT (and biofeedback PFMT)
programmes allowed sufficient time with therapists to support a treatment effect;70 both interventions
were based on BCTs;8 both demonstrated that some women achieved self-efficacy for PFMT;71 both groups
received therapist-mediated vaginal feedback; and one group also received biofeedback.7 Although it is
possible that if biofeedback PFMT had been compared with a less robust basic PFMT programme there
would have be been a difference between groups, it would then have been difficult to reach conclusions
about the effectiveness of adding biofeedback because of other confounding variables.7 Our conclusions
therefore support a finding that, if all other aspects of PFMT are kept equal, the addition of biofeedback
may not lead to a greater improvement in continence outcomes.
Another possible explanation for why biofeedback PFMT was not more effective than the basic PFMT is
that, although women in the biofeedback PFMT group did identify features of biofeedback as facilitators
of adherence, they also identified features of biofeedback as barriers to adherence. One tentative
hypothesis here is that the facilitators and barriers simply cancel one another out. However, this needs
further analysis.
Case study findings demonstrated that women generally reported positive experiences of the OPAL trial
interventions. Women were positive about learning to do PFMT (with or without biofeedback), which is
consistent with a previous qualitative synthesis.18 Women were also very positive about the therapists.
Women talked about the therapist in ways that suggested that the therapist was seen as a credible source
of information, a motivator and as someone who could support the learning of the necessary behavioural
skills, all of which supports the theory underlying the development of the interventions (IMB17). Furthermore,
in keeping with previous suggestions, rapport between woman and therapist was seen as a factor in
supporting adherence.18
There was a trend identified in the case study data for women to perceive that their UI was better at
2 years than it was when they started the trial. This was not the case for all women. It was, however,
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an important finding in the context of the worldwide evidence that UI negatively affects women’s day-to-
day lives (see, for example, Bradway,72 Delarmelindo Rde et al.73 and Hamid et al.74). Although it is possible
that the improvement described by women is not linked to the interventions, the evidence suggests that
women did perceive a link between the intervention they received, their adherence to PFMT and their
positive outcome. This link will be explored in more detail in further analysis.
Adherence to PFMT did change over time, but not differently between the allocated groups. A key reason
for including the case study alongside the trial was the recognition of the influence of context on the
effectiveness of complex interventions.67,75 It is now widely recognised that context interacts, modifies,
shapes and constrains the intervention and implementation.76 This study chose to investigate the influence
of context in-depth from the participants’ perspectives (rather than also exploring the problem, trial and
organisational contexts), because it was believed these would be the most important factors to shape the
interventions and influence their effectiveness. It is important to understand the dynamic relationship
between context, implementation and intervention to define what was implemented and understand how
works in certain contexts. It is now no longer enough to say what works, we need to explore what works,
for whom and in what context.53 It was clear that many varied personal contextual factors influenced
adherence. The longitudinal nature of the study was important in highlighting that for all women, context
and implementation were dynamic and life events got in the way. In addition, many women put the needs
of others before themselves. We need to carry out a nuanced analysis to explore the characteristics of
these women to understand the various ways women may overcome these events. Previous research
supports the links between life taking over and inconsistent adherence in UI.57,77 These findings suggest
that when delivering a PFMT intervention, or in future research, consideration should be given to helping
women balance the multiple contextual factors in ways that may support their engagement with PFMT
and their re-engagement with PFMT after a break.
Urinary incontinence symptoms were an important factor in adherence at the outset, and continued to be so
in the long term. Symptoms influenced adherence in a number of ways. Women adhered to rid themselves
of symptoms, but, conversely, when symptoms were no longer present, the trigger to exercise was no longer
there and some women then stopped exercising. Women had to perceive change and believe that it was
linked to treatment to maintain adherence in the longer term. This finding is consistent with other studies.18
It is an important feature of care delivery for therapists to keep the connection between PFMT and
symptomatic improvement at the forefront of women’s minds.
LONGITUDINAL QUALITATIVE CASE STUDY
NIHR Journals Library www.journalslibrary.nihr.ac.uk
80
Chapter 7 Results synthesis
Aims
The OPAL trial consisted of three main components: a trial, a process evaluation and a longitudinal case study.
The aim of the synthesis was to bring together findings from individual data sources to facilitate drawing
overall conclusions about why the interventions may or may not have been clinically effective [see the project
web page: www.journalslibrary.nihr.ac.uk/programmes/hta/117103/#/ (accessed 29 July 2019)] and identify
where there was agreement and disagreement between the findings.
Specifically, agreement and disagreement was assessed in the four following key areas:
1. benefit of biofeedback PFMT over basic PFMT in UI symptoms
2. whether or not the biofeedback PFMT group received an intensified intervention that could have led to
improved continence outcomes
3. whether or not the biofeedback PFMT group had greater self-efficacy for PFMT that could have
encouraged more PFMT and therefore improved continence outcomes
4. whether or not the biofeedback PFMT group had greater adherence to PFMT that could have led to
improved continence outcomes.
Methods
To achieve this aim, an approach to integrating of results from mixed-methods research described78 was
adopted: a triangulation protocol.78 The term triangulation is used here to mean a way of addressing
a study question using different methodologies to give a fuller picture. Triangulation occurs at the
interpretation stage, once the contributing data sets have each been analysed separately. One form of
triangulation protocol involves producing a convergence coding matrix, which shows findings from each
of the individual study components, with an assessment of whether there is agreement, partial agreement,
or disagreement between them. Occurrences of ‘silence’ are also noted when there is no information from
one source on a theme arising in another.
We applied this approach and produced a convergence coding matrix based on the five data sources
available:
1. data relating to all trial participants, recorded in questionnaires at each time point, exercise diaries and
TAFs (trial)
2. data from interviews with a sample of trial participants (case study)
3. data from interviews with therapists as part of the process evaluation
4. data from the checklists completed by therapists as part of the TAF at every appointment as part of the
process evaluation (checklists)
5. data from audio-recordings of a sample of therapy appointments as part of the process
evaluation (audios).
Results
The results of the synthesis are summarised in Table 34. There was evidence of full agreement from all
data sources that there was no group difference in severity of UI at the 24-month follow-up. The primary
outcome of UI severity measured by the ICIQ-UI SF at 24 months demonstrated no group difference in UI
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TABLE 34 Convergence coding matrix




ICIQ-UI SF score at 24 months
did not differ significantly
between groups, indicating
that biofeedback PFMT did
not result in less severe UI
than basic PFMT
There was no difference
between groups at 24 months
when expressed as cure or
improvement in UI
Women in both groups
reported a range of good,
intermediate and poor
UI outcomes
At 24 months there was no
obvious group difference
in changes in UI severity
from baseline
Some women in each
group valued improvement
in UI symptoms, even if this
was not what might be
measured as cure
Some therapists expected
there to be no difference
between groups
Barriers to therapist’s delivery
and women’s receipt of
biofeedback may have
had an impact on the
potential benefits
Simplicity of delivery of the
basic PFMT protocol and
of implementing it at home






In the intervention phase, in
the biofeedback PFMT group:
l 80% received biofeedback
during one or more
appointments
l 78% used the
biofeedback unit one or
more times at home
Silence (further post hoc
analysis will explore




but felt that they were
pressed for time
Therapists experienced in
using biofeedback said that
in their usual practice, they
would not use biofeedback
in the first appointment
Therapists did deliver
biofeedback PFMT and
women did receive it;
the biofeedback PFMT
group did get more
overall
The biofeedback group
got more, but some
core basic PFMT
components may have
been omitted as a result
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24 months was significantly
better in the biofeedback
PFMT group vs. basic
PFMT group
The addition of biofeedback
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line with the hypothesised
mechanism of action
(ability to visualise the
contraction giving
confidence in ability to
contract correctly)
Women in the basic PFMT
group also reported
confidence in their ability
to undertake a contraction
and the exercises
At the current stage of
analysis, there is no
obvious difference in self-
efficacy between groups.
Some women in each
group reported confidence
in their ability to undertake
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exercising a few time per
week or more at 24 months
(49% biofeedback vs.
43% basic)
Women in both groups
reported varying levels
of adherence, with no
obvious group differences
in the ways women
adhered in terms of home
exercise in the shorter or
longer term
There were many barriers
and facilitators that
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severity; this finding held when different assumptions were tested. The case study also showed that, across
the time points, women in both groups reported varying degrees of improvement (see Table 34). The
therapist interviews highlighted some issues with using biofeedback in clinic, which may have affected
delivery of the protocol. The case study also made reference to difficulties with biofeedback being
experienced by women. Biofeedback was, however, reported as being delivered in 80% of appointments
and used at home by 78% of participants in this group. The addition of biofeedback did not improve
continence outcomes at 2 years and a robust basic PFMT protocol was shown to be as effective as PFMT
plus biofeedback.
There was a conclusion of partial agreement regarding whether or not the biofeedback PFMT group
unequivocally received a more intensive intervention. There was evidence from the checklists that
participants in the biofeedback PFMT group did receive biofeedback in clinic and used biofeedback at
home, which the basic PFMT group did not have access to. From the checklists, it also appeared that the
biofeedback PFMT group received all elements of the protocol, as did the basic PFMT group (i.e. the only
difference between groups was the addition of the clinic and home-based biofeedback). There was no
evidence from our preliminary analysis of the interviews with women in the case study to allow comment
on whether the biofeedback PFMT group did or did not receive the intended intensified protocol. A
preliminary analysis of the therapist interviews and appointment audio-recordings might suggest that
some elements of the basic PFMT protocol had been left out, or were less well emphasised, in order to
accommodate delivery of biofeedback in clinic. A further analysis is planned to investigate this by doing a
more detailed cross-checking of the data sets.
Greater self-efficacy was hypothesised to be a mechanism by which biofeedback would increase the quality
and quantity of PFMT that women undertook, leading to improved continence outcomes. There was partial
agreement for this hypothesis from the data sources. The participants’ responses to the self-efficacy for
PFME scale34 indicated a small significant difference between the trial groups, with the biofeedback PFMT
group having greater self-efficacy. There is no published minimal clinically important difference for this
scale to allow assessment of the probable importance of the observed difference. However, it seems
improbable that a 2.4-point difference on a scale ranging from 17 to 85 (e.g. equating to an improvement
in one item from ‘strongly disagree’ to ‘neutral’) would be meaningful. Interviews with women provided
evidence of self-efficacy in both groups, whereas therapists saw the potential for biofeedback to further
empower some women.
There was partial agreement that initial (uptake and adoption) and longer-term (maintenance) adherence
was no greater in the biofeedback PFMT group in terms of how well women engaged with the interventions.
In the main trial, adherence was seen to be similar between the groups: similar numbers of appointments
were attended and home exercise was comparable over time. Similarly, no overall difference in adherence
between groups emerged from the interviews with women, with many barriers and facilitators being the
same for both groups. However, interviews with both women and therapists indicated that there were also
differences between the groups: some women did adhere better as a result of clinic biofeedback, and some
women lacked time and privacy to fit in home biofeedback.
Discussion
The synthesis of the available data is a work in progress and conclusions here are tentative; however, on the
whole, there was partial, if not complete, support for the main trial findings from the study components
designed to offer deeper understanding of the complex interactions and main ‘no difference’ findings.
We hypothesised that biofeedback would facilitate self-efficacy, which in turn would increase adherence
to PFMT and better outcome; however, none of these have been upheld when we have brought together
the evidence and triangulated four of the main theoretical components and associated outcomes.
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Chapter 8 Discussion and conclusions
Statement of principal findings
The results of the OPAL trial showed clearly no evidence of a difference between biofeedback PFMT and
basic PFMT in terms of UI severity for women with SUI or MUI at 2 years. This was supported when we
examined all urinary outcomes (cure/improvement, other lower urinary tract symptoms, condition-specific
quality of life, patient perception of UI improvement) both at the 2-year time point and the interim 6- and
12-month time points. Further evidence of no difference between groups was found in the other secondary
outcome measures of pelvic floor function, prolapse symptoms, bowel symptoms and uptake of other UI
treatment. There was a small difference in self-efficacy between groups, perhaps indicating a trend towards
the biofeedback PFMT group having more confidence relating to PFMEs, in line with the hypothesised effect
of biofeedback, but the magnitude of the difference was small and unlikely to be clinically significant.
Adherence to the intervention protocols, a potential mediator of better clinical outcomes, was similar between
groups, again in keeping with the main trial finding. There were no SAEs related to the intervention and only
one non-serious related AE, which was found to be due to a nickel allergy in a biofeedback PFMT participant.
Both interventions were found to be similarly cost-effective. The process evaluation highlighted some
challenges with, and barriers to, biofeedback delivery from the therapists’ perspective on one hand, but
offered evidence of fidelity to the protocol nonetheless. Interviews with participants in the case study
supported the finding of no evidence of a difference between groups in the UI outcome.
Although there was no evidence of a difference between the two randomised groups, improvement in
ICIQ-UI SF was observed in both treatment groups over the course of the trial, with 8% of women reporting
cure and 60% improvement in each group at 24 months.
Robustness of primary outcome analysis
The OPAL trial was large enough to detect a meaningful difference between groups if one existed, with
a sample size far exceeding the largest previous trial of its type (n = 238, PFMT plus biofeedback and
biofeedback vs. PFMT alone).79 There was limited information about the minimal clinically important
difference of the ICIQ-UI SF on which to base the sample size calculation at the outset of this trial;
however, a recent publication indicated that a 3-point difference was clinically important, supporting our
original assumption.28 In addition, the observed SD of the primary outcome was 5 points, which was lower
than our original assumption of 10 points, again pointing to the trial having sufficient statistical power.
In sensitivity analyses we showed that our primary outcome analysis was robust to the effects of missing data
(tested under assumptions of missingness at random and not at random) and treatment non-compliance.
Further analyses of the primary outcome
In further analysis of the primary outcome, we also examined whether or not specific subgroups benefited
from biofeedback PFMT compared with basic PFMT. The mechanism for the effect of PFMT in urgency UI
differs from that for SUI; therefore, we investigated whether or not there was a different treatment effect
for those women with pure SUI and those with a mix of SUI and urgency UI. There may be reasons why
older, more so than younger, women might do less well with the addition of biofeedback, such as older
women being less likely to engage with the biofeedback technology. The varying levels of severity of
UI might be due to different underlying problems, which could respond differently to the addition of
biofeedback. Finally, we explored whether or not women treated by different types of therapists might
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have different responses to the interventions. There was no evidence to suggest that women who differed
with respect to type of UI (SUI vs. MUI), age (< 50 years vs. ≥ 50 years), UI severity (mild/moderate vs. severe)
or therapist type (physiotherapist vs. non-physiotherapist) differentially benefited from either intervention type.
Strength and limitations
Strengths
A major strength of the OPAL trial was its mixed-methods design, including a RCT, with a process evaluation
and longitudinal case study alongside. This offered the potential for a much deeper understanding of the
intervention mechanisms and trial results from different perspectives.
The trial itself was conducted and reported following CONSORT recommendations [URL: www.consort-
statement.org/ (accessed 31 July 2019)]. We used an automated computer randomisation application
developed by CHaRT, accessed remotely by centre staff, to assign group allocation, thus minimising the
risk of selection bias. The analyses were conducted on an ITT basis and in accordance with a predefined
statistical analysis plan [see the project web page: www.journalslibrary.nihr.ac.uk/programmes/hta/117103/#/
(accessed 29 July 2019)], agreed with the TSC. We chose a well-validated and commonly used instrument as
our primary outcome measure (ICIQ-UI SF) and a long duration of follow-up.
Participants were recruited from various outpatient and community settings, adding to the generalisability
of the findings. At baseline, the two groups were highly comparable, indicating that the allocation process
implemented in the trial had been successful. Our follow-up questionnaire response rates were high, indicating
a low risk of attrition bias, with rates of 74% at 6 months, 84% at 12 months and 78% at 24 months. The
lower response rate at 6 months is probably because of a less intensive process for contacting non-responders
at this time point, which was not the primary end point. Such high retention rates limited the impact of
missing data on our findings and this was confirmed by the sensitivity analyses, which showed no impact on
the primary outcome analysis findings of various assumptions about missing responses.
All elements of the trial delivery were standardised, as far as possible, to minimise the risk of performance
bias. Therapists in trial centres received training in all aspect of the interventions, including using the
biofeedback equipment, delivering the PFMT protocol and incorporating the core and optional BCTs.
This information was also provided to all therapists in a detailed intervention manual.
Limitations
Reasons for exclusion of women from the trial were kept to a minimum; however, one reason for women
being ineligible was being unable to contract their pelvic floor muscles. Such women were excluded based
on the NICE guideline, which recommends that women who cannot actively contract their pelvic floor
muscles should be offered biofeedback.1 If we had included these women, half would have been allocated
to basic PFMT and therefore denied biofeedback. This means, however, that conclusions cannot be drawn
from the trial about this subpopulation of women with UI.
It was not possible to blind participants as to which group they were in because of the nature of the
interventions, and for the same reason it was not possible to blind treating therapists. The risk of detection
bias was, therefore, high, given that participants were the main source of outcome data. The pelvic floor
assessment at 6 months was, however, carried out by a clinician who was blind to the participant’s group
and, in keeping with other outcomes, the finding was no evidence of a difference between groups.
Approximately one-third of women in both groups attended all six of their scheduled therapy appointments
(109/295, biofeedback PFMT and 106/298, basic PFMT). Women commented in interviews on the lack of
time to attend frequent appointments. This would reflect the situation in clinical practice, in which the
‘did not attend’ rate for PFMT appointments is high.
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Another potential limitation is that biofeedback equipment is advancing rapidly and biofeedback units are
now available that incorporate bluetooth and smartphone technology. These new features, not widely
available at the time of developing this trial, may mean that therapists and women would now be less
constrained in using such devices. Thus, there may be potential for an enhanced effect of biofeedback
delivered using newer devices. These advancements may also have overcome some of the technical issues
associated with biofeedback reported by therapists and women in the OPAL trial.
Interpretation of results
Chapters 4–6 provided discussions of the health economics, process evaluation and case study findings,
respectively. Here, we consider how to interpret the totality of the OPAL trial findings, drawing on the
synthesis described in Chapter 7.
Our main research objective in the OPAL trial was to compare biofeedback PFMT with basic PFMT in terms
of clinical effectiveness and cost-effectiveness. We met this objective and concluded that there was no
evidence of a difference in clinical outcomes and there was no difference in cost-effectiveness. The process
evaluation, with its focus on intervention fidelity, confirmed that an intensified PFMT intervention was
delivered in the biofeedback PFMT group as intended, but this did not lead to improved clinical outcomes
for participants in this group. The case study focused mainly on women’s adherence and found varying
levels of adherence in both groups, with the barriers to and facilitators of adherence (such as self-efficacy)
having more similarities than differences. The finer-grain analysis described in Chapters 5 and 6 found some
possible reasons why there were no differences between trial groups. These included difficulties associated
with the delivery of biofeedback in clinic, and the influence of other contextual and time factors influencing
the opportunity for women to use biofeedback (or undertake PFMT) at home. The interpretation of the
study findings, however, remains, that a benefit of biofeedback was not found. This is in keeping with the
recommendations in national guidelines, stating that EMG biofeedback should not be used as a routine part
of PFMT.1
The Cochrane review relating to biofeedback as an adjunct to PFMT for UI, published in 2011, concluded
that there may be a benefit of adding biofeedback to PFMT, but that the apparent benefit could be due to
differences between the trial arms in the amount of health professional contact.7 The OPAL trial sought to
address this shortcoming in previous trials by specifying the same number and duration of appointments
in both trial groups. Despite this, participants in the biofeedback PFMT group received 26 minutes more
contact over the duration of their treatment than those in the basic PFMT group. Even with this extra
contact time, however, there was no difference between groups.
A number of trials of biofeedback in women have been published since the publication of the Cochrane
review. These have been characterised by small sample sizes and short-term follow-up. Four trials80–83
were not directly comparable to the OPAL trial. Ibrahim et al.80 carried out a randomised comparison
of manometric biofeedback-assisted PFMT with PFMT alone in a mixed group of 52 women with either
SUI (n = 26) or faecal incontinence, with or without prolapse (n = 26). At 12 weeks, more women in the
biofeedback PFMT group improved their symptoms than in the PFMT alone group. Ahadi et al.81 carried
out a randomised pilot trial of PFMT compared with PFMT plus biofeedback in 40 women with prolapse,
with short-term outcomes suggestive of better quality of life in the biofeedback PFMT group at 12 weeks.
Liu et al.82 carried out a comparison of biofeedback plus electrical stimulation compared with conventional
PFMT and no treatment in perimenopausal SUI. In before-and-after comparisons, both groups receiving
treatment improved, whereas the no-treatment group did not. Terlikowski et al.83 also compared EMG
biofeedback plus electrical stimulation with a placebo for SUI (n = 112). It was unclear what the placebo
was, but this group had significantly worse urine leakage after 8 weeks.
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Five trials84–88 were more directly comparable to the OPAL trial and had mixed findings. Hirakawa et al.84
compared PFMT plus biofeedback (unspecified) with PFMT for SUI (n = 46) and found no differences between
groups after 12 weeks in any of the parameters assessed, including the King’s Health Questionnaire. In a
similar study, Fitz et al.85 also compared PFMT plus biofeedback (unspecified) with PFMT for SUI (n = 40)
and did find differences between groups in the King’s Health Questionnaire at 12 weeks, favouring the
biofeedback PFMT group in all but one domain. In another trial by Fitz et al.,86 of 72 women with SUI,
PFMT (clinic and home) was compared with PFMT at home augmented with pressure biofeedback in clinic,
with a primary outcome of frequency of exercises after 3 months. Biofeedback did not increase the frequency
of women’s home exercise. Bertotto et al.87 compared the effect on muscle strength of PFMT with and
without EMG biofeedback in women with SUI (n = 49). The biofeedback PFMT group had significantly
more improvement in muscle strength than the PFMT-only group. Özlü et al.88 conducted a three-arm trial in
women with SUI, comparing PFMT with PFMT plus pressure biofeedback with PFMT plus EMG biofeedback
(n = 53). Severity of UI, cure/improvement and pelvic floor muscle strength outcomes were superior in both
biofeedback PFMT groups compared with PFMT alone.
We plan to pool the findings of our much larger trial results, where possible, with the results of other
comparable trial in a meta-analysis. The overall finding is highly likely to be one of no evidence of an effect
of adjunctive biofeedback.
Despite the finding of no evidence of a difference in relation to our primary outcome, we did observe an
improvement in ICIQ-UI SF scores in both groups. This could suggest that both interventions had a benefit.
This is in keeping with current Grade A evidence for PFMT for the treatment of SUI.89 The magnitude of the
improvement in the scores we observed was in line with the benefit in ICIQ-UI SF reported in the recently
updated Cochrane review,90 which compared PFMT with no treatment or inactive control, suggesting that
the improvements in ICIQ-UI SF score we observed in both groups were real effects, rather than effects of
the women being involved in research. The three relevant trials in the Dumoulin et al.90 review, however,
differed from each other and from the OPAL trial in terms of the PFMT intervention content and duration.
The pattern of a sustained improvement in ICIQ-UI SF score was also observed in other outcomes: for all
the outcomes with an observed improvement from baseline to 6 months, this was continued throughout
follow-up. This was the case despite the fact that most participants had completed therapy appointments
in the active treatment phase at the 6-month time point, following which they could no longer rely on the
motivating force of their therapist for continuing their PFMT. Encouragingly, almost half of women (49%
and 43% of women in the biofeedback PFMT and basic PFMT groups, respectively) were exercising a few
times a week or more at 24 months. There are few PFMT trials with similar long-term follow-up to the
OPAL trial for comparison. Only one trial out of 31 in the Dumoulin et al.90 review had follow-up to 1 year,
and this trial also found that the effect of PFMT on UI symptoms and condition-specific quality of life persisted.91
Implications for health care
l Health-care practitioners and policy-makers can be confident that routine use of EMG biofeedback as
part of PFMT in all cases does not confer benefit for women with SUI or MUI in terms of their long-term
incontinence severity, and is not more cost-effective than PFMT alone. The combined PFMT and
biofeedback intervention evaluated did not improve secondary outcomes over PFMT alone.
l Our theoretically developed interventions relied on women carrying out PFMT (and using biofeedback)
at home, as well as at appointments. The interventions incorporated a range of established and
effective BCTs with which women and therapists engaged. These techniques could be highlighted to
women and health-care professionals as potential ways of helping increase adherence to PFMT.
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Future research implications
l Future research would be useful to investigate other ways of intensifying PFMT that may improve
women’s outcomes compared with a basic PFMT programme. Biofeedback was one possible approach,
but others exist. Additional health professional contact to support adherence to PFMT is one option, but
careful consideration would need to be given to design of such a service and the availability of staff to
resource it.
l Although the OPAL trial found no evidence of benefit of biofeedback, if biofeedback devices evolve
sufficiently, more research may ultimately be needed to evaluate new technology that would overcome
barriers associated with earlier devices.
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Baseline 6 months 12 months 24 months
Urinary outcomes
l ICIQ-UI SF ✗ ✗ ✗ ✗
l PGI-S ✗
l PGI-I ✗ ✗ ✗
l Uptake of surgery for UI ✗ ✗ ✗
l Uptake of other treatment for UI ✗ ✗ ✗
l Other urinary symptoms (ICIQ-FLUTS) ✗ ✗ ✗ ✗
Quality-of-life outcomes
l UI-specific quality of life (ICIQ-FLUTSqol) ✗ ✗ ✗ ✗
l General health (EQ-5D-3L) ✗ ✗ ✗ ✗
Pelvic floor-related outcomes
l Prolapse symptoms (POP-SS) ✗ ✗ ✗ ✗
l Bowel symptoms (early version of International Consultation on
Incontinence Questionnaire Bowel Short Form)
✗ ✗ ✗ ✗
l Self-efficacy for PFMT ✗ ✗ ✗ ✗
l Adherence to PFMT ✗ ✗ ✗ ✗
Economic outcomes
l Cost and use of NHS services ✗ ✗
l Cost to the women and their families/carers ✗
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Appendix 3 Recruitment by centre
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Appendix 4 Reasons for ineligibility
There were 51 women who were screened who were ineligible.
Ineligible
Unable to contract their pelvic floor muscles (n = 18).
Known nickel allergy or sensitivity (n = 16).
Prolapse stage 2, pelvic cancer, cognitive impairment or neurological disease (n = 7).
Urgency UI alone (n = 6).
Previous formal instruction in PFMT (n = 3).
Pregnant or < 1 year postnatal (n = 1).
Antimuscarinic medication (n = 0).
Currently participating in other research relating to their UI (n = 0).
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Appendix 5 Sensitivity analysis under
assumptions of missing not at random
A pattern mixture modelling approach was used to explore the effect of missing data under MNARassumptions. Missing ICIQ-UI SF values were assumed to be between 2.5 units lower and 2.5 units
greater, on average, than the observed values in (1) the biofeedback PFMT group only, (2) the basic PFMT
group only and (3) in both groups. It was considered that 2.5 points was a minimum clinically important
difference and, hence, a meaningful systematic difference to test in the sensitivity analyses. The pattern
mixture model (Figure 12) tested data, assuming values of delta equal to −2.5, −1.5, −0.5, +0.5, +1.5 and
+2.5. None of the analyses produced a statistically significant treatment effect and therefore this sensitivity
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FIGURE 12 Pattern mixture model under assumptions of MNAR. Reproduced with permission from Hagen et al.38
This is an Open Access article distributed in accordance with the Creative Commons Attribution Non Commercial
(CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially,
and license their derivative works on different terms, provided the original work is properly cited and the use is
non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/. The figure includes minor additions and
formatting changes to the original figure.
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Appendix 6 Subgroup analysis
Variable Subgroup n Mean SD
Effect
estimate 95% CI p-value
Overall ICIQ−UI SF Basic PFMT 235 8.5 4.9 –0.09 –0.92 to 0.75 0.84
Biofeedback PFMT 225 8.2 5.1
Type of incontinence SUI 182 7.4 4.8 –0.80 –2.13 to 0.53 0.24
MUI 278 8.9 5.0 0.38 –0.69 to 1.45 0.49
Interaction 1.18 –0.53 to 2.89 0.18
Age (years) < 50 265 8.3 5.1 –0.23 –1.32 to 0.87 0.68
≥ 50 195 8.3 4.8 0.12 –1.17 to 1.40 0.86
Interaction 0.34 –1.35 to 2.03 0.69
Severity of incontinencea Mild/moderate 206 6.6 3.8 –0.75 –2.03 to 0.53 0.25
Severe 254 9.7 5.4 0.28 –0.87 to 1.43 0.63
Interaction 1.03 –0.69 to 2.75 0.24
Type of therapist Physiotherapist 406 8.1 4.8 –0.24 –1.12 to 0.64 0.60
Not physiotherapist 54 9.9 5.7 1.15 –1.38 to 3.68 0.37
Interaction –1.39 –4.07 to 1.29 0.31
a An ICIQ-UI SF score of < 13 is mild/moderate; an ICIQ-UI SF score of ≥ 13 is severe.
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Appendix 7 Patient Global Impression of
Improvement in urinary incontinence
Time point Response
Treatment group
Biofeedback PFMT Basic PFMT
N n % N n %
6 months Very much better 219 37 16.9 221 37 16.7
Much better 219 59 26.9 221 48 21.7
A little better 219 73 33.3 221 83 37.6
No change 219 34 15.5 221 46 20.8
A little worse 219 12 5.5 221 7 3.2
Much worse 219 4 1.8 221 0 0
Very much worse 219 0 0 221 0 0
12 months Very much better 249 39 15.7 250 36 14.4
Much better 249 62 24.9 250 56 22.4
A little better 249 79 31.7 250 81 32.4
No change 249 51 20.5 250 52 20.8
A little worse 249 13 5.2 250 17 6.8
Much worse 249 4 1.6 250 7 2.8
Very much worse 249 1 0.4 250 1 0.4
24 months Very much better 227 43 18.9 236 42 17.8
Much better 227 50 22 236 48 20.3
A little better 227 58 25.6 236 54 22.9
No change 227 41 18.1 236 47 19.9
A little worse 227 22 9.7 236 32 13.6
Much worse 227 8 3.5 236 10 4.2
Very much worse 227 5 2.2 236 3 1.3
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Appendix 8 Bowel and prolapse symptoms
TABLE 35 Bowel symptoms
Symptom response
Treatment group
Biofeedback PFMT Basic PFMT
N n % N n %
Baseline
Difficulty emptying bowels?
Never 289 85 29.4 296 79 26.7
Occasionally 289 101 34.9 296 94 31.8
Sometimes 289 68 23.5 296 83 28
Most of the time 289 25 8.7 296 26 8.8
All of the time 289 10 3.5 296 14 4.7
Rush to toilet?
Never 289 104 36 296 111 37.5
Occasionally 289 97 33.6 296 102 34.5
Sometimes 289 62 21.5 296 55 18.6
Most of the time 289 18 6.2 296 22 7.4
All of the time 289 8 2.8 296 6 2
Stool leak?
Never 289 213 73.7 295 217 73.6
Occasionally 289 52 18 295 45 15.3
Sometimes 289 19 6.6 295 30 10.2
Most of the time 289 4 1.4 295 3 1
All of the time 289 1 0.3 295 0 0
How often bowels open?
Three or more times a day 286 24 8.4 297 29 9.8
Twice a day 286 60 21 297 61 20.5
Once a day 286 139 48.6 297 125 42.1
Two or three times a week 286 53 18.5 297 74 24.9
Once a week or less 286 10 3.5 297 8 2.7
Motions usually?
Watery 284 3 1.1 293 3 1
Sloppy 284 29 10.2 293 32 10.9
Soft and formed 284 216 76.1 293 198 67.6
Hard 284 36 12.7 293 60 20.5
continued
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TABLE 35 Bowel symptoms (continued )
Symptom response
Treatment group
Biofeedback PFMT Basic PFMT
N n % N n %
6 months
Difficulty emptying bowels?
Never 180 66 36.7 176 49 27.8
Occasionally 180 59 32.8 176 51 29
Sometimes 180 33 18.3 176 54 30.7
Most of the time 180 14 7.8 176 14 8
All of the time 180 8 4.4 176 8 4.5
Rush to toilet?
Never 180 76 42.2 176 70 39.8
Occasionally 180 68 37.8 176 67 38.1
Sometimes 180 28 15.6 176 31 17.6
Most of the time 180 5 2.8 176 6 3.4
All of the time 180 3 1.7 176 2 1.1
Stool leak?
Never 180 136 75.6 176 137 77.8
Occasionally 180 33 18.3 176 27 15.3
Sometimes 180 10 5.6 176 11 6.3
All of the time 180 0 0 176 1 0.6
Most of the time 180 1 0.6 176 0 0
How often bowels open?
Three or more times a day 178 15 8.4 176 13 7.4
Twice a day 178 29 16.3 176 37 21
Once a day 178 98 55.1 176 85 48.3
Two or three times a week 178 29 16.3 176 35 19.9
Once a week or less 178 7 3.9 176 6 3.4
Motions usually?
Watery 178 1 0.6 173 2 1.2
Sloppy 178 14 7.9 173 12 6.9
Soft and formed 178 134 75.3 173 126 72.8
Hard 178 29 16.3 173 33 19.1
12 months
Difficulty emptying bowels?
Never 187 62 33.2 183 50 27.3
Occasionally 187 67 35.8 183 64 35
Sometimes 187 44 23.5 183 43 23.5
Most of the time 187 12 6.4 183 20 10.9
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TABLE 35 Bowel symptoms (continued )
Symptom response
Treatment group
Biofeedback PFMT Basic PFMT
N n % N n %
All of the time 187 2 1.1 183 6 3.3
Rush to toilet?
Never 188 80 42.6 182 83 45.6
Occasionally 188 75 39.9 182 65 35.7
Sometimes 188 27 14.4 182 26 14.3
Most of the time 188 4 2.1 182 6 3.3
All of the time 188 2 1.1 182 2 1.1
Stool leak?
Never 188 144 76.6 182 145 79.7
Occasionally 188 35 18.6 182 26 14.3
Sometimes 188 6 3.2 182 9 4.9
Most of the time 188 2 1.1 182 1 0.5
All of the time 188 1 0.5 182 1 0.5
How often bowels open?
Three or more times a day 187 11 5.9 181 13 7.2
Twice a day 187 39 20.9 181 38 21
Once a day 187 100 53.5 181 84 46.4
Two or three times a week 187 29 15.5 181 39 21.5
Once a week or less 187 8 4.3 181 7 3.9
Motions usually?
Watery 185 3 1.6 178 1 0.6
Sloppy 185 11 5.9 178 11 6.2
Soft and formed 185 150 81.1 178 130 73
Hard 185 21 11.4 178 36 20.2
24 months
Difficulty emptying bowels?
Never 161 59 36.6 167 37 22.2
Occasionally 161 64 39.8 167 69 41.3
Sometimes 161 25 15.5 167 44 26.3
Most of the time 161 10 6.2 167 12 7.2
All of the time 161 3 1.9 167 5 3
Rush to toilet?
Never 162 71 43.8 168 70 41.7
Occasionally 162 54 33.3 168 60 35.7
Sometimes 162 30 18.5 168 26 15.5
continued
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TABLE 35 Bowel symptoms (continued )
Symptom response
Treatment group
Biofeedback PFMT Basic PFMT
N n % N n %
Most of the time 162 4 2.5 168 10 6
All of the time 162 3 1.9 168 2 1.2
Stool leak?
Never 162 129 79.6 167 125 74.9
Occasionally 162 24 14.8 167 29 17.4
Sometimes 162 8 4.9 167 9 5.4
Most of the time 162 1 0.6 167 4 2.4
How often bowels open?
Three or more times a day 161 11 6.8 168 15 8.9
Twice a day 161 31 19.3 168 36 21.4
Once a day 161 82 50.9 168 68 40.5
Two or three times a week 161 28 17.4 168 41 24.4
Once a week or less 161 9 5.6 168 8 4.8
Motions usually?
Watery 159 2 1.3 167 3 1.8
Sloppy 159 13 8.2 167 16 9.6
Soft and formed 159 130 81.8 167 118 70.7
Hard 159 14 8.8 167 30 18
Reproduced with permission from Hagen et al.38 This is an Open Access article distributed in accordance with the Creative
Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build
upon this work non-commercially, and license their derivative works on different terms, provided the original work is
properly cited and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/. The table includes minor
additions and formatting changes to the original table.
TABLE 36 Prolapse symptoms (POP-SS)
Time point
Treatment group
Biofeedback PFMT Basic PFMT
n Mean SD n Mean SD
Baseline 274 6.4 5.7 286 6.7 5.6
6 months 174 4.9 5.1 167 5.0 4.9
12 months 176 4.6 4.8 172 5.0 5.1
24 months 157 4.5 5.0 161 4.9 5.0
Reproduced with permission from Hagen et al.38 This is an Open Access article distributed in accordance with the Creative
Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build
upon this work non-commercially, and license their derivative works on different terms, provided the original work is
properly cited and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/. The table includes minor
additions and formatting changes to the original table.
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Appendix 9 Estimation of unit cost of
biofeedback machines per participant





Biofeedback unit 2013 NeuroTrac 89.95 99.37
2014 NeuroTrac 104.95 113.89
2014 Peritone (Neen; Performance Health,
Huthwaite, UK)
125.84 136.56
2014 Peritone 113.49 123.16
2015 Simplex Plus 94.00 100.30 114.66
Two packets of
electrodes
2013 Reusable 5.00 5.52
2014 Reusable 3.75 4.07
2014 Reusable 4.25 4.61
2014 Reusable 9.90 10.74
2015 Reusable 13.50 14.41 7.87
One probe 2013 Periform® (Neen; Performance Health,
Huthwaite, UK)
14.75 16.29
2014 Periform 13.50 14.65
2015 Periform 9.90 10.56 13.84
Laptop 2013 IBM thinkpad (IBM Corporation,
Armonk, NY, USA)
390.00 430.84
2015 HP laptop (HP Inc., Palo Alto, CA, USA) 450.00 480.17 455.51
Software 2014 Licence 203.00 220.29
2014 Licence 182.31 197.84
2014 Licence 101.00 109.60
2014 Licence 122.67 133.12 165.22
Printer 2013 HP 45.00 49.71
2014 HP 75.00 81.39 65.55
855.04




Total cost per woman 42.92
Total cost per woman
(discounted at 3.5%)
37.40
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of tablets) Drug tariff (£)
SUI
Duloxetine (Yentreve; Eli Lilly and
Company, Indianapolis, IN, USA)
40 mg twice daily Ongoing 56 5.45
Solifenacin (Vesicare) 5 mg initially, increased to
10mg once daily
Ongoing 30 27.62 (5 mg); 35.91
(10 mg)




5 mg (twice a day on average) Ongoing 56 1.32
Tolterodine tartrate (Detrusitol;
Pfizer Inc., New York, NY, USA)
2 mg twice daily
(immediate release)
Ongoing 56 2.17
Tolterodine (Mariosea XL; Teva
Pharmaceutical Industries Ltd,
Petah Tikva, Israel) (all capsules)
4 mg once daily
(moderate release)
Ongoing 28 (capsules) 11.60 (2-mg capsules);
25.78 (4-mg capsules)
Trospium chloride (Regurin;
Contura Ltd, London, UK)








4 mg once daily, increased if
necessary up to 8 mg once daily
Ongoing 28 25.78
Darifenacin (Emselex; Merus
Labs Luxco S.á R.L., Luxembourg)
7.5 mg once daily, increased to
15mg after 2 weeks





200 mg twice daily Ongoing 14 (28) 0.73 (1.46)
Cefalexin (AAH Pharmaceuticals) Antibacterial prophylaxis of
recurrent urinary tract infection:





50 mg four times a day 5–7 days 28 11.36
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Appendix 11 Unit cost of incontinence products








Interlude (Toiletry Sales Ltd, Wakefield, UK) incontinence pads 12 1.95 0.16
Interlude incontinence pads: extra 10 1.95 0.20
Interlude incontinence pads: extra plus 8 1.95 0.24
Suprem (Ontex Group, Aalst, Belgium) heavy incontinence pads 20 7.95 0.40
Suprem light incontinence pads 28 2.95 0.11
Suprem light incontinence pads: mini 20 1.45 0.07
Suprem moderate incontinence pads 25 5.95 0.24
Suprem severe incontinence pads 20 7.95 0.40
Suprem all in one incontinence pads: extra 24 10.95 0.46
Suprem all in one incontinence pads: maxi 20 10.95 0.55
Suprem all in one incontinence pads: super 22 11.65 0.53
Suprem all in one incontinence pads: extra large 20 12.95 0.65
Suprem all in one incontinence pads: extra large – maxi 20 11.25 0.56
Suprem all in one incontinence pads: large – extra 24 10.95 0.46
Suprem all in one incontinence pads: large – super 22 11.25 0.51
Suprem all in one incontinence pads: regular 26 10.95 0.42
Suprem all in one incontinence pads: small – extra 20 8.95 0.45
Suprem all in one incontinence pads: small – maxi 20 8.95 0.45
Average 0.38
Disposable bed pads (cm)
60 × 90 25 7.95 0.32
60 × 60 25 5.95 0.24
40 × 60 25 4.25 0.14
60 × 75 25 6.45 0.26
Average 0.24
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Pearson correlation test 0.5781 0.5991
Pregibon link test 0.1660 0.1436





Inverse Gaussian 20.2876 0.0000
Identity/Gaussian Log/Gaussian
Pearson correlation test 1.0000 0.9726
Pregibon link test 0.4330 0.3771
Modified Hosmer–Lemeshow 0.2751 0.2031
DOI: 10.3310/hta24700 HEALTH TECHNOLOGY ASSESSMENT 2020 VOL. 24 NO. 70
© Queen’s Printer and Controller of HMSO 2020. This work was produced by Hagen et al. under the terms of a commissioning contract issued by the Secretary of State for
Health and Social Care. This issue may be freely reproduced for the purposes of private research and study and extracts (or indeed, the full report) may be included in professional
journals provided that suitable acknowledgement is made and the reproduction is not associated with any form of advertising. Applications for commercial reproduction should
be addressed to: NIHR Journals Library, National Institute for Health Research, Evaluation, Trials and Studies Coordinating Centre, Alpha House, University of Southampton Science
Park, Southampton SO16 7NS, UK.
125

Appendix 13 Missing data (costs)
Variable
Treatment group, n/N (%)
Basic PFMT Biofeedback PFMT
Treatment cost 2/300 (0.67) 5/300 (1.67)
GP visits
6 months 117/300 (39.00) 117/300 (39.00)
12 months 114/300 (38.00) 113/300 (37.67)
24 months 168/300 (56.00) 175/300 (58.33)
Total GP visits 200/300 (66.67) 201/300 (67.00)
General practice nurse visits
6 months 120/300 (40.00) 120/300 (40.00)
12 months 117/300 (39.00) 122/300 (40.67)
24 months 172/300 (57.33) 173/300 (57.67)
Total nurse visits 206/300 (68.67) 204/300 (68.00)
Hospital doctor visits
6 months 137/300 (45.67) 144/300 (48.00)
12 months 119/300 (39.67) 115/300 (38.33)
24 months 169/300 (56.33) 176/300 (58.67)
Total hospital doctor visits 211/300 (70.33) 217/300 (72.33)
Nurse/physiotherapist visits
6 months 121/300 (40.33) 123/300 (41.00)
12 months 119/300 (39.67) 119/300 (39.67)
24 months 171/300 (57.00) 176/300 (58.67)
Total nurse/physiotherapist visits 207/300(69.00) 206/300(68.67)
Hospital stay
6 months 121/300 (40.33) 120/300 (40.00)
12 months 125/300 (41.67) 120/300 (40.00)
24 months 169/300 (56.33) 176/300 (58.67)
Total hospital stay 206/300 (68.67) 216/300 (72.00)
Surgical interventions
6 months 136/300 (45.33) 128/300 (42.67)
12 months 90/300 (30.00) 96/300 (32.00)
24 months 138/300 (46.00) 146/300 (48.67)
Total surgical interventions 214/300 (71.33) 219/300 (73.00)
Medications
6 months 96/300 (32.00) 91/300 (30.33)
12 months 68/300 (22.67) 66/300 (22.00)
24 months 126/300 (42.00) 132/300 (44.00)
Total medications 172/300 (57.33) 175/300 (58.33)
Total cost (missing either some
intervention or follow-up data)
262/300 (87.33) 260/300 (86.67)
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Appendix 14 Missing data (utility measures)
Variable
Treatment group, n/N (%)
Basic PFMT Biofeedback PFMT
EQ-5D-3L scores
Baseline 5/300 (1.67) 13/300 (4.33)
6 months 71/300 (23.67) 75/300 (25.00)
12 months 59/300 (19.67) 65/300 (21.67)
24 months 129/300 (43.00) 134/300 (44.67)
First-year QALY 98/300 (32.67) 108/300 (36.00)
Second-year QALY 158/300 (52.67) 174/300 (58.00)
ICIQ-LUTSqol scores
Baseline 3/300 (1.00) 8/300 (2.67)
6 months 120/300 (40.00) 114/300 (38.00)
24 months 165/300 (55.00) 172/300 (57.33)
First-year QALY 147/300 (49.00) 140/300 (46.67)
Second-year QALY 200/300 (66.67) 202/300 (67.33)
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Appendix 15 Proportion of participants
experiencing any problems on each of the EQ-5D-3L















Basic PFMT 38/297 (12.79) 13/297 (4.38) 50/297 (16.84) 106/296 (35.81) 102/296 (34.46)
Biofeedback PFMT 48/289 (16.61) 19/289 (6.57) 57/289 (19.72) 114/288 (39.58) 105/288 (36.45)
6 months
Basic PFMT 36/230 (15.65) 12/230 (6.52) 45/230 (19.57) 77/230 (33.48) 72/229 (31.44)
Biofeedback PFMT 39/227 (17.18) 21/228 (9.21) 50/227 (22.03) 76/228 (33.33) 94/228 (41.23)
12 months
Basic PFMT 38/248 (15.32) 17/246 (6.91) 48/249 (19.28) 86/247 (34.82) 85/246 (34.55)
Biofeedback PFMT 48/241 (19.92) 32/244(13.11) 56/244 (22.95) 95/242 (39.26) 93/241 (38.59)
24 months
Basic PFMT 26/174 (14.94) 13/174 (7.47) 43/174 (24.71) 62/172 (36.05) 56/171 (32.75)
Biofeedback PFMT 38/168 (22.62) 18/168 (10.71) 37/168 (22.95) 50/168 (29.76) 56/167 (33.53)
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Appendix 16 Proportion of participants who
reported issues on each domain of the ICIQ-LUTSqol:



















Basic PFMT 244/297 (82.15) 279/297 (93.94) 154/297 (51.85) 244/297 (82.15) 168/297 (56.57)
Biofeedback PFMT 246/292 (84.25) 282/292 (96.58) 165/292 (56.51) 244/292 (83.56) 182/292 (62.33)
6 months
Basic PFMT 109/182 (59.89) 151/182(82.97) 62/180 (34.44) 112/180(62.22) 83/180 (46.11)
Biofeedback PFMT 120/186 (64.51) 161/186 (86.56) 67/186 (36.02) 119/186 (63.98) 77/186 (41.40)
12 months
Basic PFMT 103/184 (55.98) 146/184 (79.34) 62/184(33.70) 115/184(62.50) 84/184 (45.65)
Biofeedback PFMT 109/189 (57.67) 158/189 (83.60) 68/189 (35.98) 114/189 (60.31) 86/189 (45.50)
24 months
Basic PFMT 74/136 (54.41) 111/136 (81.62) 40/136 (29.41) 81/135 (60.00) 65/135 (48.15)
Biofeedback PFMT 69/129 (53.49) 108/130 (83.07) 43/132 (32.58) 78/132 (59.09) 51/132 (38.64)
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Appendix 17 Sensitivity analysis cost-
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Biofeedback vs. basic
FIGURE 14 Scatterplot of incremental cost and incremental QALYs: SUI subgroup analysis.
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FIGURE 17 Cost-effectiveness acceptability curve: age < 50 years subgroup analysis.
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FIGURE 20 Scatterplot of incremental costs and incremental QALYs: age ≥ 50 years subgroup analysis.
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FIGURE 22 Scatterplot of incremental cost and incremental QALYs: lower severity incontinence level (ICIQ-UI SF
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FIGURE 23 Cost-effectiveness acceptability curve: higher severity incontinence level (ICIQ-UI SF score of ≥ 13)
subgroup analysis.
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FIGURE 24 Scatterplot of incremental costs and incremental QALYs: higher severity incontinence level (ICIQ-UI SF
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FIGURE 26 Scatterplot of incremental costs and incremental QALYs: using ICIQ-LUTSqol scores as a utility measure.
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FIGURE 29 Cost-effectiveness acceptability curve: discounted costs and effects at 6%.
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FIGURE 32 Scatterplot of incremental cost and incremental QALYs: unadjusted cost-effectiveness analysis.
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Appendix 18 Examples of core and optional
components of the basic PFMT and biofeedback
PFMT intervention protocols, as worded on the
therapist assessment form checklists
Appointment Basic PFMT core component Biofeedback core component
1 Practise ‘the Knack’
Record and both initial PFMT goal in
exercise diary
Teach probe and electrode insertion/removal, turn
biofeedback unit on/off
Record and both initial biofeedback behaviour goal in
exercise diary
6 Collect exercise diary
Praise any PFMT achievements
Download biofeedback unit data and save
Praise any biofeedback achievements
Optional component
1 Suggest one fast contraction every time
PFMT remembered
Praise for intention to do home PFMT
Allay anxiety about biofeedback and its use
Praise for intention to use biofeedback
6 Remark on disparity between PFMT goals
and actions
Offer information/teaching for self-feedback
Remark on disparity between biofeedback goal
and actions
Offer information/teaching of alternatives to biofeedback
DOI: 10.3310/hta24700 HEALTH TECHNOLOGY ASSESSMENT 2020 VOL. 24 NO. 70
© Queen’s Printer and Controller of HMSO 2020. This work was produced by Hagen et al. under the terms of a commissioning contract issued by the Secretary of State for
Health and Social Care. This issue may be freely reproduced for the purposes of private research and study and extracts (or indeed, the full report) may be included in professional
journals provided that suitable acknowledgement is made and the reproduction is not associated with any form of advertising. Applications for commercial reproduction should
be addressed to: NIHR Journals Library, National Institute for Health Research, Evaluation, Trials and Studies Coordinating Centre, Alpha House, University of Southampton Science









Part of the NIHR Journals Library
www.journalslibrary.nihr.ac.uk
This report presents independent research funded by the National Institute for Health Research (NIHR).  
The views expressed are those of the author(s) and not necessarily those of the NHS, the NIHR or the  
Department of Health and Social Care
Published by the NIHR Journals Library
